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Recent	   genome	  wide	   association	   studies	   in	  Alzheimer’s	   disease	  have	  highlighted	   the	  
importance	   of	   the	   complement	   cascade	   in	   the	   pathogenesis	   of	   Alzheimer’s	   disease.	  	  
However,	  the	  cellular	  and	  molecular	  roles	  of	  these	  complement	  proteins	  are	  not	  fully	  
understood.	   	  Microglia	   express	   complement	   receptors	   and	   the	   activation	   of	   specific	  
receptors	   may	   increase	   Aβ	   clearance	   and	   reduce/prevent	   neurodegeneration.	   The	  
work	   presented	   in	   this	   thesis	   was	   aimed	   at	   investigating	   the	   contribution	   of	  
Complement	   receptor	   1	   (CR1),	   the	   second	  most	   significant	   hit	   in	   GWAS	   studies,	   on	  
microglia	  to	  neuronal	  damage.	  
To	   explore	   the	   consequences	   of	   blocking	   CR1	   to	   microglial-­‐neuronal	   interactions,	  
primary	   rat	  microglia	  were	   treated	  with	  a	  CR1	   functional	  blocking	  antibody	   together	  
with	  microglial	  activators	  for	  24	  h.	  It	  was	  found	  that	  microglia	  displaying	  an	  activated	  
phenotype	  demonstrated	  an	   increase	   in	  CR1	  expression.	  Activation	  of	  microglial	  CR1	  
was	   found	   to	   be	   detrimental	   to	   neurons	   and	   this	   correlated	   with	   an	   increase	   in	  
microglial	   intracellular	   superoxide	   generation,	   nitric	   oxide	   (NO)	   production,	   tumor	  
necrosis	  factor-­‐α	  (TNFα)	  and	  interleukin-­‐1	  β	  (IL-­‐1β)	  secretion.	  Amyloid-­‐β	  1-­‐42	  (Aβ1-­‐42)-­‐
treated	   microglia	   displayed	   an	   increased	   ability	   to	   phagocytose	   dextran	   beads	  
following	   antibody	   blockade	   of	   CR1	   but	   a	   decreased	   capacity	   to	   phagocytose	  
fluorescent-­‐tagged	   Aβ1-­‐42.	   CR1	   immunoreactivity	   was	   investigated	   by	  
immunohistochemistry	   in	  AD	  and	   control	   human	  post-­‐mortem	  brain	   tissue.	  A	  higher	  
level	  of	  CR1	  immunoreactivity	  was	  found	  in	  areas	  of	  high	  Aβ	  plaque	  burden	  in	  AD	  brain	  
tissue.	   A	   difference	   in	   CR1	   expression	   on	   red	   blood	   cells	   between	   individuals	   was	  
5	  
	  
measured	  by	  flow	  cytometry.	  Together,	  these	  results	  indicate	  that	  microglial	  CR1	  plays	  
a	  role	  in	  the	  neuronal	  death	  observed	  in	  AD	  and	  investigating	  this	  further	  may	  provide	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Aβ	   	   	   amyloid-­‐β	  
ABC	   	   	   avidin-­‐biotin	  complex	  
AD	   	   	   Alzheimer’s	  disease	  
AGE	   	   	   advanced	  glycation	  end	  product	  
AMC	   	   	   aged-­‐matched	  control	  
APLT	   	   	   ATP-­‐dependent	  aminophospholipid	  translocase	  
APP	   	   	   amyloid	  precursor	  protein	  
APS	   	   	   ammonium	  persulfate	  
Apo	   	   	   apocynin	  
ApoE	  	   	   Apolipoprotein	  E	  
Ara-­‐C	  	   	   cytosine	  furanoarabinoside	  
BDNF	  	   	   brain	  derived	  neurotrophic	  factor	  
BSA	   	   	   bovine	  serum	  albumin	  
CD59	  	   	   complement	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  59	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   cerebellar	  granule	  cells	  
CNS	   	   	   Central	  nervous	  system	  
CSF	   	   	   cerebrospinal	  fluid	  
C3	   	   	   complement	  3	  
COX	   	   	   cyclooxygenase	  
COX-­‐2	   	   cycleoxygenase-­‐2	  
Crry	   	   	   CR1-­‐related	  protein	  Y	  
DAB	   	   	   diaminobenzine	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DHE	   	   	   dihydroethidium	  
DIV	   	   	   days	  in	  vitro	  
DMEM	   	   Dulbecco’s	  Modified	  Eagle’s	  Medium	  
dsRNA	   	   double-­‐stranded	  ribonucleic	  acid	  
EA	   	   	   ethacrynic	  acid	  
EBSS	   	   	   Earl’s	  Balanced	  Salts	  Solution	  
ECL	   	   	   enhanced	  chemiluminescence	  
EDTA	  	   	   ethylene	  tetraacetic	  acid	  
EGTA	  	   	   ethylene	  glycol	  tetraacetic	  acid	  
ELISA	  	   	   enzyme-­‐linked	  immunosorbent	  assay	  
EOAD	  	   	   early	  onset	  Alzheimer’s	  disease	  
ERK	   	   	   extracellular-­‐signal-­‐regulated	  kinase	  
eNOS	  	   	   endothelial	  nitric	  oxide	  synthase	  
FBS	   	   	   foetal	  bovine	  serum	  
GPI	   	   	   glycophosphinositol	  
GSH	   	   	   glutathione	  
GSSG	  	   	   glutathione	  disulphide	  
GWAS	   	   genome-­‐wide	  association	  studies	  
H2O2	   	   	   hydrogen	  peroxide	  
HBSS	   	   	   Hank’s	  Balanced	  Salt	  Solution	  
HPLC	   	   	   high	  performance	  liquid	  chromatography	  
HRP	   	   	   horseradish	  peroxidise	  
ICC	   	   	   immunocytochemistry	  
IF	   	   	   immunofluorescence	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IFN	   	   	   interferon	  
IHC	   	   	   immunohistochemistry	  
IL	   	   	   interleukin	  
iNOS	   	   	   inducible	  nitric	  oxide	  synthase	  
JNK	   	   	   c-­‐Jun	  N-­‐terminal	  kinase	  
L-­‐Arg	  	   	   L-­‐arginine	  
LCRs	   	   	   low-­‐copy	  repeats	  
LHR	   	   	   long	  homologous	  repeat	  
LME	   	   	   L-­‐leucine-­‐methyl-­‐ester	  
LOAD	  	   	   late-­‐onset	  Alzheimer’s	  disease	  
LPS	   	   	   lipopolysaccharide	  	  
MAC	   	   	   membrane	  attack	  complex	  
MAPKs	   	   mitogen-­‐activated	  protein	  kinase	  
MCB	   	   	   monochlorobimane	  
MEM	  	   	   Minimum	  Essential	  Medium	  
MGCM	   	   microglial	  conditioned	  medium	  
MHC	   	   	   major	  histocompatibility	  complex	  
mRNA	   	   messenger	  ribonucleic	  acid	  
mTNFα	   	   membrane	  TNFα	  
NaOH	   	   sodium	  hydroxide	  
NBT	   	   	   nitroblue-­‐tetrazolium	  
NFKB	   	   	   nuclear	  factor	  KB	  
NGF	   	   	   nerve	  growth	  factor	  	  
mtNOS	   	   mitochondrial	  nitric	  oxide	  synthase	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NADPH	   	   nicotinamide	  adenine	  dinucleotide	  phosphate	  
NO	   	   	   nitric	  oxide	  
NOS	   	   	   nitric	  oxide	  synthase	  
nNOS	  	   	   neuronal	  nitric	  oxide	  synthase	  
NFT	   	   	   neurofibrillary	  tangle	  
NT	   	   	   neurotrophin	  
O2
.-­‐	   	   	   superoxide	  anion	  
ONOO-­‐	   	   peroxynitrite	  
PBS	   	   	   Phosphate	  buffered	  saline	  
PDL	   	   	   poly-­‐dextro	  lysine	  
PET	   	   	   positron	  emission	  tomography	  
PI	   	   	   propidium	  iodide	  
PI-­‐3K	   	   	   phos-­‐phoinositide	  3-­‐kinase	  
PNS	   	   	   Peripheral	  nervous	  system	  
PS	   	   	   phosphatidylserine	  
PTK	   	   	   protein	  tyrosine	  kinase	  
PVDF	  	   	   polyvinylidene	  difluoride	  
RAGE	  	   	   receptor	  for	  advanced	  glycation	  end	  product	  
RBC	   	   	   red	  blood	  cell	  
RISC	   	   	   ribonucleic	  acid	  induced	  silencing	  complex	  
RNA	   	   	   ribonucleic	  acid	  
RNS	   	   	   reactive	  nitrogen	  species	  
ROS	   	   	   reactive	  oxygen	  species	  
SBTI	   	   	   soybean	  trypsin	  inhibitor	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SC	   	   	   serum	  containing	  
SCR	   	   	   short	  consensus	  repeat	  
SCR	   	   	   short	  consensus	  repeat	  
SDS-­‐PAGE	   	   sodium	  dodecly	  sulphate	  polyacrylamide	  gel	  electrophoresis	  
SEM	   	   	   standard	  error	  of	  the	  mean	  
SF	   	   	   serum	  free	  
SH2	   	   	   src-­‐homology	  2	  
siRNA	   	   small	  interfering	  ribonucleic	  acid	  
smFRET	   	   single-­‐molecule	  fluorescence	  resonance	  energy	  transfer	  
SOD	   	   	   superoxide	  dismutase	  
ssRNA	   	   sequence-­‐specific	  ribonucleic	  acid	  
sTNFα	   	   soluble	  TNFα	  
TACE	   	   	   TNFα	  converting	  enzyme	  
TBS	   	   	   tris-­‐buffered	  saline	  
TBS-­‐T	  	   	   tris-­‐buffered	  saline	  with	  tween	  20	  
TEMED	   	   tetramethylethylenediamine	  
TLRs	   	   	   Toll-­‐like	  receptors	  
TNF	   	   	   tumour	  necrosis	  factor	  
Trks	   	   	   tyrosine	  kinase	  receptors	  
XO	   	   	   xanthine	  oxidase	  
























1.1	  Cells	  of	  the	  Central	  Nervous	  System	  
The	   mammalian	   brain	   and	   spinal	   cord	   constitute	   the	   central	   nervous	   system	  
(CNS),	  which	   is	  made	  up	  of	  a	  1:1	  ratio	  of	  neuronal	  to	  non-­‐neuronal	  cells	  at	  86	  billion	  
each	   (Azevedo	   et	   al.	   2009).	   Non-­‐neuronal	   cells	   collectively	   known	   as	   glia,	   support,	  
maintain	  and	  protect	  neurons	  and	  it	  is	  these	  neuronal-­‐glial	  interactions	  that	  will	  play	  a	  
fundamental	  role	  in	  our	  understanding	  of	  AD	  progression.	  
	  
1.1.1	  Neurons	  
There	  are	  at	  least	  86	  billion	  neurons	  in	  the	  brain	  and	  they	  are	  responsible	  for	  the	  
transmission	   of	   chemically	   mediated	   electrical	   messages	   within	   the	   CNS	   and	   the	  
peripheral	   nervous	   system	   (PNS).	   Neurons	   consist	   of	   the	   soma,	   typically	   20	   µm	   in	  
diameter	   containing	   the	   nucleus	   and	   the	   majority	   of	   the	   organelles,	   branched	  
projections	  called	  dendrites	  that	  receive	  the	  majority	  of	  electrochemical	  signals	  to	  the	  
cell,	  and	  a	  branched	  axon	  which	  is	  responsible	  for	  the	  neuronal	  output	  of	  the	  cell	  (Fig	  
1.1).	   The	   axon	   extends	   from	   the	   axon	   hillock	   to	   the	   terminal	   bouton.	   It	   is	   at	   this	  
terminal	  site	  where	  the	  axon	  comes	  into	  contact	  with	  dendrites	  from	  other	  neurons	  to	  
pass	  information	  on	  to	  them.	  The	  axon	  hillock	  is	  where	  the	  membrane	  potentials	  are	  
propagated	   from	   synaptic	   inputs,	   and	   the	   communication	   of	   this	   information	   to	   the	  
terminal	   bouton	   of	   the	   same	   axon	   is	   called	   conduction.	   Neurons	   have	   a	   negative	  
resting	  membrane	  potential	  of	  -­‐70	  mV,	  and	  are	  described	  as	  polarized.	  A	  neural	  signal	  
is	  sent	  when	  the	  membrane	  potential	  reaches	  a	  voltage-­‐dependent	  threshold,	  usually	  
20	  
	  
about	  10	  mV	  more	  positive	  than	  the	  resting	  membrane	  potential,	   initiating	  an	  action	  
potential	   resulting	   in	  a	  brief	  depolarisation	  of	   the	  cell	   to	  a	  value	  of	  approx.	  +40	  mV.	  
This	   is	   followed	   by	   repolarisation	   and	   a	   refractory	   period,	   which	   all	   occur	   under	   1	  
millisecond	  (Purves	  et	  al.	  2012;	  Bear	  et	  al.	  2007).	  
As	  previously	  mentioned,	   the	   site	  at	  which	   the	   terminal	  bouton	  communicates	  
with	   a	   dendrite	   or	   another	   cell	   type	   to	   pass	   information,	   is	   called	   the	   synapse.	   This	  
specialised	   structure	   is	   composed	   of	   the	   pre-­‐synaptic	   terminal,	   the	   post-­‐synaptic	  
terminal,	   the	  glial	   terminals	  and	   the	  synaptic	   cleft.	  When	   the	  action	  potential	  during	  
depolarization	  reaches	  the	  terminal	  bouton,	  the	  pre-­‐synaptic	  terminal	  in	  the	  case	  of	  a	  
chemical	   synapse,	   releases	   chemicals	   known	   as	   neurotransmitters	   into	   the	   synaptic	  
cleft	   mediating	   neurotransmission	   to	   the	   post-­‐synaptic	   terminal.	   Neurons	   are	   also	  
coupled	   through	   gap	   junctions	   known	   as	   an	   electrical	   synapse	   that	   can	   transmit	  
information	  without	  the	  need	  for	  neurotransmitters	  (Hormuzdi	  et	  al.	  2004).	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1.1.2	  Cerebellar	  granule	  neurons	  
Recent	   studies	  have	   indicated	   that	   the	  cerebellum,	  not	  only	   controls	   voluntary	  
movement	   and	   balance,	   but	   is	   also	   responsible	   for	   non-­‐motor	   aspects	   of	   behaviour	  
such	  as	  cognitive	  function	  (Ravizza	  et	  al.	  2006;	  Strick	  et	  al.	  2009).	  More	  than	  90%	  of	  the	  
neurons	  in	  cerebellum	  are	  granule	  neurons,	  and	  they	  make	  up	  the	  largest	  homogenous	  
neuronal	  population	  of	   the	  mammalian	  brain	   (Contestabile	  2002).	  Cerebellar	  granule	  
cells	  (CGCs)	  develop	  postnatally,	  making	  them	  a	  good	  source	  of	  primary	  neurons	  to	  be	  
used	   in	   vitro	   for	   the	   study	   of	   cell	   and	  molecular	  mechanisms	   of	   neurodegeneration.	  
Typically	  the	  cerebellum	  was	  not	  thought	  to	  be	  affected	  by	  Alzheimer’s	  disease	  (AD),	  
but	  morphometric	  analysis	  of	  11	  subjects	  who	  died	   in	   the	   final	   stages	  of	  Alzheimer’s	  
disease	  demonstrated	  atrophy	  of	  the	  molecular	  and	  granule	  layers	  of	  the	  cerebellum,	  
Figure	  0.1:	  Schematic	  of	  a	  neuron	  and	  synaptic	  
cleft.	  
Classic	  anatomy	  of	  a	  neuron	  includes	  the	  soma,	  
highly	  branched	  dendrites,	  a	  large	  myelinated	  axon	  
which	  propagates	  the	  action	  potential	  and	  a	  nerve	  
bouton,	  which	  is	  rich	  in	  synaptic	  vesicles	  containing	  
neurotransmitters	  and	  other	  factors	  ready	  for	  
release	  into	  the	  synaptic	  cleft.	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which	  correlated	  with	  a	  30%	  reduction	  of	  granule	  cells	  (Wegiel	  et	  al.	  1999).	  This	  may	  
suggest	  that	  cerebellar	  pathways	  play	  a	  role	  in	  AD.	  
The	  cerebellum	  is	  composed	  of	  three	  distinct	  layers	  (Fig.	  1.2).	  At	  the	  bottom	  lies	  
the	  granule	  cell	  layer,	  densely	  packed	  with	  granule	  cells	  along	  with	  golgi	  interneuron’s.	  
The	  middle	   layer,	   called	   the	   Purkinje	   layer,	   consists	   of	   a	   single	   row	   of	   Purkinje	   cell	  
bodies.	   Finally	   the	   outermost	   layer,	   called	   the	   molecular	   layer,	   is	   composed	   of	   the	  
branching	   Purkinje	   cell	   dendrites	   positioned	   at	   right-­‐angles	   to	   parallel	   fibres	   and	  
basket	  cell	   interneuron’s.	  Excitatory	   information	  is	  transferred	  to	  Purkinje	  cells	   in	  the	  
molecular	   layer	   from	   climbing	   fibres	   (originating	   from	   the	   inferior	   olive),	   and	   to	  
granule	   neurons	   in	   the	   granule	   layer	   by	   mossy	   fibres	   (arising	   from	   cerebral	   cortex,	  
spinal	  cord	  and	  vestibular	  system)	  (Purves	  et	  al.	  2012).	  
	  
Figure	  0.2:	  Circuitry	  of	  the	  cerebellum.	  
A	   longitudinal	   representation	  of	   the	   three	  distinct	   layers	  of	   the	  cerebellum	  shows	   the	  molecular	   layer,	  
consisting	  of	  the	  dendritic	  projections	  of	  the	  purkinje	  cells,	  the	  purkinje	  layer,	  containing	  the	  purkinje	  cell	  
bodies	  and	  the	  granule	  layer,	  containing	  the	  cerebellar	  granule	  cells.	  The	  mossy	  fibres	  provide	  excitatory	  
signals	   for	   the	  granule	   cells	   and	   the	  excitatory	   signal	   from	   the	   climbing	   fibres	  are	  propagated	   into	   the	  






Microglia	  are	  a	  distinct	  population	  of	  cell	  in	  the	  CNS	  that	  were	  first	  described	  by	  
the	  Spanish	  neuroanatomist,	  del	  Rio-­‐Hortega	   in	  1932	  and	  represent	  20%	  of	   the	   total	  
glial	  population	  in	  the	  CNS.	  As	  previously	  mentioned,	  the	  1:1	  ratio	  of	  neuronal	  to	  glial	  
cells	  in	  the	  brain	  would	  therefore	  suggest	  that	  that	  10%	  of	  all	  brain	  cells	  are	  microglia	  
(Azevedo	   et	   al.	   2009).	   Microglia	   are	   the	   innate	   immune	   cells	   of	   the	   CNS	   and	   are	  
derived	  from	  primitive	  haematopoiesis	  in	  the	  foetal	  yolk	  sac	  and	  migrate	  into	  the	  CNS	  
at	   embryonic	   day	   10.5	   where	   by	   contrast,	   the	   macrophage	   lineage	   is	   derived	   from	  
definitive	   haematopoises	   in	   the	   bone	   marrow	   (Ginhoux	   et	   al.	   2010;	   Saijo	   &	   Glass	  
2011).	   In	   the	   presence	   of	   CNS	   insult,	   a	   large	   increase	   in	   microglia	   population	   is	  
observed	  known	  as	  microgliosis	  (Reitz	  et	  al.	  2012;	  Fellner	  et	  al.	  2011),	  which	  in	  the	  past	  
was	  thought	  to	  be	  partly	  supplied	  from	  bone-­‐marrow	  derived	  progenitors	  through	  an	  
impaired	  blood-­‐brain	  barrier	  caused	  by	  neuroinflammation	   (Djukic	  et	  al.	  2006;	  Flügel	  
et	  al.	  2001;	  King	  et	  al.	  2009).	  This	  is	  argued	  however,	  by	  other	  studies	  that	  suggest	  the	  
increased	   numbers	   of	   microglia	   are	   as	   a	   result	   of	   local	   proliferation	   (Lawson	   et	   al.	  




“Resting”	   or	   ramified	   microglia	   are	   capable	   of	   extending	   their	   processes	   to	  
analyse	  their	  surrounding	  environment	  allowing	  a	  fast	  response	  to	  pathogens	  or	  tissue	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injury	   (Wilkinson	   &	   Landreth	   2006).	   In	   this	   state	   they	   have	   a	   small	   soma,	   thin	   and	  
highly	   branched,	   constantly	   moving	   processes	   that	   extend	   around	   to	   survey	   the	  
surrounding	   area.	   Studies	   using	   in	   vivo	   two-­‐photon	   laser-­‐scanning	   microscopy	  
recorded	  little	  movement	  of	  the	  soma	  of	  the	  resting	  microglia	  in	  the	  healthy	  brain	  but	  
a	  continuous	  extension	  and	  retraction	  of	  the	  branched	  process	  at	  a	  speed	  that	  would	  
suggest	  the	  brain	  is	  thoroughly	  scanned	  (Nimmerjahn	  et	  al.	  2005;	  Davalos	  et	  al.	  2005).	  
As	  described	   there	  are	  no	  periods	  of	  microglial	   inactivity;	   it	   is	  of	   the	  general	  opinion	  
that	  microglia	  move	  from	  a	  surveillance	  resting	  state	  to	  other	  states	  over	  the	  course	  of	  
activation	  (Kettenmann	  et	  al.	  2011).	  
	  
Activated	  microglia	  
In	  response	  to	  inflammation	  these	  resting	  microglia	  transform	  into	  an	  ‘activated’	  
state	  altering	  the	  microglia	  into	  an	  ameboid	  morphology,	  including	  an	  enlargement	  of	  
the	   soma,	   shortening	   of	   cellular	   processes	   and	   expression	   of	   cell-­‐surface	   molecules	  
including	   CD14,	   major	   histocompatibility	   complex	   (MHC)	   molecules	   and	   chemokine	  
receptors	   and	   are	   able	   to	   multiply	   in	   number	   and	   gather	   around	   the	   site	   of	   injury	  
(Verkhratsky	  &	  Butt	  2007).	  In	  this	  activated	  state,	  microglia	  up-­‐regulate	  the	  expression	  
of	   cell	   surface	   activation	   antigens,	   pattern	   recognition	   receptors	   and	   secrete	   free	  
radicals	  such	  as	  nitric	  oxide	  (NO)	  and	  reactive	  oxygen	  species	  (ROS)	  (Meda	  et	  al.	  2001).	  
In	   response	   to	   injury,	   microglia	   also	   express	   the	   immunological	   receptors	   such	   as	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complement	   and	   cytokine	   receptors	   to	   recruit	   peripheral	   immune	   cells,	   to	   influence	  
the	  pathologic	  process	  (Lee	  et	  al.	  2002).	  	  
As	   close	   ‘relatives’	   to	   the	  peripheral	  monocytes,	   activated	  microglia	   act	   as	   the	  
macrophages	  of	  the	  CNS.	  Microglia	  play	  a	  phagocytic	  role	   in	  the	  CNS	  to	  engulf	  tissue	  
debris	  and	  dead	  cells	   in	  an	  effort	  to	  restore	  homeostasis.	  Phagocytosis	   is	  the	  process	  
by	  which	  a	  cell	  engulfs	  a	  solid	  particle	  with	  its	  cytoplasm,	  leading	  to	  the	  formation	  of	  a	  
phagosome	  that	  will	  be	  internalized	  by	  a	  form	  of	  endocytosis	  (Kettenmann	  &	  Ransom	  
2013).	   In	   this	   state	   microglia	   take	   on	   an	   ameboid	   morphology	   with	   cytoplasmic	  
hypertrophy,	  shortened	  or	  absent	  processes	  and	  cell-­‐surface	  expression	  of	  CD68	  (Streit	  
et	  al.	  1999).	  Triggering	  microglial	  phagocytosis	   is	  dependent	  on	  the	  particle	  requiring	  
engulfing.	   	  Bacteria	  stimulate	  phagocytosis	  through	  Toll-­‐like	  receptor	  signalling	  which	  
promotes	   a	   pro-­‐inflammatory	   response,	   involving	   IL-­‐1,	   TNFα	   and	   NO	   production	  
(Ravichandran	  2003).	  Although	  this	  reaction	  is	  important	  to	  successfully	  eliminate	  the	  
infectious	  agent,	  when	  exaggerated	  it	  can	  cause	  damage	  to	  the	  neighbouring	  tissue	  in	  
the	  CNS.	   Invading	  microbes	   are	   further	   cleared	   through	  antigen	  presentation	  on	   the	  
cell	  surface	  via	  MHC	  class	  II	  molecules,	  contributing	  to	  a	  recruitment	  of	  CD4+	  helper	  T	  
cells	  (Mantegazza	  et	  al.	  2013).	  	  
Apoptotic	  neurons	  can	  also	  trigger	  microglial	  phagocytosis	  through	  firstly	  release	  
of	   ‘find-­‐me’	  signals	   to	   recruit	   the	  phagocyte	   to	   the	  proximity	  of	   the	  cell,	   followed	  by	  
exposure	   of	   ‘eat-­‐me’	   signals	   on	   the	   surface	   of	   the	   cell	   to	   initiate	   engulfment	  
(Ravichandran	   2010).	   The	   dying	   neuron	   releases	   factors	   such	   as	   ATP,	   ADP	   and	   UTP	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which	  mediate	  microglial	  chemotaxis	  and	  induce	  their	  migration	  towards	  the	  apoptotic	  
neuron	   (Davalos	   et	   al.	   2005).	   Once	   in	   the	   vicinity,	   the	   apoptotic	   neuron	   exposes	   an	  
‘eat-­‐me’	  signal,	  of	  which	  phosphatidylserine	  (PS)	  is	  the	  most	  universally	  observed	  and	  
best	   studied	   (Ravichandran	   2010).	   The	   localization	   of	   PS	   is	   maintained	   by	   an	   ATP-­‐
dependent	  aminophospholipid	  translocase	  (APLT),	  which	  can	  control	   the	  transport	  of	  
PS	   from	   the	   outer	   to	   the	   inner	   leaflet	   of	   the	   plasma	   membrane	   in	   healthy	   cells	  
(Zachowski	  et	  al.	  1986).	  In	  a	  dying	  neuron,	  PS	  is	  translocated	  to	  the	  outer	  leaflet.	  The	  
mechanism	  by	  which	   it	   does	   this	   is	   not	  well	   understood,	   but	   it	   has	   been	   associated	  
with	  a	  loss	  of	  APLT	  activity	  and	  calcium-­‐dependent	  movement	  of	  phospholipids	  across	  
the	  membrane	  (Bratton	  1997).	  PS	  is	  recognised	  by	  receptors	  on	  the	  phagocyte	  and	  it	  
can	   bound	   directly	   by	  members	   of	   the	   TIM	   family;	   1,3	   and	   4	   (DeKruyff	   et	   al.	   2010;	  
Rodriguez-­‐Manzanet	   et	   al.	   2010;	   Wong	   et	   al.	   2010),	   brain	   angiogenesis	   inhibitor	   1	  
(Park	   et	   al.	   2007)	   or	   Stabilin-­‐2	   (Park	   et	   al.	   2008).	   It	   can	   also	   be	   bound	   indirectly	   via	  
soluble	   bridging	   molecules	   such	   as	   milk	   fat	   globule	   EGF	   factor-­‐8	   (MGF-­‐E8)	   to	   ανβ3	  
integrins	  on	  the	  phagocyte	  (Hanayama	  et	  al.	  2002;	  Hanayama	  et	  al.	  2004),	  Gas	  6	  and	  
Protein	  S	  to	  Tyro-­‐3-­‐Axl-­‐Mer	  family	  of	  receptors	  (Scott	  et	  al.	  2001;	  Rothlin	  et	  al.	  2007).	  
Microglial	  phagocytosis	  of	  apoptotic	  neurons	  is	  not	  associated	  with	  a	  pro-­‐inflammatory	  
response	  but	  it	  is	  met	  with	  the	  secretion	  of	  anti-­‐inflammatory	  cytokines	  transforming	  
growth	   factor-­‐β	   (TGFβ)	  and	   interleukin-­‐10	   (IL-­‐10)	   (Savill	   et	   al.	   2002)	  which	   is	   ideal	   in	  





1.2	  Microglial	  mediators	  of	  neurotoxicity	  and	  neuroprotection	  
1.2.1	  Cytokines	  
	   Cytokines	  comprise	  a	  diverse	  group	  of	  small	  polypeptides	  ranging	  between	  8-­‐30	  
kDa	   in	   size,	  which	  work	   as	   signalling	  molecules	   to	   assist	   in	   the	   execution	   of	   cellular	  
activities.	   Cytokine	   production	   is	   rapidly	   upregulated	   in	   response	   to	   tissue	   injury,	  
infection	   or	   inflammation	   due	   to	   their	   important	   role	   in	   tissue	   repair	   (Smith	   et	   al.	  
2012).	   Depending	   on	   the	   action	   carried	   out	   in	   the	   peripheral	   tissue,	   they	   can	   be	  
grouped	   as	   either	   pro-­‐inflammatory	   or	   anti-­‐inflammatory	   cytokines.	   As	   mentioned,	  
microglia	  are	  constantly	  surveying	  their	  environment	  and	  react	   fast	   to	  signs	  of	   tissue	  
injury	   or	   pathogen	   infiltration,	   and	   cytokine	   production	   is	   one	   of	   the	   microglial	  
responses.	   These	   include	   interferons	   (IFN),	   interleukins	   (IL),	   tumour	   necrosis	   factors	  
(TNF),	  chemokines	  and	  growth	  factors	  (Allan	  &	  Rothwell	  2001).	  One	  of	  the	  most	  potent	  
stimuli	  for	  release	  of	  cytokines	  such	  as	  TNF-­‐α,	  IL-­‐1β	  and	  Il-­‐6	  from	  microglia	  is	  bacterial	  
endotoxin	  lipopolysaccharide	  (LPS),	  which	  is	  derived	  from	  the	  outer	  cell	  wall	  of	  gram-­‐
negative	   bacteria	   (Olson	   &	   Miller	   2004)	   and	   such	   cytokine	   release	   is	   mediated	   by	  
mitogen-­‐activated	  protein	  kinases	  (MAPKs),	  protein	  tyrosine	  kinases	  and	  transcription	  
factors	  such	  as	  nuclear	  factor	  KB	  (NFKB)	  (Qin	  et	  al.	  2005).	  Chronic	  microglial	  production	  
of	   IL-­‐1,	   IL-­‐6,	   TNFα	   and	   IFNγ	   have	   received	   considerable	   attention	   recently	   for	   their	  
roles	  in	  neurodegeneration	  (Panitch	  et	  al.	  1987;	  Hüll,	  Strauss,	  et	  al.	  1996;	  Collins	  et	  al.	  
2000;	   Simi	   et	   al.	   2007;	   Shaftel	   et	   al.	   2008).	   Cytokine	   production	   does	   not	   entirely	  
depend	   on	   microglia	   though,	   as	   astrocytes	   are	   implicated	   as	   another	   source	   of	  
cytokine	   production	   involved	   in	   CNS	   insult	   (Li	   et	   al.	   2011).	   An	   association	   between	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microglial	   cytokine	   production	   and	   AD	   has	   been	   supported	   by	   a	   number	   of	   studies	  
ranging	  from	  post-­‐mortem	  identification	  of	  pro-­‐inflammatory	  cytokines	  near	  AD	  lesion	  
sites	   (Griffin	   et	   al.	   1995;	   Hüll,	   Berger,	   et	   al.	   1996)	   to	   genetic	   studies	   linking	  
polymorphisms	  in	  genes	  encoding	  TNFα	  and	  IL-­‐1β	  to	  disease	  progression	  (Di	  Bona	  et	  al.	  
2008;	  Di	  Bona	  et	  al.	  2009).	  
	  
1.2.2	  Chemokines	  
	   Chemokines	   belong	   to	   a	   highly	   conserved	   superfamily	   of	   secreted	   proteins	   of	  
about	  8-­‐14	  kDa	  in	  size	  that	  can	  be	  classified	  into	  4	  main	  subfamilies:	  CXC,	  CC,	  CX3C	  and	  
XC.	   They	   are	   small	   cytokines	   that	   bind	   to	   G	   protein-­‐coupled	   receptors	   causing	  
conformational	  changes	  such	  as	  the	  separation	  of	  the	  G	  protein	  heterodimer	  into	  its	  α	  
and	  βγ	  subunits	   initiating	  several	  parallel	  signalling	  pathways.	  6	  of	   the	  40	  chemokine	  
receptors	  have	  been	   identified	   in	   the	  human	  CNS	   (CCR2,	  CCR3,	  CCR5,	  CXCR2,	  CXCR3	  
and	  CXCR4)	  with	  microglia	  among	  the	  cell	  types	  that	  have	  been	  identified	  as	  a	  source	  
of	  chemokines	  in	  the	  brain	  (Cartier	  et	  al.	  2005).	  They	  can	  be	  classified	  by	  their	  function	  
as	  either	   inflammatory	  or	  homeostatic	   chemokines,	  with	  expression	  of	   inflammatory	  
chemokines	   attracting	   immune	   cells	   to	   the	   site	   of	   inflammation	   in	   response	   to	   pro-­‐
inflammatory	   cytokines,	   and	   constitutively	   produced	   homeostatic	   chemokines	  
involved	   controlling	   the	   migration	   of	   cells	   in	   normal	   tissue	   maintenance	   or	  
development	  (Sallusto	  et	  al.	  2000).	  Chemokine	  receptors	  and	  an	  increased	  presence	  of	  
their	   ligands	   have	   been	   detected	   in	   a	   number	   of	   brain	   regions	   such	   as	   the	  
hippocampus,	  cortex,	  cerebellum	  and	  striatum	  in	  the	  AD	  brain	  with	  a	  couple	  (CCR3	  and	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CCR5)	  exhibiting	  an	  elevated	  expression	  on	  reactive	  microglia	  (Xia	  et	  al.	  1998;	  Cartier	  
et	  al.	  2005).	  
	  
1.2.3	  Neurotrophins	  
	   Microglia	  are	  also	  a	  source	  of	  neurotrophic	  factors	  which	  are	  a	  family	  of	  proteins	  
including	   nerve	   growth	   factor	   (NGF),	   brain	   derived	   neurotrophic	   factor	   (BDNF)	   and	  
neurotrophins	   3	   and	   4	   (NT-­‐3/4)	   that	   all	   bind	   separately	   to	   specific	   tyrosine	   kinase	  
receptors	   (Trks)	   to	   enhance	   neuronal	   survival	   (Hempstead	   2006;	   Allen	   et	   al.	   2011).	  
Since	  the	  1980’s	  the	  Neurotrophic	  Factor	  Hypothesis	  has	  linked	  NGF	  and	  BDNF	  to	  AD	  
with	  studies	  demonstrating	  an	  increase	  measurement	  of	  NGF	  in	  the	  AD	  brain	  (Crutcher	  
et	  al.	  1993;	  Scott	  et	  al.	  1995)	  and	  neuroprotective	  effects	  of	  BDNF	  in	  animal	  models	  of	  
AD	  (Nagahara	  et	  al.	  2009).	  
	  
1.2.4	  Nitric	  oxide	  
	   Nitric	  oxide	  (NO)	  is	  a	  small	  signalling	  molecule	  synthesized	  by	  a	  group	  of	  enzymes	  
known	  as	  nitric	  oxide	  synthases	  (NOS),	  of	  which	  there	  are	  four:	  neuronal	  NOS	  (nNOS)	  
and	   it’s	   isoform	  mitochondrial	   NOS	   (mtNOS),	   endothelial	   NOS	   (eNOS)	   and	   inducible	  
NOS	  (iNOS)	  (Guix	  et	  al.	  2005).	  NOS	  catalyzes	  the	  synthesis	  of	  NO	  from	  L-­‐arginine	  in	  the	  
presence	   of	   nicotinamide	   adenine	   dinucleotide	   phosphate	   oxidase	   (NADPH	   oxidase)	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nNOS	  and	  eNOS	  are	  Ca2+calmodulin-­‐dependent	  constitutively	  expressed	  enzymes	  with	  
short-­‐lasting	  release	  of	  picomoles	  of	  NO	  but	  iNOS	  is	  Ca2+calmodulin-­‐independent	  with	  
long-­‐lasting	  release	  of	  nanomoles	  of	  NO	  (Alderton	  et	  al.	  2001).	  Although	  not	  typically	  
expressed	   in	   the	   brain	   following	   immunological	   insult	   or	   inflammatory	   stimulation,	  
iNOS	  is	  expressed	  in	  microglia	  (Murphy	  2000).	  NO	  has	  a	  number	  of	  physiological	  roles	  
from	  diffusion	  and	  signalling	  to	  cytotoxic	  effects.	  iNOS	  mediated	  NO	  production	  causes	  
toxicity	   through	   inactivation	   of	   the	   mitochondrial	   respiratory	   complex	   I	   causing	  
apoptosis	   in	   the	   target	   cell	   (Brown	   &	   Borutaite	   2004).	   NO	   has	   been	   reported	   to	  
stimulate	   cyclooxygenase-­‐2	   (COX-­‐2),	   an	   inducible	   cyclooxygenase	   (COX)	   isoenzyme	  
thought	   to	  be	   involved	   in	   the	  pathogenesis	  of	  Alzheimer’s	  disease	   (Shin	  et	  al.	  2007),	  
through	  an	   increase	   in	   the	  production	  of	  pro-­‐inflammatory	  prostaglandins	   (Salvemini	  
et	  al.	  1993).	  NO’s	  reported	  toxic	  effects	  are	  however	  not	  likely	  to	  be	  mediated	  by	  NO	  
directly,	   they	  are	  more	   inclined	   to	  be	  due	   to	   it’s	  oxidation	  products	   (Dimmeler	  et	  al.	  
1992;	  Mohr	  et	  al.	  1994).	  Evidence	  suggests	  that	   it	   is	  the	  reaction	  of	  NO	  with	  another	  
free	   radical,	   the	   superoxide	   anion	   (O2
.-­‐),	   to	   produce	   peroxynitrite	   (ONOO-­‐)	   can	   be	  






	   Superoxide	  is	  a	  compound	  that	  contains	  O2
.-­‐,	  one	  of	  the	  reactive	  oxygen	  species	  
(ROS).	  O2
.-­‐	   is	  produced	  from	  molecular	  oxygen	  O2	   in	  the	  presence	  of	  NADPH	  oxidase,	  
COX,	  xanthine	  oxidase	  (XO)	  and	  NOS,	  and	  is	  a	  highly	  reactive	  species	  with	  the	  potential	  
to	  damage	  cells.	  Microglia	  express	  three	  isoforms	  of	  NADPH	  oxidase,	  Nox1,	  Nox2	  and	  
Nox4,	   therefore	   triggering	   the	   production	   of	   O2
.-­‐	   in	   microglia	   (Mead	   et	   al.	   2012a).	  
There	  are	  also	  antioxidant	  mechanisms	   in	  place	  such	  as	  superoxide	  dismutase	  (SOD),	  
which	  catalyses	  the	  dismutation	  of	  O2
.-­‐	  into	  O2	  and	  hydrogen	  peroxide	  (H2O2)	  which	  is	  
further	  catalyzed	  into	  water	  and	  oxygen	  by	  catalase	  and	  glutathione	  (Kamata	  &	  Hirata	  
1999;	  Klabunde	  2011)	  (Fig.	  1.3).	  
	  
Figure	  0.3:	  Metabolic	  pathways	  of	  reactive	  oxygen	  species.	  	  
Reactive	  oxygen	  species	  (ROS),	  such	  as	  O2
.-­‐,	  H2O2	  and	  OH
.	  are	  generated	  through	  several	  pathways	  in	  the	  cell.	  
Nitric	  oxide	  synthase	  (NOS)	  catalyses	  the	  conversion	  of	  L-­‐arginine	  (L-­‐Arg)	  to	  nitric	  oxide	  (NO)	  in	  the	  presence	  
of	  NADPH	  oxidase.	  NADPH	  oxidase,	  xanthine	  oxidase	   (XO),	  cycloxygenase	   (COX)	  and	  NOS	  contribute	   to	   the	  
generation	  of	  the	  superoxide	  anion	  (O2
.-­‐)	   from	  molecular	  oxygen	  (O2).	  The	  products	  of	  these	  two	  reactions,	  
O2.
.-­‐	  and	  NO-­‐	  can	  react	  to	  form	  highly	  toxic	  peroxynitrite	  (ONOO-­‐).	  Superoxide	  dismutase	  (SOD)	  converts	  O2.
.-­‐	  
into	  hydrogen	  peroxide	   (H2O2)	  which	   is	  mostly	  degraded	   to	  water	   (H2O)	  by	   catalase	  and	  glutathione	   (GSH)	  
peroxidase.	  H2O2	  also	  produces	  a	  highly	  reactive	  radical,	  OH
.	  by	  the	  Fenton	  or	  Haber-­‐Weiss	  reactions.	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   As	   previously	   mentioned	   O2
.-­‐	   quickly	   binds	   to	   NO	   which	   also	   has	   an	   unpaired	  
electron	   to	   form	   the	   highly	   toxic	   ONOO-­‐.	   Peroxynitrite	   oxidises	   proteins	   and	   other	  
macromolecules	  and	  also	  causes	  nitration	  of	  tyrosyl	  residues	  in	  proteins	  (Torreilles	  et	  
al.	   1999),	   therefore	   nitrosyl	   residue	   detection	   was	   used	   in	   a	   number	   of	   studies	   to	  
investigate	   a	   link	   between	   oxidative	   stress	   and	   a	   contribution	   to	   AD	   pathogenesis.	  	  
Region	  specific	  accumulation	  of	  these	  residues,	  with	  5	  to	  8-­‐fold	  greater	  concentrations	  
than	   in	   cognitively	   normal	   subjects	   have	   been	   seen	   in	   the	   AD	   brain	   (Hensley	   et	   al.	  
1998).	  There	  has	  also	  been	  evidence	  for	  the	  presence	  of	  nitrotyrosine	  in	  neurofibrillary	  
tangles	   (NFTs),	   one	   of	   the	   hallmarks	   of	   AD	   (Good	   et	   al.	   1996)	   further	   implicating	  
oxidative	  stress	  in	  AD	  pathogenesis.	  	  
	  
1.2.6	  Glutathione	  
	   Glutathione	  (GSH)	  is	  an	  anti-­‐oxidant	  that	  is	  produced	  by	  the	  cell	  to	  maintain	  the	  
redox	  state	  of	  the	  cell.	   It	  does	  this	  by	  serving	  as	  an	  electron	  donor	  to	  other	  unstable	  
molecules	  such	  as	  ROS,	  thereby	  converting	  it	  to	  its	  oxidised	  form	  glutathione	  disulfide	  
(GSSG),	   of	  which	   can	   be	   reduced	   back	   by	   glutathione	   reductase	   using	  NADPH	   as	   an	  
electron	   donor	   (Kamata	   &	   Hirata	   1999;	   Couto	   et	   al.	   2013).	   GSH	   eliminates	   H2O2,	  
previously	   generated	   from	  O2
.-­‐	   by	   SOD,	   and	   converts	   it	   to	   H2O	   (Fig.	   1.3).	   This	   redox	  
balance	  in	  the	  cell	  is	  important	  to	  maintain	  the	  health	  and	  survival	  of	  the	  cell.	  An	  age-­‐
related	  decline	  of	  GSH	   in	   rodents,	  has	  been	   found	   linked	  to	  a	  downregulation	  of	   the	  
enzyme	  required	  for	  GSH	  synthesis,	  glutamate	  cysteine	  ligase	  (Liu	  2002).	  Together	  with	  
the	   significant	   decrease	   in	   GSH	   observed	   in	   red	   blood	   cells	   of	   male	   AD	   patients	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suggests	   a	   possible	   contributor	   of	   GSH	   levels	   with	   AD	   pathology	   (Honglei	   Liu	   et	   al.	  
2004).	  
	  
1.3	  Alzheimer’s	  disease	  
Alzheimer’s	  disease	  (AD)	   is	  the	  most	  common	  form	  of	  dementia	  accounting	  for	  
50-­‐60%	  of	  all	  cases	  (Blennow	  et	  al.	  2006).	  According	  to	  the	  World	  Alzheimer’s	  Report	  
2010	  there	  are	  currently	  35.6	  million	  people	  worldwide	   living	  with	  the	  condition	  and	  
this	   is	   estimated	   to	   rise	   to	   65.7	   million	   people	   by	   2030	   (Alzheimer’s	   Disease	  
International,	  2010).	  In	  the	  United	  Kingdom	  alone	  this	  presents	  a	  huge	  socioeconomic	  
burden,	  with	  AD	   costing	   the	  UK	  economy	  £23	  billion	  per	   year	   (Alzheimer’s	  Research	  
Trust,	  2010).	  	  
AD	   typically	   involves	   slow	  progressive	  memory	  degeneration	  and	  deterioration	  
of	   other	   cognitive	   domains.	   Plaques	   composed	   of	   amyloid	   β	   (Aβ)	   and	   tangles	   of	  
hyperphospholyated	   tau	  are	   the	  universally	   accepted	  neuropathological	   hallmarks	  of	  
the	  disease	  (Blennow	  et	  al.	  2006).	  Senile	  plaques	  are	  primarily	  composed	  of	  Aβ	   in	   its	  
fibrillar	   form	   which	   can	   lead	   to	   a	   number	   of	   pathologies	   resulting	   in	   neuronal	  
dysfunction	  and	  neurodegeneration	  (Deshpande	  et	  al.	  2006).	  Aβ	  undergoes	  a	  number	  
of	   conformational	   changes	   prior	   to	   fibrillization	   which	   can	   also	   be	   toxic	   at	   lower	  
nanomolar	   concentrations	   (Sakono	   &	   Zako	   2010)	   and	   these	   soluble	   Aβ	   species,	  
consisting	  of	  forms	  such	  as	  monomers,	  oligomers	  and	  protofibrils,	  have	  been	  found	  in	  
the	   cerebrospinal	   fluid	   (CSF)	   of	   AD	   patients	   (Georganopoulou	   et	   al.	   2005).	   It	   is	  
important	   to	   note	   that	   different	   conformations	   of	   Aβ	   can	   contribute	   to	   the	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pathogenesis	   of	   AD	   though	   distinct	   mechanisms	   (Deshpande	   et	   al.	   2006).	   The	  
formation	   of	   Aβ	   through	   endopeptidase	   cleavages	   (discussed	   later)	   of	   the	   amyloid	  
precursor	   protein	   (APP)	   result	   in	   a	   number	   of	   Aβ	   species	   being	   formed.	   Aβ	   species	  
ending	  at	  position	  40	  being	  are	  the	  most	  abundant	  (Aβ40)	  but	  the	  slightly	  longer	  Aβ42	  is	  
the	  principle	  species	  deposited	  in	  the	  AD	  brain	  (Selkoe	  2001;	  Murphy	  &	  LeVine	  2010).	  
Aside	  from	  the	  C-­‐terminal	  variants	  (Aβ40	  and	  Aβ42),	  N-­‐terminally	  truncated	  species	  such	  
as	  pyroGlu-­‐3	  Aβ	  and	  pyroGlu-­‐11	  Aβ,	  have	  also	  been	  frequently	  found	  in	  the	  AD	  brain	  
(Frost	  et	  al.	  2013).	  It	  should	  also	  be	  noted	  that	  neurodegeneration	  has	  been	  shown	  to	  
occur	  within	   AD	   regions:	   the	   hippocampus,	   temporal	   lobe,	   frontal	   lobe	   and	   parietal	  
lobe,	  regardless	  of	  Aβ	  deposition	  suggesting	  that	  other	  features	  of	  AD	  pathology	  may	  
be	  important	  during	  the	  preclinical	  stages	  of	  the	  disease	  (Wirth	  et	  al.	  2013).	  	  
Death	   of	   the	   patient	   typically	   occurs	   between	   3	   to	   9	   years	   after	   diagnosis	  
(Querfurth	   &	   LaFerla	   2010).	   Alzheimer’s	   disease	   can	   be	   divided	   into	   early-­‐onset	   AD	  
(EOAD)	  and	   late-­‐onset	  AD	   (LOAD),	  a	  classification	   that	   is	  usually	  distinguished	  by	   the	  
presence	   of	   the	   first	   disease	   symptoms	   before	   or	   after	   the	   age	   of	   65	   respectively	  
(Kowalska	   2004).	   There	   are	   both	   non-­‐genetic	   and	   genetic	   risk	   factors	   for	   the	  
development	   of	   AD.	   Increasing	   age	   is	   the	   greatest	   known	   risk	   factor	   for	   the	  
development	   of	   AD,	   which	   along	   with	   cerebrovascular	   disease	   and	   type	   II	   diabetes	  
mellitus	  have	  been	  reported	  as	  non-­‐genetic	  risk	  factors	  for	  the	  disease	  (Luchsinger	  et	  
al.	  2001;	  Lindsay	  et	  al.	  2002;	  Reitz	  &	  Mayeux	  2014).	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  Familial	  EOAD	  is	  typically	  inherited	  in	  an	  autosomal	  dominant	  fashion	  and	  three	  
genes	   have	   been	   found	   to	   harbour	   AD	   causative	   mutations:	   the	   amyloid	   precursor	  
protein,	   presenilin	   1	   and	   presenilin	   2	   genes	   (Bekris	   et	   al.	   2010).	   Until	   recently	   the	  
genetics	   of	   LOAD	   were	   not	   well	   understood	   and	   the	   ε4	   allele	   of	   Apolipoprotein	   E	  
(ApoE)	  was	  the	  only	  confirmed	  risk	  factor	  (Chartier-­‐Harlin	  et	  al.	  1994).	  However,	  recent	  
genome-­‐wide	  association	  studies	  (GWAS)	  have	  indicated	  common	  genetic	  variations	  in	  
CLU,	   CR1,	   TREM2,	   PICALM,	  ABCA7,	   BIN1,	   EPHA1,	   CD33,	   CD2AP	   and	   the	  MS4A	   gene	  
cluster	   as	   additional	   risk	   factors	   for	   the	   development	   of	   LOAD	   (Harold	   et	   al.	   2009;	  
Lambert	  et	  al.	  2009;	  Hollingworth	  et	  al.	  2011;	  Naj	  et	  al.	  2011;	  Guerreiro	  et	  al.	  2012).	  
The	  finding	  of	  complement	  receptor	  1	  (CR1)	  and	  CLU	  by	  GWAS	  suggests	  a	  central	  role	  
for	  complement	  in	  AD	  pathogenesis.	  
	  
1.4	  Complement	  receptor	  1	  gene	  
CR1	   is	   found	   on	   chromosome	   1	   at	   the	   locus	   1q32	   in	   a	   genetic	   cluster	   of	  
complement	   related	   proteins	   (Weis	   et	   al.	   1987).	   Membrane-­‐bound	   complement	  
regulatory	  proteins	  have	  evolved	  from	  the	  same	  structural	  and	  functional	  domain,	  the	  
short	   consensus	   repeat	   (SCR),	   comprised	   of	   roughly	   60	   amino	   acids	   each	  which	   are	  
further	   grouped	   into	   four	   long	   homologous	   repeats	   (LHRs)	   (Jacobson	  &	  Weis	   2008).	  
Four	  alleles	  of	  different	  sizes	  are	  known	  and	  the	  variation	  is	  due	  to	  genetic	  duplications	  
and	  deletions	  (Krych-­‐Goldberg	  et	  al.	  2002).	  This	  is	  a	  process	  thought	  to	  arise	  as	  a	  result	  
of	   imprecise	  chromosome	  crossing	  over	   (Holers	  et	  al.	  1987).	  The	  different	  alleles	  are	  
known	  by	  different	  names	  depending	  on	  the	  group	  studying	  them.	  The	  smaller	  alleles	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are	   known	   in	   ascending	   order	   of	   size	   as	   CR1-­‐C	   or	   CR1-­‐F’	   (160kDa);	   CR1-­‐A	   or	   CR1-­‐F	  
(190kDa);	  CR1-­‐B	  or	  CR1-­‐S	  (220kDa);	  and	  CR1-­‐D	  (250kDa).	  	  
The	   relative	   frequencies	   of	   the	   four	   alleles	   vary	   only	   slightly	   between	  
populations	   (Wong	   1990).	   The	   most	   frequent	   alleles	   are	   CR1-­‐A/F	   and	   CR1-­‐B/S.	   In	  
Caucasians	   these	   alleles	   have	   frequencies	   of	   0.87	   and	   0.11	   respectively.	   This	   is	  
different	  to	  0.82	  and	  0.11	  in	  African	  Americans,	  0.89	  and	  0.11	  in	  Mexicans	  (Moulds	  et	  
al.	  1996)	  and	  0.916	  and	  0.084	  in	  Asian	  Indians	  (Katyal	  et	  al.	  2003).	  The	  remaining	  two	  
alleles,	   CR1-­‐C/F’	   and	   CR1-­‐D	   are	   infrequent	   in	   all	   populations	   (Eikelenboom	   &	   FC	   C.	  
Stam	  1982;	  Wong	  et	  al.	  1983;	  Moulds	  et	  al.	  1996).	  The	  relative	  scarcity	  of	  the	  smallest	  
and	   largest	   alleles	   is	   likely	   due	   to	   population	   selection	   effects	   which	   can	   confer	   a	  
survival	   advantage,	   such	   as	   resistance	   to	  Mycobacterium	   tuberculosis	   (Noumsi	   et	   al.	  
2011).	  
Although	   the	   differences	   between	   these	   alleles	   seem	   large,	   the	   functional	  
differences	   in	   the	   resultant	  proteins	  are	  apparently	   subtle.	   The	   increased	  number	  of	  
LHR	   regions	   means	   that	   the	   larger	   alleles	   (CR1-­‐B/S	   and	   CR1-­‐D)	   have	   an	   additional	  
C3b/C4b	   binding	   site	   (Fig.	   1.4).	   The	   smaller	   CR1-­‐C/F’	   allele	   has	   only	   one	   of	   these	  
binding	  sites	  and	  although	  the	  functional	  implication	  of	  this	  is	  unclear	  there	  seems	  to	  
be	   some	   sort	   of	   loss	   of	   function	   associated	   with	   this	   allele	   (Wong	   1990;	   Liu	   &	   Niu	  
2009).	  Brouwers	  et	  al.,	  (2011)	  showed	  an	  association	  between	  one	  of	  the	  isoforms	  of	  
CR1,	  CR1-­‐B/S,	  and	  AD	  risk.	  CR1-­‐S	  contains	  an	  extra	  binding	  site	  for	  C3b/C4b	  therefore	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suggesting	  increased	  complement	  activity	  and	  AD	  risk	  in	  these	  carriers	  (Brouwers	  et	  al.	  
2011).	  
	  
1.5	  Species	  homology	  of	  CR1	  
Human	  and	  mouse	  CR1	  are	  produced	  differently	  however	  we	   know	   that	   there	  
are	  similarities	  between	  both,	  such	  as	  mouse	  CR1	  containing	  six	  N-­‐terminal	  SCRs	  which	  
are	  homologous	  to	  1-­‐6	  of	  human	  CR1	  SCRs.	  The	  expression	  and	  distribution	  of	  CR1	  in	  
humans	  and	   rodents	   contrast	  because	  human	  CR1	   is	  encoded	  by	  a	   separate	  gene	   to	  
human	  CR2,	  but	  murine	  CR2	  encodes	  both	  CR1	  and	  CR2	  (Kurtz	  et	  al.	  1990;	  Molina	  et	  al.	  
1990).	  However	  the	  protein	  sequence	  and	  function	  of	  the	  murine	  specific	  gene,	  CR1-­‐
related	  protein	  Y	  (Crry),	  displays	  more	  likeness	  to	  human	  CR1	  than	  mouse	  CR1	  (Killick	  
et	   al.	   2012).	   In	   addition,	   the	   structure	  of	   rat	   CR1	  may	  be	   closer	   to	   human	  CR1	   than	  
Figure	  0.4:	  Schematic	  showing	  the	  exon	  structure	  of	  the	  major	  CR1	  alleles.	  
Analogous	   exons	   are	   represented	   by	   the	   same	   colour.	   Previously,	   different	   names	   have	  
been	   used	   to	   describe	   the	   major	   isoforms	   of	   CR1.	   (A)	   The	   exons	   of	   the	   CR1-­‐A	   allele	  
otherwise	  known	  as	  the	  F	  isoform	  or	  the	  L	  allele.	  This	  CR1	  coding	  region	  includes	  low-­‐copy	  
repeats	  (LCRs),	  LCR	  1	  and	  LCR	  2.	  (B)	  The	  exons	  of	  the	  CR1-­‐B	  allele	  otherwise	  known	  as	  the	  
S-­‐isoform,	  or	  the	  H	  allele.	  This	  allele	  contains	  the	  LCRs,	  LCR1,	  LCR2	  and	  additional	  LCR1’.	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mouse	  as	  demonstrated	   in	  a	  study	  using	  a	  nucleotide	  probe	  for	  SCR	  11-­‐14	  of	  human	  




1.6	  The	  Complement	  system	  
The	   complement	   system	   is	   composed	   of	   a	   series	   of	   soluble	   and	   membrane-­‐
associated	  proteins	  present	  in	  the	  blood,	  which	  play	  a	  role	  in	  host	  defence	  through	  the	  
identification,	   opsonisation	   and	   lysis	   of	   pathogenic	   targets	   (Morgan	  &	  Gasque	   1996;	  
Yasojima	  et	  al.	  1999;	  Dunkelberger	  &	  Song	  2010).	  	  Activation	  of	  complement	  leads	  to	  
an	   enzymatic	   cascade	  whereby	   one	   protein	   promotes	   the	   sequential	   binding	   of	   the	  
following	   protein	   (Sarma	   &	   Ward	   2010).	   There	   are	   three	   pathways	   through	   which	  
complement	  activation	  can	  occur:	  classical,	   lectin	   and	  alternative	   (Fig.	  1.5).	  Although	  
these	   pathways	   depend	   on	   different	   binding	   molecules	   for	   their	   initiation,	   they	   all	  
ultimately	   lead	   to	   the	   production	   of	   complement	   3	   (C3)	   convertase	   which	   is	  
responsible	  for	  the	  actions	  of	  complement	  (Murphy	  et	  al.	  2008).	  The	  initiation	  of	  the	  
classical	   pathway	   involves	   the	   binding	   of	   C1q,	   the	   first	   protein	   in	   the	   complement	  
cascade,	   to	  an	  antigen-­‐bound	  antibody	   complex	   (IgG	  or	   IgM)	   to	  either	   the	  pathogen	  
surface	  or	  to	  the	  C-­‐reactive	  protein	  bound	  to	  the	  pathogen	  leading	  to	  the	  generation	  
of	   the	   protease	   C3	   convertase	   through	   C4	   and	   C2	   cleavage	   (Dunkelberger	   &	   Song	  
2010).	   Lectin	   pathway	   activation	   involves	   carbohydrate	   binding	   proteins	   such	   as	  
mannose-­‐binding	  lectin	  (MBL)	  or	  Ficolin	  binding	  to	  carbohydrate	  elements	  present	  on	  
39	  
	  
the	  surface	  of	  pathogens,	  further	  leading	  to	  the	  production	  of	  C3	  convertase	  (Sørensen	  







Figure	  0.5:	  Pathways	  activating	  and	  inhibiting	  complement.	  
The	  three	  complement	  activation	  pathways	  converge	  at	  the	  formation	  of	  the	  enzyme	  C3	  convertase	  (or	  
C4b/C2a),	  activation	  of	  which	  leads	  to	  the	  formation	  of	  C3b,	  the	  ligand	  for	  complement	  receptor	  1	  (CR1,	  
also	   known	   as	   CD35).	   Activation	   of	   the	   complement	   pathways	   can	   ultimately	   lead	   to	   the	   release	   of	  
inflammatory	  mediators,	  opsonisation	  of	  pathogens,	  and	  the	  membrane	  attack	  complex	  (MAC).	  The	  C1	  
complex	   of	   the	   classical	   complement	   pathway	   is	   comprised	   of	   C1q,	   C1r	   and	   C1s.	   The	   endogenous	  
complement	   C1	   inhibitor/C1-­‐esterase	   inhibitor	   (C1-­‐Inh),	   which	   regulates	   the	   activation	   of	   the	   C1	  
complex,	   is	   decreased	   in	   AD.	   C5b,	   C6,	   C7,	   C8	   and	   C9	   form	   the	   MAC	   complex	   in	   the	   alternative	  
complement	  activation	  pathway.	  CD59,	  an	  endogenous	  regulator	  of	  the	  MAC	  complex,	   is	  decreased	  in	  
AD	   whilst	   C9	   may	   be	   increased.	   Levels	   of	   Factor	   H,	   a	   regulatory	   glycoprotein	   of	   the	   alternative	  
complement	  cascade,	  may	  also	  be	  perturbed	  in	  AD.	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The	   third	   pathway,	   the	   alternative	   pathway,	   is	   different	   in	   that	   there	   is	   a	  
constant	   low	   level	   of	   activation	  due	   to	   the	   spontaneous	  hydrolysis	   of	   C3	   to	  C3(H2O)	  
and	   this	   forms	   C3	   convertase	   through	   the	   cleavage	   of	   Factor	   B	   by	   Factor	   D	   and	  
positively	   and	   negatively	   regulated	   by	   the	   protein	   properdin	   and	   factor	  H	   (Qu	   et	   al.	  
2009).	  C3	  convertase,	  the	  protease	  formed	  by	  all	  three	  complement	  pathways,	  further	  
binds	  to	  the	  pathogen	  surface	  to	  cleave	  C3,	  generating	  C3b	  which	  serves	  as	  a	  ligand	  for	  
complement	  receptor	  1	  (CR1)	  (Liu	  &	  Niu	  2009).	  CR1	  does	  not	  have	  enzymatic	  activity,	  
however,	  along	  with	  factor-­‐H,	  a	  co-­‐factor	  for	  plasma	  factor	  I,	  it	  is	  able	  to	  convert	  C3b	  
to	  iC3b	  (Tuveson	  et	  al.	  1991;	  Holers	  2014).	  
	  
1.7	  Complement	  and	  Alzheimer’s	  disease	  
Although	   the	   recruitment	   of	   phagocytes	   and	   the	   destruction	   of	   pathogenic	  
targets	  by	  complement	  activation	  are	  in	  the	  main	  beneficial,	  under	  certain	  conditions,	  
these	   processes	  may	   prove	   harmful.	   Classical	  markers	   of	   immune-­‐mediated	   damage	  
have	  been	   identified	   in	  AD	  brains	   including	  major	  histocompatability	   complex	   class	   I	  
(MHC-­‐I)	   and	   II	   (MHC-­‐II)	   positive	   microglia	   (McGeer	   et	   al.	   1987;	   Tooyama	   1990;	  
Perlmutter	   et	   al.	   1992),	   glial	   cells	   expressing	   inflammatory	   cytokines	   (Griffin	   et	   al.	  
1989)	  and	  the	  acute	  phase	  protein	  α1-­‐antichymotrypsin	  (Abraham	  1988).	  Early	  studies	  
identified	  complement	  proteins	  of	  the	  classical	  pathway	  in	  AD	  brains	  (Eikelenboom	  &	  
FC	  C.	  Stam	  1982)	  and	  subsequent	  studies	  established	  the	  presence	  of	  all	  of	  the	  native	  
complement	  proteins	  as	  well	  as	  their	  activation	  products	  C4d,	  C3d,	  and	  the	  membrane	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attack	  complex	  (MAC)	  in	  AD	  brain	  (Yasojima	  et	  al.	  1999).	  However,	  the	  lack	  of	  classical	  
immune	  complexes,	  lead	  to	  the	  search	  for	  other	  complement	  activators.	  Rogers	  et	  al.,	  
(1992)	   demonstrated	   that	   Aβ	   was	   able	   to	   bind	   and	   activate	   C1q,	   the	   classical	  
complement	  cytolytic	  pathway,	  and	  that	  this	  occurred	  in	  the	  absence	  of	  antibody,	  and,	  
furthermore,	  that	  such	  complement	  activation	  was	  localised	  to	  areas	  of	  AD	  pathology.	  
C1q	  was	  subsequently	  shown	  to	  be	  intimately	  associated	  with	  Aβ	  plaques	  (Afagh	  et	  al.	  
1996).	   Studies	   have	   shown	   that	   Aβ42	   can	   bind	   to	   erythrocyte	   CR1	   through	   a	   C3b-­‐
dependent	   mechanism	   suggesting	   that	   there	   may	   be	   peripheral	   clearance	   of	   Aβ	  
occuring	  in	  the	  body	  (Rogers	  et	  al.	  2006).	  Although	  the	  primarily	  identified	  function	  of	  
CR1	  on	  erythrocytes	  is	  to	  bind	  complement	  tagged	  particles	  for	  their	  removal	  through	  
the	  liver	  and	  spleen,	  it	  has	  been	  shown	  that	  PDZ	  domains	  in	  CR1’s	  cytoplasmic	  tail	  bind	  
to	   PDZ	   domains	   of	   the	   scafolding	   protein	   Fas-­‐associated	   phosphate	   1	   (FAP-­‐1),	  
suggesting	   a	   means	   by	   which	   CR1	   can	   interact	   with	   the	   cytoskeleton	   (Ghiran	   et	   al.	  
2008a).	   The	   search	   for	  antibody-­‐independent	  activators	  of	   the	  complement	  pathway	  
continued	   with	   the	   investigation	   of	   tau,	   the	   primary	   protein	   component	   of	  
neurofibrillary	   tangles.	   Shen	   et	   al.,	   (2001)	   demonstrated	   complement	   activation	   by	  
neurofibrillary	   tangle	  material	   extracted	   from	  AD	  brains,	   and	   furthermore	  by	  human	  
recombinant	   tau.	   The	   ability	   of	   Aβ	   plaques	   and	   neurofibrilliary	   tangles,	   classical	  
hallmarks	   of	   AD,	   to	   activate	   the	   complement	   pathway	   may	   contribute	   towards	   an	  
explanation	   for	   low	   levels	   of	   inflammation	   observed	   throughout	   the	   disease	   course.	  
Although	  most	  research	  on	  complement	  activation	  in	  AD	  has	  focussed	  on	  the	  classical	  
pathway,	   alternative	  pathway	   activation	   also	  occurs,	   since	   the	  presence	  of	  mRNA	  of	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the	  essential	  alternative	  pathway	  element,	  factor	  B,	  has	  been	  observed	  in	  the	  frontal	  
cortex	  of	  the	  AD	  brain	  (Strohmeyer	  2000).	  
	  
1.7.1	  Membrane	  attack	  complex	  
The	  membrane	  attack	  complex	  (MAC)	  is	  a	  macromolecular	  complex	  consisting	  of	  
a	   number	   of	   complement	   components;	   C5b,	   C6,	   C7,	   C8	   and	   several	   C9	   molecules	  
whose	   function	   is	   to	  allow	   the	   influx	  of	  Ca+	   though	   its	   ring-­‐like	   structure	   resulting	   in	  
lysis	   of	   the	   target	   cell	   (Kim	   et	   al.	   1987).	  Most	   cells	   express	   complement	   defence	   59	  
(CD59)	   and	   this	   provides	   protection	   against	   MAC	   as	   the	   glycophosphinositol	   (GPI)-­‐
anchored	   membrane	   protein	   prevents	   the	   complete	   assembly	   and	   insertion	   of	   the	  
complex	  into	  the	  membrane	  (Meri	  et	  al.	  1990).	  The	  hippocampus	  and	  frontal	  cortex	  of	  
AD	  patients	   display	   significantly	   less	   CD59	   expression	   compared	  with	   non-­‐demented	  
control	  brains	  (Yang	  et	  al.	  2000)	  although	  evidence	  for	  changes	  in	  CD59	  expression	  in	  
AD	  remain	  inconclusive(McGeer	  et	  al.	  1989;	  McGeer	  et	  al.	  1991).	  	  
	  
1.7.2	  C1q	  
C1q	  is	  the	  initiating	  protein	  of	  the	  classical	  complement	  cascade	  that	  is	  known	  to	  
be	  expressed	   in	  AD	  brains	   (Eikelenboom	  &	  FC	  C.	   Stam	  1982;	  Afagh	  et	   al.	   1996).	   The	  
role	  of	  C1q	   in	  AD	  has	  been	  experimentally	  addressed	   in	  studies	  using	  animal	  models	  
deficient	   in	   the	   protein.	   One	   such	   study	   involved	   the	   crossing	   of	   C1q-­‐deficient	  mice	  
with	   a	   Tg2576	   mouse	   model	   which	   exhibits	   an	   age-­‐dependent	   increase	   in	   Aβ,	  
dystrophic	  neurites	  and	  activated	  glial	   cells	   (microglia	  and	  astrocytes)	   (Fonseca	  et	  al.	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2004).	   These	   authors	   reported	   that	   the	   number	   of	   activated	   glia	   surrounding	   Aβ	  
plaques	  was	   lower	   in	  the	  C1q-­‐deficient	  mice	  compared	  with	  the	  AD	  mouse	  model.	   In	  
addition	  there	  was	  a	  reduction	  in	  the	  loss	  of	  synaptophysin	  and	  MAP2	  compared	  with	  
Tg2576	  control	  mice	  (Fonseca	  et	  al.	  2004),	  leading	  to	  the	  conclusion	  that	  C1q	  may	  have	  
a	   harmful	   effect	   on	   the	   integrity	   of	   the	   neuron	   through	   initiating	   an	   inflammatory	  
response.	   C1q-­‐deficient	   mice	   also	   exhibited	   reduced	   retinal	   synapse	   elimination	   in	  
mouse	  models	   of	   glaucoma,	   leading	   to	   proposals	   that	   C1q	  mediates	   synapse	   loss	   in	  
other	   neurodegenerative	   diseases	   (Stevens	   et	   al.	   2007).	   Sárvári	   et	   al.,	   (2003),	  
investigating	   the	   effects	   on	   hippocampal	   cells	   of	   the	   C1	   complex	   inhibitor,	   C1-­‐Inh,	  
showed	   that	   inhibition	   of	   C1q	   protected	   hippocampal	   cells	   from	   Aβ-­‐induced	  
complement	  lysis.	  Neurons	  in	  the	  hippocampus	  and	  in	  the	  cortex	  are	  more	  vulnerable	  
to	  complement-­‐mediated	  damage	  as	  they	  are	  low	  in	  the	  complement	  inhibitors	  which	  
usually	   protect	   host	   tissue	   from	   complement	   lysis	   (Singhrao	   et	   al.	   2000),	   but	  
conversely	  are	  abundant	  sources	  of	  complement	  (Terai	  et	  al.	  1997).	  Since	  these	  are	  the	  
two	  brain	  areas	  which	  correlate	  with	  AD	  pathology,	   this	  may	  explain	  why	  analysis	  of	  
CSF	  of	  AD	  patients	  indicated	  significantly	  lower	  C1q	  levels	  compared	  with	  control	  CSF	  
and	  decreased	   levels	  of	  C1q	  correlate	  with	  a	  diminished	  cognitive	  function	  (Smyth	  et	  
al.	  1994).	  
	  
1.8	  Complement	  sources	  and	  functions	  
Complement	  can	  enter	   the	  brain	  via	  a	   compromised	  blood-­‐brain	  barrier	   (BBB).	  
Increasing	  evidence	  suggests	  BBB	  dysfunction	  is	  an	  early	  event	  in	  AD	  (Gay	  &	  Esiri	  1991;	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Alafuzoff	   et	   al.	   1987;	   Claudio	   1995;	   Fiala	   et	   al.	   2002;	   Minagar	   &	   Alexander	   2003;	  
Bowman	   &	   Quinn	   2008).	   This	   may	   potentiate	   the	   triggering	   of	   detrimental	   brain	  
parenchymal	  signalling	  cascades	  by	  blood	  components	  including	  serum	  factor	  proteins	  
such	   as	   albumin	   and	   fibrinogen	   (Hooper	   et	   al.	   2009;	   Piers	   et	   al.	   2011),	   as	   well	   as	  
complement.	  Additionally	  the	  presence	  of	  MAC	  component	  mRNA	  and	  proteins	  in	  the	  
AD	  brain	  has	  been	  reported,	  suggesting	  a	  possible	  CNS	  origin	  of	  synthesis	  (Shen,	  Li,	  et	  
al.	  1997;	  Van	  Beek	  et	  al.	  2000;	  Walker	  et	  al.	  1995).	  Neurons	  are	  an	  abundant	  source	  of	  
complement	   proteins	   (Terai	   et	   al.	   1997),	   and	   the	   expression	   of	   complement	   protein	  
mRNA	  has	  been	  observed	  on	  murine	  astrocytes	  and	  microglia	  (Davoust	  et	  al.	  1999)	  and	  
in	   post-­‐mortem	   derived	   human	   CNS	   microglia	   (Walker	   et	   al.	   1995).	   	   Furthermore,	  
astrocytoma	  cell	   lines,	  astrocytes,	  and	  oligodendroglial	  cells	  have	  also	  been	  shown	   in	  
vivo	   and	   in	   vitro	   to	   produce	   complement	   proteins,	   indicating	   glial	   cells	   as	   another	  
potential	   source	   of	   complement	  within	   the	   brain	   (Gasque	   et	   al.	   1993;	  Walker	   et	   al.	  
1998;	  Hosokawa	  et	  al.	  2003;	  Rutar	  et	  al.	  2011).	  	  
The	  role	  of	  complement	  in	  the	  elimination	  of	  pathogens	  by	  phagocytic	  recruitment	  and	  
opsonisation	  occurs	  through	  binding	  with	  complement	  receptors	  (Frank	  &	  Fries	  1991;	  
McGreal	  &	  Gasque	  2002).	  
	  
1.9	  Microglia	  and	  Alzheimer’s	  disease	  
Microglia,	  resident	  in	  normal	  brain	  as	  sentinel	  cells	  (Raivich	  2005;	  Vilhardt	  2005;	  
Kettenmann	  et	  al.	  2011),	  become	  reactive	  in	  AD	  (Pocock	  et	  al.	  2002).	  In	  AD,	  microglia	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surround	   damaged	   or	   dead	   cells,	   clear	   cellular	   debris	   and	   predominate	   around	   Aβ	  
plaques	  (Fetler	  &	  Amigorena	  2005).	  Microglia	  proliferate	  around	  neurons	  prior	  to	  their	  
loss	  in	  murine	  models	  of	  AD	  (Fuhrmann	  et	  al.	  2010).	  A	  positron	  emission	  tomography	  
(PET)	   study	   detecting	   both	   activated	   microglia	   and	   an	   increase	   in	   amyloid	   load,	  
correlated	  the	  increase	  in	  activated	  microglia	  with	  cognitive	  impairment	  (Edison	  et	  al.	  
2008).	   	   Microglia	   in	   animal	   models	   of	   AD	   show	   reactivity	   before	   obvious	   amyloid	  
plaque	  deposition	  (Rodríguez	  et	  al.	  2010),	  indicating	  an	  early,	  “silent	  “	  (preclinical	  and	  
asymptomatic)	  response	  of	  microglia	  may	  occur	  in	  AD	  by	  as	  yet	  unconfirmed	  triggers.	  	  
These	   may	   include	   amyloid	   oligomers	   and	   hypoperfusion	   (Ferretti	   &	   Cuello	   2011;	  
Huang	   et	   al.	   2002),	   but	   also	   complement.	   Complement	   activation	   and	   activated	  
microglia	  are	  early	  neuropathogical	  events	  in	  AD	  brains	  (Eikelenboom	  et	  al.	  2012),	  and	  
microglial	  responses	  show	  similarity	  to	  the	  peripheral	  immune	  system	  reaction	  of	  the	  
macrophage.	  Activation	  products	  of	  the	  early	  complement	  components	  C1,	  C4,	  and	  C3	  
are	   found	   within	   neuritic	   plaques	   but	   there	   is	   little	   evidence	   of	   late	   complement	  
components	   C7	   and	   C9	   or	   of	   MAC	   in	   the	   neuropathological	   lesions	   in	   AD	   brains	  
(Eikelenboom	  &	   Veerhuis	   1996).	   This	   finding	   leads	   to	   the	   suggestion	   that	   in	   AD	   the	  
complement	   system	   does	   not	   act	   as	   an	   inflammatory	   mediator	   through	   MAC	  
formation,	  but	   through	  the	  actions	  of	   the	  early	  complement	  products	  which	   fuel	   the	  
inflammatory	  responses,	  leading	  to	  neurotoxicity	  (Eikelenboom	  &	  Veerhuis	  1996).	  	  
	  
It	   is	  thus	  increasingly	  the	  accepted	  dogma	  that	  inflammation	  can	  actively	  cause	  
neuronal	   damage	   and	   ultimately	   death	   of	   the	   neuron	   ultimately	   driving	   the	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progression	  of	  AD	  (Block	  &	  Hong	  2005;	  McGeer	  &	  McGeer	  2013).	  Recent	  findings	  that	  
the	  responsiveness	  of	  the	  innate	  immune	  system	  is	  higher	  in	  offspring	  with	  a	  parental	  
history	   of	   late-­‐onset	   AD,	   indicates	   heritable	   traits	   for	   AD	   that	   are	   related	   to	  
inflammatory	   processes	   (Eikelenboom	   et	   al.	   2011).	   	   Furthermore	   the	   correlation	   of	  
higher	  serum	  levels	  of	  certain	  acute-­‐phase	  proteins	  with	  cognitive	  decline	  or	  dementia,	  
provide	   additional	   evidence	   for	   the	   early	   involvement	   of	   inflammation	   in	   AD	  
pathogenesis	  (Eikelenboom	  et	  al.	  2011).	  
	  
Microglial	   reactivity	   is	   generally	   beneficial	   but	   the	   prolonged	   and	  progressive	  
nature	  of	   the	  microglial	   response	   in	  AD	  can	  promote	  neurodegeneration.	  Pathogenic	  
input	  to	  microglia,	  including	  the	  enhanced	  deposition	  of	  Aβ	  peptides,	  can	  result	  in	  the	  
production	   of	   excessive	   free	   radicals,	   pro-­‐inflammatory	   cytokines,	   complement	  
proteins	   and	   glutamate	   (Davenport	   et	   al.	   2010;	   Morales	   et	   al.	   2010).	   	   Amyloid	  
precursor	   protein	   (APP)	   is	   an	   integral	   membrane	   protein	   whose	   cleavage	   by	   two	  
enzymes,	   β-­‐	   and	   γ-­‐secretase,	   results	   in	   the	   formation	   of	   Aβ	   (Velliquette	   et	   al.	   2005)	  
which	   can	   behave	   as	   a	   microglial	   activator	   (Barger	   &	   Harmon	   1997).	   Additional	  
evidence	   supporting	   the	  view	   that	  microglia	   are	  active	  mediators	  of	  AD	   includes	   the	  
use	   of	   synthetic	   Aβ	   in	   the	   investigation	   of	   microglia-­‐plaque	   interactions.	   The	   10-­‐16	  
amino-­‐acid	  domain	  of	  human	  Aβ	  is	  critical	  for	  microglial	  activation	  and	  binding	  (Giulian	  
et	  al.	  1996).	  A	  number	  of	  receptors	  have	  been	  implicated	  as	  essential	  for	  microglial-­‐Aβ	  
interaction,	  including	  CD14	  which	  is	  required	  for	  the	  recognition	  and	  destruction	  of	  Aβ	  
damaged	  neurons	  by	  microglia	  (Bate	  et	  al.	  2004),	  and	  a	  cell	  surface	  receptor	  complex	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comprised	  of	  the	  scavenger	  receptor	  CD36,	  α6-­‐β1	  integrin	  and	  CD47	  (Koenigsknecht	  &	  
Landreth	   2004).	   This	   complex	   is	   responsible	   for	   the	   induction	   of	   phagocytosis	   and	  
subsequent	   internalisation	   of	   Aβ	   through	   a	   mechanism	   distinct	   from	   the	   classical	  
phagocytic	  mechanisms	  (Koenigsknecht	  &	  Landreth	  2004).	  
	  
Consequences	   of	   the	   attenuation	   of	   inflammation	   in	   AD	   are	   seen	   clearly	   in	  
animal	  studies.	  Craft	  et	  al.,	  (2004)	  demonstrated	  that	  inhibition	  of	  glial	  inflammation	  in	  
an	   animal	   AD	   model	   resulted	   in	   reduced	   neurotoxicity.	   Advanced	   glycation	   end	  
product	   (AGE)	   accumulation	   is	   accelerated	   in	   AD	   as	   it	   accumulates	   on	   plaques,	   and	  
AGE-­‐positive	   neurons	   and	   glia	   both	   increase	   with	   age	   and	   dramatically	   so	   with	   AD	  
progression	  (Lüth	  et	  al.	  2005).	  Activation	  of	  the	  receptor	  for	  AGE,	  (RAGE),	  on	  microglia	  
with	  one	  of	   its	   ligands,	  such	  as	  AGE	  or	  Aβ,	  results	   in	  the	  release	  of	  pro-­‐inflammatory	  
mediators	  (free-­‐radicals	  and	  cytokines)	  (Berbaum	  et	  al.	  2008).	  It	  has	  even	  been	  shown	  
that	   a	   combination	   of	   both	   these	   ligands	   (AGE	   and	   Aβ)	   can	   lead	   to	   an	   enhanced	  
microglial	   inflammatory	   response	   (Gasic-­‐Milenkovic	   et	   al.	   2003).	   These	   data	   taken	  
together	  with	  similar	  findings	  have	  promoted	  the	  search	  for	  therapeutics	  designed	  to	  
modify	  these	  pathways.	  Presenilins	  function	  as	  part	  of	  the	  γ-­‐secretase	  protein	  complex	  
which	  together	  with	  β-­‐secretase,	  cleaves	  APP	  resulting	  in	  the	  formation	  of	  Aβ	  (Cole	  &	  
Vassar	  2008).	  One	  of	   the	  major	  causes	  of	  AD	   is	  mutations	   in	  presenilins	  1	  and	  2.The	  
loss	   of	   presenilin	   function	   in	   presenilin-­‐conditional	   knockout	  mice	   resulted	   in	   an	  up-­‐
regulation	  in	  inflammatory	  markers,	  and	  including	  C1q,	  suggesting	  that	  presenilins	  may	  




1.10	  Aims	  and	  Objectives	  
Microglia	   are	   increasingly	   recognised	   as	   important	   mediators	   in	   AD,	   playing	  
opposing	   roles	   in	   the	   pathogenesis	   of	   the	   disease	   both	   eliminating	   β-­‐amyloid	  
aggregates	   via	   phagocytosis	   and	   causing	   inflammation	   and	   as	   such	   releasing	  
neurotoxic	   factors,	   thereby	  killing	  neighbouring	  neurons	   (Cameron	  &	  Landreth	  2010;	  
Krabbe	   et	   al.	   2013).	   The	   recent	   genome-­‐wide	   association	   studies	   linking	  
polymorphisms	  of	  CR1	  to	  AD	  (Lambert	  et	  al.	  2009;	  Carrasquillo	  et	  al.	  2010;	  Corneveaux	  
et	   al.	   2010;	   Zhang	  et	   al.	   2010)	  have	  directed	   this	   research	   to	   investigate	   its	  possible	  
contribution	  to	  AD	  disease	  pathogenesis.	  Here,	  our	  main	  aim	  is	  to	  try	  and	  elucidate	  the	  
roles	  of	  CR1	  signalling	  and	  how	  it	  is	  has	  an	  influence	  on	  microglial	  phenotype	  following	  
activation	  with	  neuroinflammatory	  markers.	  This	  will	  be	  performed	  using	  basic	  in	  vitro	  
culture	   models	   with	   pharmacologic	   manipulation	   where	   required.	   This	   thesis	   also	  
aimed	   to	  address	   the	  question	  of	  whether	  CR1	  expression	  showed	  correlation	   in	   the	  
human	  brain	   and	   this	  was	  performed	   through	   analysis	   of	   human	  post-­‐mortem	  brain	  
tissue	   from	   AD	   patients.	   By	   the	   end	   of	   this	   thesis	   it	   is	   hoped	   that	   the	   following	  
questions	  will	  have	  been	  answered:	  
• 	  	  	  Does	  CR1	  play	  a	  role	  in	  microglial	  phagocytosis	  during	  a	  neuroinflammatory	  state?	  
• 	  	  	  Can	  modulating	  CR1	  affect	  the	  neurotoxic	  role	  of	  microglia	  in	  neuroinflammation?	  
• 	  	  	  Can	  microglial	  CR1	  influence	  neuronal	  toxicity?	  
• 	  	  	  Does	  CR1	  expression	  vary	  within	  regions	  of	  the	  human	  AD	  brain	  and	  does	  it	  correlate	  





















2.	  Materials	  and	  Methods	  
2.1	  Animals	  and	  Materials	  
Sprague	   Dawley	   rats	  were	   bred	   and	   reared	   in	   house	   from	   stock	   animals	   from	  
Charles	   River	   UK	   Ltd.	   (Kent,	   UK).	   All	   chemicals	   were	   purchased	   from	   Sigma-­‐Aldrich	  
(Dorset,	  UK),	  unless	  otherwise	  stated.	  Foetal	  bovine	  serum	  (FBS),	  Dulbecco's	  Modified	  
Eagle's	  Medium	  (DMEM)	  and	  Minimum	  Essential	  Medium	  (MEM)	  were	  obtained	  from	  
Invitrogen	   (Paisley,	   UK).	   Tissue	   culture	   plastic-­‐ware	   was	   obtained	   from	   Triple	   Red	  
(Buckinghamshire,	   UK)	   and	   coverslips	   were	   obtained	   from	   Scientific	   Laboratory	  
Supplies	   (Nottingham,	   UK).	   Phosphate	   buffered	   saline	   (PBS)	   powder	   was	   purchased	  
from	  ICN	  Biomedicals	  (Maidenhead,	  UK).	  Anti-­‐CD35	  functional	  blocking	  antibody,	  C3b	  
receptor	   was	   from	   antibodies-­‐online.com	   (Atlanta,	   USA),	   anti-­‐iNOS	   was	   from	   BD	  
Biosciences	   (Oxford,	   UK),	   anti-­‐NeuN	   was	   from	  Millipore	   (Oxforshire,	   UK),	   anti-­‐CD35	  
antibodies	   raised	  against	   purified	  human	  C3bR	  were	   from	  Hycult	  Biotech	   (Uden,	   the	  
Netherlands)	   and	   the	   E11	   antibody	   (ab25)	   from	   Abcam	   (Cambridge,	   UK).	   The	  
remaining	  CR1	  antibodies	  were	  a	  kind	  gift	  from	  Dr	  Anne	  Nicholson-­‐Weller	  and	  Dr	  Ionita	  
Ghiran	  (see	  Table	  3).	  The	  Aβ	  antibodies	  R1282	  and	  3A1	  were	  both	  kind	  gifts	   from	  Dr	  
Dennis	   Selkoe	   and	   Dr	   Brian	   O’Nuallian	   respectively	   (see	   Table.3).	   The	   mouse	   non-­‐
immune	   IgG	   antibody	  was	   from	  Abcam	   (St	   Louis,	  MO,	  USA),	   rabbit	   non-­‐immune	   IgG	  
antibody	   was	   from	   Invitrogen	   (Paisley,	   UK),	   anti-­‐NeuN	   antibody	   was	   from	   Merck	  
Millipore	   (Oxfordshire,	   UK),	   Cleaved	   caspase-­‐3	   antibody	   was	   from	   Cell	   Signaling	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Technology	  (MA,	  USA),	  dextran	  beads	  were	  from	  Molecular	  Probes,	  Invitrogen	  (Paisley,	  
UK),	   β-­‐Amyloid	   (1-­‐42)	   HiLyte	   FluorTM	   488-­‐labeled	   was	   from	   AnaSpec	   (Fremont,	   CA,	  
USA),	   Vectashield	   mountant	   for	   fluorescence	   was	   from	   Vector	   (Peterborough,	   UK),	  
enhanced	   chemiluminesence	   reagent	   (ECL)	   was	   from	   Amersham	   Pharmacia	  
(Buckinghamshire,	   UK).	   Alexa-­‐fluor	   488	   and	   Cy3	   IgGs	   were	   from	   Life	   Technologies	  
(Paisley,	   UK).	   ON-­‐TARGETplus	   Crry	   siRNA	   and	   Cyclophilin	   B	   control	   siRNA	   was	  
purchased	  from	  Thermo-­‐Biosciences	  (San	  Jose,	  CA,	  USA).	  Flow	  Cytometry	  reagents	  and	  
consumables	   were	   from	   Becton	   Dickinson	   (BD)	   Biosciences	   (San	   Jose,	   CA,	   USA).	  	  
Quantikine	  Rat	  TNFα	  and	  IL-­‐1β	  Immunoassay	  kits	  were	  from	  R&D	  Systems	  (Abingdon,	  
UK).	  Anti-­‐β-­‐actin	  and	  all	  other	  reagents	  were	  from	  Sigma	  (Dorset,	  UK).	  	  
Table	  2.1	  outlines	  the	  compounds	  used	  to	  treat	  cells,	  the	  concentration	  at	  which	  these	  











Compound	   Description	   Final	  
Concentration	  
Supplier	  
LPS	   Microglial	  activator	  
through	  binding	  TLR4	  
1	  µg/mL	   Sigma	  L2762	  
Serotype:	  026:B6	  
(Dorset,	  UK)	  
CR1	  blocking	  antibody	  
Clone:	  J3D3	  
Functional	  CR1	  blocking	  
antibody	  which	  binds	  to	  
purified	  C3b	  receptor	  




Aβ1-­‐42	   Activate	  a	  tyrosine-­‐
kinase	  based	  signaling	  
response	  resulting	  in	  
production	  of	  neurotoxic	  
secretory	  products,	  
proinflammatory	  
cytokines	  and	  ROS	  	  
20	  nM	   Sigma	  A-­‐9810	  
	  (Dorset,	  UK)	  
1400W	  Dihydrochloride	  	   Highly	  selective	  inhibitor	  
of	  inducible	  nitric	  oxide	  
synthase	  (iNOS)	  
100	  μM	   Tocris	  1415	  
(Bristol,	  UK)	  
Thalidomide	   Selective	  inhibitor	  of	  
tumor	  necrosis	  factor	  α	  
(TNFα)	  synthesis	  




NADPH	  oxidase	  activator	   10	  ng/mL	   Sigma	  P1505	  
(Dorset)	  
apocynin	   NADPH	  oxidase	  inhibitor	   10	  μM	   Calbiochem	  
178385	  
(Nottingham,	  UK)	  









2.2.1	  Primary	  cell	  culture	  preparation	  and	  treatment	  
2.2.1.1	  Rat	  Cerebellar	  granule	  neurons	  
	   Cerebellar	   granular	   cultures	   (CGC)	   were	   prepared	   as	   described	   by	   (Evans	   &	  
Pocock	  1999),	  with	  modifications.	  Animals	  were	  sacrificed	  through	  cervical	  dislocation	  
and	   decapitation	   in	   accordance	  with	   the	  Animals	   (Scientific	   Procedures)	   Act	   of	   1986	  
(United	   Kingdom).	   	   Cerebellar	   from	   five	   day	   old	   Sprague	   Dawley	   rat	   pups	   were	  
collected	  on	  ice	  into	  a	  buffer	  consisting	  of	  153	  mM	  Na+Cl,	  4	  mM	  K+,	  1.5	  mM	  Mg2+,	  139	  
mM	  Cl-­‐,	   10	  mM	  PO4
2-­‐,	   1.5	  mM	  SO4
2-­‐,	   14	  mM	  glucose,	   and	  50	  µM	  BSA	   (pH,	  7.4).	   The	  
cerebellar	  were	  chopped	  finely	  with	  a	  sterile	  razor	  blade	  and	  collected	  into	  the	  buffer	  
containing	  0.5	  mg/ml	  trypsin	  and	  incubated	  for	  5	  minutes	  at	  37°C	  with	  gentle	  shaking	  
every	   1-­‐2	  min	   to	   catalyse	   the	   enzymatic	   reaction.	   Neutralization	   of	   the	   extracellular	  
matrix	   digestion	   was	   then	   performed	   by	   addition	   of	   20	  mL	   of	   a	   buffer	   containing	   8	  
µg/mL	   soybean	   trypsin	   inhibitor	   (SBTI)	   and	   8	   U/ml	   DNAase.	   Following	   several	  
inversions	  to	  ensure	  the	  enzyme	  was	  fully	  neutralised,	  the	  suspension	  was	  centrifuged	  
at	  65	  x	  g	  for	  5	  min	  (Eppendorf	  Centrifuge	  5804R).	  The	  supernatant	  was	  discarded,	  and	  
the	  pellet	  was	   triturated	  until	   a	   smooth	   suspension	  was	   formed,	   using	   three	   flamed	  
Pasteur	  pipettes	  with	  progressively	  narrowed	  ends,	  in	  3	  ml	  triturating	  medium	  (buffer	  
containing	   3	   mM	   Mg2+	   and	   SO4
2-­‐	   supplemented	   with	   50	   µg/mL	   SBTI	   and	   50	   U/ml	  
DNAase).	  Perikarya	  were	  collected	  by	  underlying	  the	  supernatant	  with	  5	  ml	  4%	  BSA	  in	  
Ca2+-­‐free	  Earle’s	  Balanced	  Salts	  Solution	  (EBSS)	  and	  centrifuging	  for	  5	  min	  at	  100	  x	  g.	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The	  pellet	  was	  resuspended	   in	  warm	  CGC	  medium	  MEM	  containing	  10%	  fetal	  bovine	  
serum,	   20	  mM	  KCl,	   30	  mM	  D-­‐glucose,	   2	  mM	   L-­‐glutamine,	   25	  mM	  NaHCO4,	   50	  U/ml	  
penicillin,	  50	  µM	  streptomycin,	  and	  6	  µg/ml	  ampicillin)	  at	  a	  density	  of	  86	  cells/ml.	  Cells	  
were	   plated	   on	   13	   mm	   diameter	   poly-­‐Dextro-­‐lysine	   (PDL)	   -­‐coated	   coverslips	   at	   a	  
density	  of	  8	  x	  105	  per	  coverslip.	  Additional	  CGC	  medium	  was	  not	  added	  until	  at	  least	  1	  
hour	  after	  plating	  to	  give	  time	  for	  the	  perikarya	  to	  adhere.	  After	  24	  hours,	  the	  medium	  
was	   changed	   and	   supplemented	   with	   10	   µM	   cytosine	   furanoarabinoside	   (Ara-­‐C)	   to	  
prevent	   further	   glial	   proliferation.	   Our	   laboratory	   has	   previously	   shown	   that	   the	  
cultures	  then	  contain	  <5%	  microglia.	  Ara-­‐C	  was	  added	  to	  all	  CGC	  cultures	  used	  in	  this	  
thesis.	  The	  cultures	  were	  kept	  at	  37°C	  in	  a	  humidified	  atmosphere	  of	  5%	  CO2.	  Cultures	  
were	  viable	  for	  experimentation	  after	  6	  days	  in	  vitro	  (DIV).	  
	  
2.2.1.2	  Rat	  hippocampal	  neurons	  
Mixed	   cultures	   of	   hippocampal	   neurons	   and	   glial	   cells	   were	   prepared	   as	  
described	   previously	   with	   modifications,	   from	   2-­‐4	   day	   old	   Sprague-­‐Dawley	   rat	   pups	  
(Vaarmann	   et	   al.	   2010).	   Animals	   were	   sacrificed	   through	   cervical	   dislocation	   and	  
decapitation	   in	   accordance	   with	   the	   Animals	   (Scientific	   Procedures)	   Act	   of	   1986	  
(United	  Kingdom).	  	  Hippocampi	  were	  removed	  into	  ice-­‐cold	  phosphate	  buffered	  saline	  
(PBS;	   in	  mM:	  140	  NaCl,	   5	  KCl,	   25	  Na2HPO4,	  2.9	  Na2HPO4.2H20,	  11	  glucose,	  plus	  0.2%	  
bovine	  serum	  albumin	  (BSA),	  pH	  7.4).	  The	  tissue	  was	  chopped	  finely	  with	  a	  sterile	  razor	  
blade	  and	  collected	  in	  buffer	  containing	  0.25%	  trypsin	  and	  incubated	  for	  5	  min	  at	  37°C	  
in	  a	  water-­‐bath	  with	  occasional	  shaking	  of	  the	  tube.	  The	  cells	  were	  centrifuged	  at	  65	  g	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for	   5	   min	   and	   washed	   in	   3	   ml	   DMEM	   with	   10%	   FBS,	   supplemented	   with	   2	   mM	   L-­‐
glutamine,	   100	   U/ml	   penicillin	   and	   100	   mg/ml	   streptomycin	   (GIBCO,	   Carlsbad,	   CA).	  
Centrifugation	   and	   washing	   steps	   were	   repeated	   and	   this	   was	   followed	   by	   careful	  
tituration	  using	  a	  flame	  Pasteur	  pipette	  until	  cloudy.	  The	  cells	  were	  centrifuged	  at	  65	  g	  
for	  5	  min,	  the	  supernatant	  was	  discarded	  and	  the	  resulting	  pellet	  was	  suspended	  in	  1	  
ml	   DMEM.	   For	   quantification	   of	   cells,	   10	   µl	   of	   the	   cell	   suspension	   was	   analysed	   by	  
counting	  4	  quadrants	  of	  a	  haemocytometer,	  equating	  to	  the	  number	  of	  cells	  present	  in	  
0.1	   µl	   of	   the	   suspension	   volume.	   Cells	   were	   plated	   on	   PDL-­‐coated	   coverslips	   and	  
cultured	   in	   DMEM.	   Cell	   density	   per	   well	   was	   calculated	   so	   that	   the	   microglia	   were	  
initially	  plated	  in	  a	  volume	  of	  100	  µl	  to	  provide	  optimum	  adherence	  conditions.	  After	  1	  
h	   in	   an	   incubator	   at	   37°C	   in	   a	   humidified	   atmosphere	  with	   5%	  CO2,	   culture	  medium	  
well	  volume	  was	  increased	  to	  500	  µl	  and	  plates	  were	  returned	  to	  the	  incubator	  and	  left	  
for	  approximately	  24	  h	  before	  being	  gently	  washed	  with	  pre-­‐warmed	  media	  to	  remove	  
debris.	   Cultures	   were	   maintained	   at	   37°C	   at	   5%	   CO2	   and	   were	   viable	   for	  
experimentation	  at	  7	  DIV.	  
	  
2.2.1.3	  Rat	  microglia	  
Primary	  microglia	  were	   isolated	   from	   5	   day	   old	   Sprague	  Dawley	   rat	   pups	   by	   a	  
modification	   of	   methods	   previously	   described	   (Slepko	   &	   Levi	   1996;	   Kingham	   et	   al.	  
1999).	   Animals	   were	   sacrificed	   through	   cervical	   dislocation	   and	   decapitation	   in	  
accordance	   with	   the	   Animals	   (Scientific	   Procedures)	   Act	   of	   1986	   (United	   Kingdom).	  
Brains	  were	  transferred	  into	  ice-­‐cold	  phosphate-­‐buffered	  saline,	  on	  ice	  (137	  mM	  NaCl,	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5.37	  mM	  KCl,	   5.65	  mM	  NaH2PO4.H2O,	   13.3	  mM	  Na2HPO4.7H2O),	   supplemented	  with	  
11.1	  mM	  D-­‐glucose,	  0.02%	  BSA,	  100	  units/ml	  penicillin,	  100	  µg/ml	  streptomycin,	  and	  3	  
μg/ml	  ampicillin.	  The	  solution	  was	  made	  up	  in	  filtered,	  UV-­‐treated	  dH2O,	  pH	  7.4.	  Brains	  
were	   then	   gently	   homogenised	   using	   10	   –	   12	   strokes	   of	   a	   Potter-­‐Elvehjem	   tissue	  
grinder	  with	  a	  Teflon	  pestle	   (VWR,	  Leicester,	  UK).	  The	  smooth	  homogenate	  was	  split	  
and	  transferred	  to	  two	  50	  ml	  tubes	  (no	  more	  than	  4	  brains	  per	  tube)	  and	  centrifuged	  
at	  500	  g	  for	  5	  min	  (Eppendorf	  Centrifuge	  5804R).	  The	  supernatant	  was	  discarded	  and	  
the	   pellet	  was	   resuspended	   in	   10	  ml	   70%	  Percoll.	   A	   gradient	  was	   then	   produced	   by	  
overlaying	  the	  cells	  containing	  70%	  Percoll	  solution	  with	  10	  ml	  of	  30%	  Percoll	  solution.	  
Addition	  of	  the	  overlaying	  30%	  solution	  was	  done	  very	  gently,	  so	  as	  not	  to	  disturb	  the	  
layer	   below.	   The	   Percoll	   gradient	   was	   then	   centrifuged	   at	   1250	   g	   (Eppendorf	  
Centrifuge	  5804R)	  with	  no	  acceleration	  or	  breaking	  for	  50	  min	  to	  allow	  separation	  of	  
the	  microglia	   from	   the	   other	   brain	   tissue,	  which	   could	   be	   collected	   at	   the	   70%/30%	  
Percoll	  gradient	  interface.	  	  
	  
	   Figure	  2.1:	  Microglial	  preparation	  using	  a	  percoll	  gradient.	  
(a)	  The	  brain	  homogenate	   is	   resuspended	   in	  70%	  Percoll,	  which	   is	  overlaid	  with	  30%	  
percoll.	   (b)	   Following	   centrifugation	   at	   1250	   x	   g	   for	   50	  minutes,	   the	  myelin	   layer	   is	  
removed	   and	   microglia	   are	   separated	   from	   the	   homogenate	   and	   migrate	   to	   the	  





Microglia	  were	  collected	  and	  washed	  in	  50ml	  sterile	  PBS	  to	  allow	  for	  the	  dilution	  of	  the	  
Percoll	   concentration.	   The	   solution	   was	   then	   centrifuged	   at	   500	   g	   (Eppendorf	  
Centrifuge	   5804R)	   for	   5	   min.	   The	   resulting	   pellet	   was	   resuspended	   in	   1	   ml	   of	   pre-­‐
warmed	  medium	  (Minimal	  Essential	  Medium	  -­‐	  MEM)	  supplemented	  with	  10%	  FBS,	  20	  
mM	  KCl,	  30	  mM	  D-­‐glucose,	  2	  mM	  L-­‐glutamine,	  25	  mM	  NaHCO4,	  50	  U/ml	  penicillin,	  50	  
µg/ml	   streptomycin,	   and	   6	   µg/ml	   ampicillin).	   As	   previously	   described,	   cells	   were	  
quantified	  using	  a	  haemocytometer	  (see	  hippocampal	  method).	  
Microglia	   were	   cultured	   in	   the	   same	   medium	   as	   the	   CGCs	   cultures	   to	   enable	  
microglial	   conditioned	  medium	   (MGCM)	   to	   be	   added	   to	   the	   CGCs	   as	   a	   treatment.	   It	  
was	   previously	   observed	   in	   the	   laboratory	   that	   primary	  microglia	   did	   not	   adhere	   to	  
tissue	  culture	  plastic	  so	  cells	  were	  always	  plated	  on	  sterile	  13	  mm	  glass	  coverslips	  at	  a	  
density	  of	  1	  x	  105/well	  in	  24	  well	  plates.	  Cell	  density	  per	  well	  was	  calculated	  so	  that	  the	  
microglia	  were	   initially	   plated	   in	   a	   volume	  of	   100	   µl	   to	   provide	   optimum	  adherence	  
conditions.	  After	  1	  h	  in	  an	  incubator	  at	  37°C	  in	  a	  humidified	  atmosphere	  with	  5%	  CO2,	  
culture	  medium	  well	  volume	  was	  increased	  to	  500	  µl	  and	  plates	  were	  returned	  to	  the	  
incubator	  and	  left	  for	  approximately	  24	  h	  before	  being	  washed	  3	  times	  in	  pre-­‐warmed	  
medium	   to	   remove	   significant	   debris.	   Finally,	   serum-­‐containing	   (SC)	   medium	   was	  
replaced	  with	  serum-­‐free	  (SF)	  medium	  (MEM	  supplemented	  with	  20	  mM	  KCl,	  30	  mM	  
D-­‐glucose,	   2	   mM	   L-­‐glutamine,	   25	   mM	   NaHCO4,	   50	   U/ml	   penicillin,	   50	   µg/ml	  
streptomycin,	   and	   6	   µg/ml	   ampicillin),	   due	   to	   observations	   made	   previously	   in	   the	  
laboratory	  that	  the	  cultures	  appeared	  more	  ramified	  and	  responded	  better	  to	  stimuli.	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The	  cultures	  were	  left	  to	  rest	  for	  a	  further	  3	  h	  before	  treatment.	  Microglia	  were	  used	  
within	  48	  h	  of	  isolation.	  	  
	  
2.2.2	  BV2	  cell	  culture	  
The	   BV2	   cell	   line	   was	   a	   kind	   gift	   from	   Dr	   Claudie	   Hooper	   (MRC	   Centre	   for	  
Neurodegenerative	   Research,	   Institute	   of	   Psychiatry,	   Kings	   College	   London,	   UK)	   and	  
was	  originally	  obtained	  from	  Dr	  FS	  Tzeng	  (Department	  of	  Life	  Sciences,	  National	  Cheng	  
Kung	  University,	   Taiwan).	   BV2	   cells	   are	   a	  mouse	  microglial	   cell	   line,	   immortalized	  by	  
the	   inclusion	  of	  a	  v-­‐raf/v-­‐myc	  oncogene	  carrying	   retrovirus	   J2	   (Blasi	  et	  al.	  1990).	  The	  
cells	   retain	   the	  morphological	   and	   phenotypical	   characteristics	   of	   primary	  microglial	  
cells	   in	   culture	   conditions,	   and	   LPS	   treatment	   of	   BV2	   microglia	   induces	   the	   up-­‐
regulation	   of	   inflammatory	   genes	   also	   seen	   following	   LPS	   treatment	   of	   primary	  
microglia,	  suggesting	  that	  BV2	  microglia	  respond	  in	  the	  same	  way	  as	  primary	  microglia	  
to	  activating	  stimuli,	  however	  BV2	  activation	  is	  less	  pronounced	  (Lund	  et	  al.	  2006). BV2	  
microglia	   were	   maintained	   in	   T175	   culture	   flasks	   (Appleton	   Woods,	   Bucks,	   UK)	   in	  
DMEM	  with	  10%	  FBS,	  supplemented	  with	  2	  mM	  L-­‐glutamine,	  100	  U/ml	  penicillin	  and	  
100	   mg/ml	   streptomycin	   at	   37°C	   in	   a	   humidified	   atmosphere	   with	   5%	   CO2.  
Cryopreservation	  of	  cells	  was	  routinely	  performed	  to	  increase	  longevity	  of	  the	  cell	  line.	  
The	   BV2	   microglia,	   at	   a	   density	   of	   1	   x	   106/ml	   were	   suspended	   in	   Sigma	   freezing	  
medium	  (DMEM,	  20%	  FBS,	  2	  mM	  L-­‐glutamine,	  100	  U/ml	  penicillin,	  and	  10%	  DMSO	  –	  to	  
prevent	  membrane	  rupture)	  and	  stored	  at	  -­‐80°C.	  Once	  required,	  a	  frozen	  vial	  of	  cells	  
was	   thawed	  and	  added	   to	  pre-­‐warmed	  BV2	  medium	   in	  a	  T25	   culture	   flask.	   The	   cells	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were	  maintained	  at	   37°C	   in	   a	  humidified	   atmosphere	  with	  5%	  CO2	   and	  medium	  was	  
replaced	  after	  2-­‐3hrs	  to	  remove	  the	  cytotoxic	  components	  of	  the	  freezing	  medium.	  For	  
experimental	   procedures	   and	   passaging,	   BV2	   microglia	   were	   harvested	   from	   the	  
culture	   flasks	   enzymatically	   by	   incubation	   for	   5	  minutes	   at	   37°C	  with	   ~	   10	  ml	   of	   0.5	  
mg/ml	  trypsin	  (1:10	  dilution	  of	  5	  mg/ml	  stock;	  Sigma).	  Neutralisation	  of	  the	  trypsin	  was	  
performed	  by	  adding	  10ml	  of	  BV2	  medium	  to	  the	  flask.	  The	  cells	  were	  then	  pelleted	  by	  
centrifugation	  at	  3645	  g	  for	  5	  minutes	  at	  room	  temperature	  and	  resuspended	  in	  5	  ml	  
of	   fresh	   warm	   medium.	   As	   previously	   described,	   cells	   were	   quantified	   using	   a	  
haemocytometer	  (see	  hippocampal	  method).	  The	  BV2	  cell	   line	  was	  used	  for	  Western	  
Blotting	  and	   superoxide	   live	   imaging	   (Figs.	   3.6	   (d),	   3.8,	   3.9).	   The	   cells	  were	   routinely	  
plated	   on	   6	   well	   plates	   at	   a	   density	   of	   2	   x	   105/well.	   Cultures	   were	   exposed	   to	   SF	  
medium	  (DMEM,	  2	  mM	  L-­‐glutamine,	  100	  U/ml	  penicillin	  and	  100	  µg/ml	  streptomycin),	  
and	  left	  to	  rest	  for	  at	  least	  2	  hr	  before	  treatment.	  
	  
2.2.3	  Cell	  treatments	  
2.2.3.1	  Direct	  treatments	  of	  cultures	  
Primary	   microglia	   and	   the	   BV2	   microglial	   cell	   line	   were	   routinely	   plated	   24	   h	  
prior	  to	  treatment	  and	  the	  cell	  medium	  was	  changed	  to	  serum-­‐free	  media	  at	  least	  2	  h	  
before	  treatment	  to	  ensure	  cells	  were	  down-­‐regulated	  and	  in	  a	  resting	  state.	  Microglia,	  
BV2s,	  CGCs	  and	  hippocampal	  neurons	  were	  activated	  with	  LPS	  and	  Aβ1-­‐42	  alone	  or	   in	  
combination	  with	  CR1	  blocking	  antibody	  for	  1-­‐48	  hrs.	  The	  Aβ1-­‐42	  was	  previously	  tested	  
and	  found	  to	  be	  endotoxin	  free	  and	  after	  which	  was	  pipetted	  into	  aliquots	  and	  stored	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at	  -­‐80°C.	  The	  aggregation	  state	  of	  the	  peptide	  is	  unknown	  and	  possible	  experiments	  to	  
determine	  this	  are	  discussed	  in	  the	  future	  work	  section	  of	  this	  thesis.	  	  
	  CR1	   blocking	   antibody,	   clone	   J3D3,	   is	   a	   monoclonal	   antibody	   to	   CD35	   (CR1)	  
(tested	  to	  be	  endotoxin	  free)	  which	  has	  been	  shown	  to	  bind	  with	  high	  affinity	  to	  CR1	  
on	   erythrocytes,	   polymorphonuclear	   leukocytes	   and	   lymphocytes	   to	   inhibit	   CR1	  
mediated	  decay	  of	  cells	  (Cook	  et	  al.	  1985).	  To	  inhibit	  TNFα	  synthesis	  prior	  to	  activation	  
with	   the	   above	   treatments,	   cultures	  were	   pre-­‐treated	  with	   Thalidomide	   1	   h	   before.	  
Inhibition	  of	  iNOS	  activity	  was	  performed	  in	  the	  same	  manner	  by	  pre-­‐treating	  cultures	  
30	  minutes	   before	   activation	  with	   1400W	  dihydrochloride.	   Superoxide	   activation	   via	  
NADPH	   oxidase	   was	   induced	   by	   administration	   of	   PMA	   to	   LPS	   cultures	   for	   24	   h.	  
Inhibition	  of	  this	  induction	  was	  performed	  by	  co-­‐treatment	  of	  cultures	  with	  apocynin.	  
All	  compounds	  with	  concentrations	  used	  to	  treat	  cultures	  are	  provided	  in	  Table	  
2.1.	  The	  concentrations	  selected	  are	  justified	  in	  the	  corresponding	  result	  chapters	  and	  
were	  determined	  by	  concentration	  dependent	  analysis,	  from	  previous	  experiments	  in	  
the	  laboratory	  or	  from	  the	  literature.	  
	  
2.2.3.2	  Microglial	  conditioned	  medium	  administration	  to	  neuronal	  cultures	  
CGCs	  were	  treated	  with	  MGCM	  to	  assess	  survival	   following	  the	  release	  of	  toxic	  
or	  protective	   factors	   from	  microglia	  after	  modulation	  of	  CR1,	  and	  also	   to	   investigate	  
the	  signalling	  pathways	  involved	  in	  neuronal	  survival	  or	  death.	  Microglia	  were	  plated	  in	  
24	  well	  plates	  as	  described	  and	  treated	  as	  shown	  in	  Table	  1	  for	  24	  h	  and	  the	  medium	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was	   collected	   into	   Eppendorf	   tubes	   and	   placed	   immediately	   on	   ice.	   MGCM	   was	  
centrifuged	   at	   15,800	   g	   at	   4°C	   for	   5	   minutes	   to	   remove	   significant	   debris	   and	  
immediately	  snap	  frozen	  with	  dry	  ice,	  followed	  by	  storage	  at	  -­‐20°C.	  During	  the	  MGCM	  
assays,	  half	  of	  the	  medium	  already	  on	  the	  CGCs	  (250µL)	  was	  removed	  from	  each	  well,	  
and	   replaced	  with	   250µL	  of	  MGCM.	  Only	   half	   the	  media	   could	   be	   removed	   as	   CGCs	  
release	  growth	  factors	  which	  are	  essential	  to	  their	  survival,	  therefore	  removing	  these	  
fully	  would	  have	  a	  detrimental	  effect	  on	  neuronal	  survival	  and	  may	  also	   increase	  cell	  
death	   in	   a	   way	   not	   attributed	   to	   the	  MGCM	   (Taylor	   et	   al.	   2002).	   Following	  MGCM	  
treatment,	   CGCs	   were	   imaged	   to	   assess	   cell	   death	   by	   nuclear	   morphology	   and	  
propidium	  iodide	  staining.	  
	   	  
2.2.4	  Microglial	  depletion	  from	  neuronal	  cultures	  
Following	  previously	   described	  methodology	   (Morgan	  et	   al.	   2004)	   depletion	  of	  
microglia	   from	   CGC	   cultures	   was	   carried	   out	   using	   L-­‐leucine-­‐methyl-­‐ester	   (LME)	  
treatment	   for	  24	  h.	   LME	   is	  a	   lysosomatropic	  agent	  which	  was	  originally	  employed	   to	  
selectively	   deplete	  macrophages	   (Thiele	   et	   al.	   1983),	   however	   a	   number	  of	   research	  
groups	  have	  used	  it	  to	  selectively	  deplete	  microglia	  from	  astrocyte	  or	  oligodendrocytes	  
cultures	  (Giulian	  et	  al.	  1993;	  Hewett	  et	  al.	  1999).	  The	  methodology	  followed	  previously	  
published	   studies	   from	   this	   laboratory	   (Morgan	   et	   al.	   2004),	   with	   has	   been	   further	  
adapted	   in	   the	   laboratory	   using	   a	   previously	   published	   methodology	   (Hamby	   et	   al.	  
2006).	  25	  mM	  LME	  had	  been	  demonstrated	  to	  be	  the	  optimum	  concentration	  with	  a	  
significant	  decrease	  microglia	  number,	  yet	  no	  increased	  death	  seen	  in	  the	  CGC	  culture.	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At	  6	  DIV	  CGCs	  were	  treated	  with	  25	  mM	  LME	  for	  1	  hr.	   Initially,	  LME	  was	  dissolved	  in	  
culture	  medium,	  the	  pH	  was	  returned	  to	  7.4	  using	  1	  M	  sodium	  hydroxide	  (NaOH),	  and	  
filter	   sterilised.	   LME	   concentration	   dissolved	   in	   the	  medium	  was	   equal	   to	   twice	   the	  
concentration	   required.	   Half	   the	   culture	   medium	   was	   removed	   from	   each	   CGC-­‐
containing	   well	   and	   retained	   at	   37°C,	   followed	   by	   administration	   of	   double	  
concentrated	   LME	   to	   the	   CGC-­‐containing	   wells,	   i.e.	   diluted	   1:1	   giving	   the	   desired	  
concentration.	  The	  cultures	  were	  then	  incubated	  at	  37°C	   in	  a	  humidified	  atmosphere	  
with	  5%	  CO2	  for	  1	  h.	  LME	  was	  removed	  from	  the	  cultures	  following	  two	  washes	  with	  
pre-­‐warmed	   CGC	  medium.	   The	   retained	   cell	  medium	   plus	   an	   equal	   volume	   of	   fresh	  
CGC	  medium	  was	  then	  added	  to	  the	  corresponding	  wells.	  Finally,	  cultures	  were	  left	  to	  
rest	   for	   24	   h,	   then	   fixed	   and	   analysed	   as	   previously	   described	   with	   IB4	   and	   DAPI	  
staining.	  Control	   cultures	  were	   treated	   the	   same	  but	  CGC	  medium	  without	   LME	  was	  
used	  instead.	  
	  
2.2.5	  Phagocytic	  assay	  
Treated	  microglia	  were	   incubated	  with	  10	  kDa	  TRITC-­‐conjugated	  dextran	  beads	  
(20	  µg/mL)	  for	  3	  h	  or	  with	  2	  µM	  fluorescently-­‐labelled	  HiLyte	  Fluor	  488-­‐Aβ1-­‐42	  for	  2	  h	  at	  
37°C.	  Cells	  were	  then	  incubated	  with	  5	  µg/mL	  of	  the	  nuclear	  stain	  2’-­‐[epoxyphenyl]-­‐5-­‐
[4-­‐methyl-­‐1-­‐piperazinyl]-­‐2,5’-­‐bi-­‐1H-­‐benzimidazol	   Hoechst-­‐33342	   (Hoechst-­‐33342)	   for	  
10	  min	  and	  then	  washed	  in	  PBS	  to	  remove	  loose	  beads	  and	  bead	  uptake	  was	  visualized	  
by	   fluorescence	  microscopy.	   Fluorescence	   images	  were	   captured	   using	   a	   TRITC	   filter	  
set	   on	   a	   Zeiss	   fluoresce	   microscope	   plus	   40x	   Neoflaur	   objective	   (Zeiss	   Axioskop	   2,	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Oberkochen,	   Germany).	   A	   phase	   contrast	   image	   of	   the	   same	   field	   of	   view	  was	   also	  
captured	   for	  quantification	  of	   total	   cell	   number.	  Data	  were	   collected	   from	  at	   least	  3	  
fields	  of	  view	  per	  coverslip	  with	  each	  condition	  repeated	  on	  3	  coverslips	  in	  3	  separate	  
experiments.	  	   Labelled	   cells	   were	   counted	   as	   a	   percentage	   of	   total	   cells	   per	   field.	  	  
Control	  cells	  were	  incubated	  with	  beads	  alone	  at	  37oC	  for	  all	  conditions	  or	  at	  4oC,	  the	  
latter	  as	  a	  binding	  control.	  
	  
2.2.6	  Assessment	  of	  apoptosis	  and	  cell	  death	  
Neuronal	   death	  was	   assessed	  by	  nuclear	  morphology	   and	   the	   incorporation	  of	  
propidium	  iodide	  (PI)	  into	  necrotic	  and	  late	  apoptotic	  nuclei.	  Apoptosis	  is	  programmed	  
cell	   death	  which	   is	  morphologically	   characterized	   by	  membrane	   blebbing	   and	   bright	  
pyknotic	  nuclei,	  due	  to	  chromatin	  condensation	  (Kerr	  et	  al.	  1972;	  Kroemer	  et	  al.	  2009).	  
These	   morphological	   features	   can	   be	   identified	   in	   cultures	   using	   the	   nuclear	   stain	  
Hoechst-­‐33342.	  This	  membrane	  permeable	  DNA	  stain	  binds	  preferentially	  to	  adenine-­‐
thymine	  (A-­‐T)	  regions	  of	  the	  minor	  groove	  in	  the	  DNA,	  and	  can	  access	  the	  nucleus	  at	  all	  
stages	  of	  cell	  survival	  and	  death,	  allowing	  for	  assessment	  of	  health.	  The	  necrotic	  and	  
late	  apoptotic	  marker	  PI	  is	  not	  membrane	  permeable,	  and	  is	  only	  incorporated	  into	  the	  
nucleus	  when	  the	  plasma	  membrane	   is	  compromised,	  which	   is	  not	  seen	  during	  early	  
apoptosis	  and	  therefore	  allows	  for	  the	  distinction	  between	  the	  different	  types	  of	  cell	  
death.	  Nuclear	  staining	  was	  performed	  on	  live,	  unfixed	  CGCs	  to	  determine	  the	  effects	  
of	   both	   direct	   treatment	   and	  MGCM	   treatment	   on	   neuronal	   survival.	   Treated	   CGC’s	  
were	  incubated	  with	  5	  µg/mL	  PI	  for	  30	  min	  and	  5	  µg/mL	  Hoechst-­‐33342	  for	  20	  min	  as	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previously	  described	  (Pinteaux-­‐Jones	  et	  al.	  2008).	  The	  apoptotic	  cells,	  which	  stained	  to	  
show	  bright	  pyknotic	  nuclei	  and	  the	  necrotic	  cells,	  which	  stained	  red,	  were	  observed	  
using	   the	   TRITC	   (red	   fluorochrome,	   543	   nm)	   and	   DAPI	   (blue	   fluorochrome	   364	   nm)	  
filters	  on	  a	  Zeiss	   fluoresce	  microscope	  plus	  40x	  Neoflaur	  objective	   (Zeiss	  Axioskop	  2,	  
Oberkochen,	  Germany).	  	  Cell	  counts	  were	  performed	  on	  a	  minimum	  of	  three	  fields	  per	  
coverslip,	  three	  coverslips	  per	  treatment	  from	  three	  independent	  experiments.	  
	  
2.2.7	  Immunocytochemistry	  
Treated	   microglia	   were	   fixed	   with	   4%	   paraformaldehyde	   (PFA)	   in	   phosphate-­‐
buffered	   saline	   (PBS;	   154	   mM	   NaCl,	   1.84	   mM	   KH2PO4,	   9.81	   mM	   K2HPO4.3H2O,	   pH	  
adjusted	  to	  7.4	  with	  further	  addition	  of	  KH2PO4/K2HPO4.3H2O	  as	  necessary)	  for	  at	  least	  
30	  min	   at	   room	   temperature.	   Cultures	  were	   then	  washed	   three	   times	  with	   PBS	   and	  
permeabilized	   with	   100%	   ice-­‐cold	   methanol	   for	   20	   min	   at	   -­‐20°C	   followed	   by	   three	  
further	  washes	  with	  PBS.	   	  Cells	  were	  then	  blocked	  with	  4%	  normal	  goat	  serum	  (NGS)	  
for	   30	   min	   at	   room	   temperature	   to	   combat	   non-­‐specific	   binding	   of	   the	   secondary	  
antibody.	   The	   choice	   of	   block	   was	   due	   to	   the	   species	   the	   secondary	   antibody	   was	  
raised	   in.	  Cultures	  were	   incubated	  at	  4°C	  overnight	  with	  primary	  antibody	  diluted	   in	  
PBS,	  anti-­‐iNOS	  (1:250),	  NeuN	  (1:500)	  or	  cleaved	  caspase-­‐3	  (1:500)	  in	  a	  dark,	  humidified	  
atmosphere.	  Negative	  controls	  were	  performed	  in	  all	  experiments	  where	  the	  PBS	  was	  
used	  to	  replace	  the	  primary	  antibody.	  Cultures	  were	  then	  washed	  three	  times	  with	  PBS	  
and	  incubated	  at	  room	  temperature	  with	  the	  appropriate	  secondary	  antibody	  diluted	  
in	  PBS	  for	  2	  h	   in	  the	  dark.	  Cultures	  were	  washed	  with	  PBS	   in	  the	  dark	  and	   incubated	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with	  200	  μl	  of	  1:1000	  4',6-­‐Diamidino-­‐2-­‐Phenylindole	  (DAPI)	  in	  PBS	  for	  1	  minute	  in	  the	  
dark	  at	   room	  temperature.	  Finally	  cultures	  were	  washed	  once	  more	  with	  PBS,	   rinsed	  
with	  ddH2O	  and	  mounted	  with	  Vectashield	  on	  a	  glass	  slide.	  The	  edges	  of	  each	  coverslip	  
were	  sealed	  to	  prevent	  the	  cells	  drying	  out	  and	  the	  slides	  were	  stored	  in	  the	  dark	  at	  -­‐
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Table	  2.2:	  Summary	  of	  primary	  antibodies	  used	  in	  ICC	  experiments.	  
	  
2.2.8	  Superoxide	  production	  measurement	  
There	   are	   several	   compounds	   that	   can	   be	   used	   for	   the	   measurement	   of	  
superoxide	   production	   however	   the	   focus	   of	   this	   study	   was	   on	   the	   production	   of	  
intracellular	   superoxide	   as	   a	   signaling	   molecule	   therefore	   narrowing	   the	   method	   of	  
measurement	   to	   a	   few.	   In	   this	   study,	   two	   probes	   were	   used	   to	   investigate	   this	  
intracellular	   superoxide	   generation:	   dihydroethidium	   (DHE),	   which	   is	   oxidized	   to	   2-­‐
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hydroxyethidium	   (2-­‐Oh-­‐E+)	   by	   superoxide,	   and	   nitroblue-­‐tetrazolium	   (NBT),	   which	   is	  
reduced	  from	  a	  yellow	  liquid	  to	  a	  blue	  formazan	  precipitate	  NBTH2	  by	  superoxide.	  The	  
measurement	  of	   superoxide	   through	   the	  use	  of	   these	  probes	  also	   carries	  with	   it	   the	  
possibility	   of	   production	   of	   artifacts	   and	   so	   it	   is	   important	   to	   conduct	   measures	   to	  
reduce	  false	  positives.	  Both	  methods	  of	  measurement	  used	  in	  this	  study	  have	  proven	  
abilities	  in	  studying	  superoxide	  production,	  however	  they	  too	  have	  their	  negatives.	  For	  
example,	   probes	   that	   are	   reduced	   by	   superoxide,	   such	   as	   NBT,	   can	   lead	   to	   false	  
positive	   results	   due	   to	   possible	   superoxide	   production	   from	   redox	   cycling	   which	   is	  
caused	  by	  the	  reaction	  of	  molecular	  oxygen	  with	  a	  partially	  reduced	  probe	  (Vásquez-­‐
Vivar	   et	   al.	   1998;	   Spasojevic	   et	   al.	   2000).	   Whereas,	   DHE,	   which	   uses	   the	   oxidative	  
activity	  of	  superoxide,	  can	  also	  be	  oxidized	  by	  other	  ROS	  therefore	  making	  this	  method	  
less	   specific	   to	   superoxide	   (Dikalov	   et	   al.	   2007).	   In	   this	   thesis,	   all	   experiments	  were	  
conducted	  both	  in	  the	  presence	  of	  activating	  stimuli	  alone	  and	  in	  the	  presence	  of	  the	  
activating	   stimuli	   with	   apocynin,	   a	   nicotinamide	   adenine	   dinucleotide	   phosphate-­‐	  
oxidase	   (NADPH	   oxidase)	   inhibitor	  which	  works	   by	   preventing	   the	   translocation	   and	  
assembly	  of	  the	  enzyme	  thereby	  preventing	  the	  production	  of	  superoxide	  (Stefanska	  &	  
Pawliczak	   2008).	   Using	   this	   inhibitor	   would	   therefore	   reduce	   the	   incidence	   of	   false	  






2.2.9	  Superoxide	  live	  cell	  staining	  using	  Dihydroethidium	  (DHE)	  
DHE	   is	   a	   superoxide	   sensitive	   probe	   used	   for	   the	   detection	   of	   intracellular	  
superoxide.	   It	   functions	   by	   entering	   the	   membrane-­‐bound	   organelles	   and	   following	  
oxidation	   becoming	   positively	   charged	   and	   oxidized	   to	   2-­‐OH-­‐E+	   which	   binds	   to	   DNA	  
and	   fluoresces	   red	   (Peshavariya	   et	   al.	   2007).	   Treated	   primary	   microglia	   or	   BV2	  
microglia	  were	  assessed	   for	   superoxide	  production	  by	   incubation	  at	   37°C	   for	  40	  min	  
with	   DHE	   (5	   µM),	   and	   were	   counterstained	   with	   Hoechst-­‐33342	   as	   previously	  
described	  (Mead	  et	  al.,	  2012).	  Evidence	  has	  shown	  that	  this	  red	  fluorescence	  is	  more	  
readily	  produced	  with	  superoxide	  generating	  systems	  and	  that	  superoxide	  is	  the	  only	  
biologically	  relevant	  oxidant	  that	  can	  react	  with	  DHE	  to	  form	  2-­‐OH-­‐E+	  which	  makes	  this	  
a	  highly	  attractive	  method	  to	  measure	  superoxide	  (Benov	  et	  al.	  1998;	  Robinson	  et	  al.	  
2006;	  Zielonka	  et	  al.	  2008).	  Duplicate	  conditions	  were	  treated	  with	  apocynin	  (10	  µM)	  
as	   previously	   optimized	   in	   our	   laboratory,	   to	   verify	   superoxide	   production	   was	   via	  
NADPH	   oxidase	   activity.	   Coverslips	   for	   superoxide	   imaging	   were	   mounted	   in	   saline	  
solution	  consisting	  of	  153	  mM	  NaCl,	  3.5	  mM	  KCl,	  0.4	  mM	  KH2PO4,	  20	  mM	  TES,	  5	  mM	  
NaHCO3,	  1.2	  mM	  Na2SO4,	  1.2	  mM	  MgCl2,	  1.3	  mM	  CaCl2,	  5	  mM	  glucose,	  and	  observed	  
immediately	  by	  fluorescence	  microscopy	  using	  the	  TRITC	  (red	  fluorochrome,	  543	  nm)	  
and	   DAPI	   (to	   counterstain	   for	   total	   cell	   numbers)	   (blue	   fluorochrome	   364	   nm)	   filter	  
sets	  on	  a	  Zeiss	  fluorescence	  microscope	  (Zeiss	  Axioskop	  2,	  Oberkochen,	  Germany).	  The	  
mean	   cellular	   fluorescence	   of	   approximately	   50	   cells/field,	   from	   three	   fields	   per	  
coverslip,	  three	  coverslips	  per	  condition	  and	  from	  three	  independent	  experiments	  was	  
determined	  using	  Image	  J	  software.	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2.2.10	  NBT	  detection	  of	  intracellular	  superoxide	  
NBT	  has	  long	  been	  used	  for	  the	  detection	  of	  intracellular	  superoxide	  (Baehner	  et	  
al.	  1976).	  Following	  exposure	  of	  NBT	  to	  the	  superoxide	  anion	  (O2
.-­‐),	  it	  converts	  from	  a	  
yellow	  liquid	  to	  a	  blue	  formazan	  precipitate,	  which	  can	  quantify	  superoxide	  production	  
by	  measuring	  the	  absorbance	  of	  this	  precipitate	  at	  630	  nm	  (Choi	  et	  al.	  2006).	  The	  NBT	  
assay	   was	   optimized	   from	   published	   methodologies	   (Choi	   et	   al.	   2006;	   Mead	   et	   al.	  
2012a).	  BV2	  microglia	  were	  plated	   in	  96	  well	  plates	  at	  1x104	  cells	  per	  well	  and	  were	  
grown	  to	  70%	  confluency	  before	  the	  medium	  was	  changed	  to	  serum	  and	  phenol	   red	  
free	  media	  for	  3	  h	  before	  treatment.	  Cells	  were	  treated	  with	  PMA,	  which	   is	  a	  known	  
activator	  of	   the	  NADPH	  oxidase	  by	  phosphorolation	  of	   the	  p47phox	   subunit	   through	  
PKC	  activation	   (Tauber	  et	  al.	  1989;	  Abramov	  et	  al.	  2005).	  Cells	  were	   treated	  with	  10	  
ng/ml	  PMA	  (Mead	  et	  al.	  2012a)	  or	  1	  ug/ml	  LPS	  (Taylor	  et	  al.	  2005)	  in	  the	  presence	  of	  
10	  ug/ml	  NBT	  (Choi	  et	  al.	  2006)	  for	  4	  h	  and	  24	  h	  and	  NBT	  reduction	  was	  measured	  by	  
absorbance	  at	   630	  nm	  at	   each	   time	  point	  using	   a	   Tecan	   x	   flou4	  plate	   reader.	   It	  was	  
important	  that	  formazan	  precipitate	  production	  in	  BV2	  cells	  treated	  with	  the	  positive	  
control	   PMA	   was	   increased	   when	   compared	   to	   basal	   superoxide	   production	   in	  








2.2.11	  Glutathione	  production	  measurement	  
Monochlorobimane	   (MCB)	   is	   extensively	   used	   for	   the	   detection	   of	   glutathione	  
(GSH)	   in	   living	   cells.	   Following	   addition	   to	   cell	   medium,	   intracellular	   glutathione	   S-­‐
transferases	   form	   adducts	   with	   GSH	   that	   can	   then	   be	   fluorescently	   measured	  
(Kamencic	   et	   al.	   2000).	   Unlike	   other	   bimanes	   it	   has	   been	   shown	   to	   form	   an	   adduct	  
exclusively	  with	  GSH	   (Fernández-­‐Checa	  &	   Kaplowitz	   1990).	   Ethracrynic	   acid	   (EA)	   is	   a	  
potent	   inhibitor	   of	   glutathione	   S-­‐transferases	   (Ploemen	   et	   al.	   1993),	   therefore	  
experiments	  were	  conducted	  both	  in	  the	  absence	  and	  presence	  of	  the	  potent	  inhibitor	  
to	  reduce	  false	  positive	  results.	  
	  
2.2.12	  Glutathionine	  live	  cell	  staining	  
Treated	   primary	   microglia	   and	   BV2	   microglia	   were	   assessed	   for	   glutathione	  
production	  by	   incubation	  at	  37°C	  for	  45	  min	  with	  MCB	  (5	  µg/mL)	  and	  counterstained	  
with	   PI.	   To	   confirm	   glutathione	   production,	   cells	   were	   incubated	   with	   1	   mM	   EA,	   a	  
potent	  inhibitor	  of	  glutathione	  S-­‐transferases	  for	  10	  min	  before	  and	  during	  incubation	  
with	  MCB	  as	  previously	  described	  in	  our	  laboratory	  (Hooper	  et	  al.	  2009).	  Coverslips	  for	  
glutathione	   imaging	  were	  mounted	   in	  saline	  solution	  consisting	  of	  153	  mM	  NaCl,	  3.5	  
mM	  KCl,	  0.4	  mM	  KH2PO4,	  20	  mM	  TES,	  5	  mM	  NaHCO3,	  1.2	  mM	  Na2SO4,	  1.2	  mM	  MgCl2,	  
1.3	  mM	  CaCl2,	  5	  mM	  glucose,	  and	  observed	   immediately	  by	  fluorescence	  microscopy	  
using	   the	   FITC	   (green	   fluorochrome	   488	   nm)	   and	   DAPI	   (blue	   fluorochrome	   364	   nm)	  
filter	   sets	   on	   a	   Zeiss	   fluorescence	   microscope	   (Zeiss	   Axioskop	   2,	   Oberkochen,	  
Germany).	  The	  mean	  cellular	  fluorescence	  of	  approximately	  50	  cells/field,	  from	  three	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fields	   per	   coverslip,	   three	   coverslips	   per	   condition	   and	   from	   three	   independent	  
experiments	  was	  determined	  using	  Image	  J	  software.	  	  	  
	  
2.2.13	  Small	  interfering	  RNA	  (siRNA)	  
Ribonucleic	  acid	  (RNA),	  one	  of	  the	  information	  macromolecules,	  has	  a	  number	  of	  
functions	  in	  gene	  coding,	  decoding,	  regulation	  and	  expression.	  RNA	  molecules	  are	  able	  
to	   inhibit	   gene	   expression	   in	   a	   process	   known	   as	   RNA	   interference	   and	   small	  
interfering	   RNA	   (siRNA)	   play	   a	   pivotal	   role	   in	   this.	   The	   mechanism	   involves	   the	  
degradation	  of	  double-­‐stranded	  RNA	  (dsRNA)	  into	  short	  fragments	  of	  about	  21-­‐25	  base	  
pairs	  in	  length	  known	  as	  siRNAs,	  by	  an	  enzyme	  specific	  to	  dsRNA	  called	  Dicer.	  After	  the	  
fragment	  is	  unwound	  into	  single	  stranded	  RNA	  (ssRNA),	  the	  guide	  strand	  incorporates	  
into	  a	  sequence-­‐specific	  RNA	  endonuclease	  known	  as	  RNA	  induced	  silencing	  complex	  
(RISC).	  This	  complex	  then	  binds	  to	  a	  complementary	  messenger	  RNA	  (mRNA)	   leading	  
to	  their	  degradation	  and	  therefore	  reduced	  levels	  of	  protein	  translation,	  subsequently	  
blocking	  the	  function	  of	  the	  gene	  (Strachan	  &	  Read	  2004).	  	  
	  
2.2.13.1	  Small	  interfering	  RNA	  transfection	  
In	   this	   study	   nanoTherics	   magnet-­‐assisted	   transfection	   technology	   (Magnefect	  
nano	  II)	  was	  used.	  The	  system	  involves	  mixing	  biodegradable	   iron	  oxides	  coated	  with	  
cationic	  molecules	  to	  biomolecules	  such	  as	  siRNA	  to	  form	  a	  biomolecule/nanoparticle	  
complex,	   which	   would	   be	   then	   added	   to	   the	   cells	   to	   be	   transfected.	   The	   plate	  
containing	   the	   cells	   and	  biomolecule/nanoparticle	   complex	   is	  placed	  on	  a	  magnet	   to	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attract	   the	   complex	   to	   the	   cells	   at	   the	   bottom	   (see	   Fig.	   2.2).	   The	   oscillation	   of	   the	  
magnet	   array	   promotes	   endocytosis	   into	   the	   cell	   allowing	   for	   efficient	   transfection,	  









Initially,	   the	   transfection	  was	  optimized	   from	  published	  methodologies	   (Fouriki	  
et	   al.	   2010;	   Fouriki	   et	   al.	   2012)	  with	   transfection	  of	  nos2	   siRNA.	  A	  DNA/T-­‐Mag	  bead	  
concentration	   dependent	   assay	   (0,	   0.5,	   1,	   1.2μl)	   was	   carried	   out	   on	   BV2	   microglia	  
plated	  at	  a	  number	  of	  densities	  (2.5	  x	  103	  and	  5	  x	  104	  on	  13mm	  PDL-­‐coated	  coverslips)	  
Figure	   2.2:	   Overview	   of	   how	   transfection	   technology	   uses	   magnetic	   nanoparticles	   and	   oscillating	  
magnetic	  fields	  to	  accurately	  and	  rapidly	  transfect	  DNA	  into	  BV2	  cells.	  
(a)	   Incubation	   of	   the	   DNA	   with	   the	   magnetic	   nanoparticle	   coated	   with	   a	   positively	   charged	   polymer	  
(nTMAG)	  in	  a	  1:1	  ratio	  for	  30	  min	  with	  vigorous	  shaking	  results	  in	  hundreds	  of	  plasmids	  condensing	  onto	  
each	   nTMAG.	   (b)	   Magnefects-­‐nano	   II’s	   oscillating	   magnets	   pull	   nTMAG-­‐DNA	   particle	   onto	   the	   cell	  
surface.	   (c)	   The	   cells	   are	   stimulated	   by	   the	   oscillation	   motion	   of	   the	   particle	   to	   initiate	   endocytosis	  
enhancing	   uptake	   of	   the	   nTMAG-­‐DNA	   complex.	   The	   polymer	   coating	   facilitates	   the	   release	   into	   the	  




to	  determine	  the	  optimum	  conditions	  for	  the	  experiment.	  Further	  optimization	  of	  this	  
experiment	  was	  carried	  out	  by	  testing	  a	  range	  of	  displacement	  values	  (0.2,	  0.5mm).	  	  
The	  optimum	  conditions	  determined	  demonstrated	   inhibition	  of	   cells	  with	   the	  NOS2	  
siRNA	  expressing	  iNOS	  fluorescence	  within	  a	  favourable	  cell	  volume	  and	  were	  found	  to	  
be:	  1.2	  μl	  DNA/T-­‐Mag	  bead	  mix	  at	  1:1	   ratio	  at	  2Hz	  and	  0.5mm	  displacement	   for	  1hr	  
and	  BV2	  density	  at	  5	  x	  104	  per	  well	  of	  a	  24-­‐well	  plate	  (Fig.	  2.3).	  
	  
	  
2.2.13.3	  Crry	  siRNA	  transfection	  
BV2	  microglia	  were	  grown	  on	  a	  24-­‐well	  plate	  at	  a	  density	  of	  5	  x	  104	  per	  well	  in	  D-­‐
MEM	   supplemented	  with	   10%	   FBS,	   penicillin	   and	   streptomycin.	  ON-­‐TARGETplus	   crry	  
DNA	   (0.6	   µM)	   (Dharmacon,	   CO,	  USA)	   and	   Polymag	  beads	   (Oz	   biosciences,	  Marseille,	  
France)	  were	  added	  in	  a	  1:1	  ratio	  to	  200	  μl	  serum-­‐free	  D-­‐MEM	  per	  well	  and	  incubated	  
Figure	   2.3:	   siRNA	   optimization	   of	   nos2	  
transfection	  in	  BV2	  microglia.	  
BV2	  microglia	  at	  a	  density	  of	  5	  x	  104	  per	  well	  
were	   transfected	   with	   1.2	   μl	   DNA/T-­‐Mag	  
bead	  mix	  and	  placed	  on	  the	  magnefect	  nano	  
II	   plate	   for	   1	   hr	   at	   2Hz	   with	   0.5mm	  
displacement.	  Immunocytochemistry	  (a)	  and	  
western	   blot	   (b)	   for	   iNOS	   expression	   was	  




at	   room	   temperature	   for	   30	   mins	   with	   vigorous	   shaking.	   BV2	   microglia	   were	  
transfected	  with	  ON-­‐TARGETplus	  cyclophilin	  B	  control	  siRNA	  (Dharmacon,	  CO,	  USA)	  as	  
control.	   The	   DNA/bead	   mix	   was	   then	   added	   to	   the	   BV2	   microglia	   and	   placed	   on	   a	  
Magnefect	  nano	   II	   system	   (nanoTherics,	   Staffordshire,	  UK)	   at	   2Hz	   for	   1	  h	   at	   0.5	  mm	  
displacement	  in	  a	  tissue	  culture	  incubator	  at	  37	  oC	  in	  a	  humidified	  atmosphere	  with	  5%	  
CO2.	  BV2	  microglia	  were	  then	  incubated	  at	  37
	  oC	  for	  12	  h	  prior	  to	  treatment	  with	  LPS	  (1	  
µg/ml)	  and	  Aβ1-­‐42	  (20	  nM)	  for	  a	  further	  24	  h.	  	  
	  
2.2.14	  Enzyme	  linked	  immunosorbent	  assays	  (ELISA)	  of	  TNFα,	  IL-­‐1β	  and	  IL-­‐6	  release	  
The	   enzyme-­‐linked	   immunosorbent	   assays	   (ELISA)	   is	   a	   method	   that	   was	  
simultaneously	   developed	  by	   two	   groups	   in	   1971	  which	   is	   used	   for	   quantification	  of	  
protein	   concentration	   in	   a	   given	   sample	   (Engvall	  &	   Perlmann	   1971;	   Van	  Weemen	  &	  
Schuurs	   1971).	   This	   technique	   is	   useful	   for	   the	   quantitative	   analysis	   of	   functional	  
cytokine	  release.	  Quantitative	  sandwich	  ELISA	  kits	  for	  the	  measurement	  of	  TNFα,	  IL-­‐1β	  
and	   IL-­‐6	   from	  R&D	  Systems	  were	  used	   for	   the	   concentration	  of	  TNFα,	   IL-­‐1β	  and	   IL-­‐6	  
released	  from	  treated	  microglia.	  The	  sandwich	  ELISA	  kit	  involves	  a	  primary	  monoclonal	  
antibody	   bound	   to	   the	   surface	   of	   the	   well,	   which	   enables	   the	   antigen	   under	  
investigation	   to	   bind	   directly	   onto	   the	   bound	   antibody	   (Belanger	   et	   al.	   1973).	   The	  
antigen	   is	   visualized	   by	   a	   second	   polyclonal	   antigen-­‐specific	   antibody	   with	   a	   HRP	  
conjugation,	   providing	   a	   concentration	   dependent	   signal	   that	   is	   amplified	   and	  
visualized	  using	  a	  plate	  reader.	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Microglia	   were	   treated	   as	   required	   and	   the	   media	   was	   collected	   from	   the	  
cultures	   in	   sterile	   Eppendorf	   tubes	   centrifuged	   at	   800	   g	   in	   an	   Eppendorf	   5415R	  
benchtop	  centrifuge	   for	  5	  min	  at	  4°C	  to	  pellet	  debris.	  Supernatant	  was	  removed	  and	  
placed	   in	   fresh	  Eppendorf	   tubes	  and	  snap	  frozen	  on	  dry-­‐ice	  and	  stored	  at	   -­‐20°C	  until	  
required.	   It	   is	   important	   to	   promptly	   prepare	   and	   store	   the	   sample	   to	   prevent	  
significant	  degradation	  of	  the	  released	  cytokines.	  
	   The	   assay	   was	   performed	   according	   to	   the	   manufacturer’s	   instructions,	   in	   96	  
well	  plates	  precoated	  with	  a	  monoclonal	  rat	  TNFα/IL-­‐1β/IL-­‐6	  specific	  antibody.	  50	  μl	  of	  
assay	   diluents	  was	   added	   to	   each	  well	   followed	   by	   50	   μl	   of	   each	   of	   the	   internal	   kit	  
standard	   rat	   TNFα/IL-­‐1β/IL-­‐6	   samples	   of	   known	   concentrations,	   TNFα/IL-­‐1β/IL-­‐6	   kit	  
controls	   and	   media	   samples.	   After	   gentle	   mixing	   on	   an	   orbital	   shaker	   (Medgenix	  
Diagnostics,	  Fleurus,	  Belgim)	  for	  1	  min	  at	  60rpm,	  the	  samples	  were	  incubated	  for	  2	  h	  at	  
room	   temperature	   followed	   by	   five	   washes	   with	   wash	   buffer.	   Samples	   were	   then	  
incubated	  with	  100	  μl	  of	   rat	  TNFα/IL-­‐1β/IL-­‐6	  conjugate,	  which	  consists	  of	   the	  second	  
rat	  anti-­‐	  TNFα/IL-­‐1β/IL-­‐6	  antibody	  conjugated	  to	  horseradish	  peroxidase	  (HRP),	  for	  2	  h	  
at	   room	  temperature,	   followed	  by	   five	  washes	  with	  wash	  buffer.	  100	  μl	  of	   substrate	  
solution	   was	   added	   to	   the	   wells	   for	   30	   min	   in	   the	   dark	   at	   room	   temperature.	   The	  
substrate	   solution	   reacts	  with	   the	  HRP	   conjugate	   and	  provides	   a	   luminescent	   signal.	  
Finally,	   100	   μl	   of	   the	   stop	   solution	   (hydrochloric	   acid)	   was	   added	   to	   each	   well	   to	  
terminate	   the	   colour	   reaction.	   The	   plate	  was	   gently	   shaken	   at	   60rpm	   for	   1	  min	   and	  
optical	   density	  was	  measured	  with	   a	  microplate	   reader	   at	   450	   nm	  with	   a	   reference	  
filter	   at	   540	   nm	   to	   correct	   for	   optical	   imperfections.	   The	   plate	   optical	   density	   was	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measured	   within	   30	  min	   of	   the	   addition	   of	   the	   stop	   solution.	   The	   concentration	   of	  
TNFα/IL-­‐1β/IL-­‐6	  in	  the	  cell	  medium	  samples	  was	  determined	  against	  a	  standard	  curve	  
from	   the	   standard	   samples	   used	   on	   the	   same	   96	   well	   plate.	   Samples	   were	   run	   in	  
duplicate	  from	  three	  independent	  experiments	  to	  allow	  for	  statistical	  analysis.	  	  
	  
2.2.15	  Western	  Blotting	  
Western	  blotting	   is	  a	  gel	  electrophoresis	  and	  blotting	  method	  used	  to	  separate	  
and	   identify	   proteins	   of	   interest	   in	   a	   biological	   sample.	   This	   technique	   was	   used	   to	  
determine	  the	  expression	  levels	  of	  different	  proteins	  of	  interest.	  Denaturing	  gels	  were	  
used	   and	   the	  Western	   blotting	   protocol	   relied	   on	   the	   denaturation	   of	   all	   expressed	  
proteins	   in	   the	   cell,	   of	   which	   single	   proteins	   could	   be	   identified	   by	   immunoblotting	  
with	  antibodies	  directed	  against	  epitopes	  of	  the	  protein	  of	  interest.	  	  
	  
2.2.15.1	  Cell	  lysis	  for	  Western	  blotting	  
Cells	   were	   harvested	   into	   lysis	   buffer	   containing	   20	   mM	   Tris-­‐acetate,	   1	   mM	  
ethylene	   diamine	   tetraacetic	   acid	   (EDTA)	   to	   chelate	   calcium,	   1	  mM	   ethylene	   glycol	  
tetraacetic	   acid	   (EGTA)	   to	   chelate	   magnesium,	   10	   mM	   of	   the	   phosphatise	   inhibitor	  
sodium–β–glyerophosphate,	  1	  mM	  of	  the	  tyrosine	  phosphatise	  sodium	  orthovanadate,	  
5%	  glycerol	  to	  depress	  the	  solution’s	  freezing	  temperature,	  1%	  Triton	  X-­‐100	  membrane	  
solubiliser,	  0.27M	  sucrose,	  1	  mM	  of	  the	  protease	  inhibitor	  benzamidine,	  4	  μg/ml	  of	  the	  
protease	   inhibitor	   leupeptin,	  1	  µM	  pf	   the	  phosphatase	   inhibitor	  microcystine	   LR	  and	  
0.1%	   of	   the	   reducing	   agent	   β-­‐mercaptoethanol,	   pH	   7.4	   (Kingham	   and	   Pocock.	   2000)	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and	   incubated	  on	   ice	   for	  10	  min,	  before	  being	   centrifuged	   for	  10	  min	  at	  14,000	  g	   to	  
pellet	   the	   nuclear	   and	   membrane	   fractions.	   Supernatants	   were	   transferred	   to	   new	  
eppendorf	   tubes	  and	  all	   samples	  were	  stored	  at	   -­‐20°C	  until	  used.	  The	   formulation	  of	  
the	   lysis	   buffer	   is	   such	   that	   the	   buffer	   lyses	   the	   cells	   and	   also	   solubilises	   the	  
membranes,	   in	  addition	   to	  preserving	   the	  proteins	  at	   the	   time	  of	   lysis	  by	  preventing	  
phosphorylation,	  dephosphorylation	  and	  proteolysis.	  
	  
2.2.15.2	  Bradford	  assay	  
A	   Bradford	   protein	   determination	   assay	   (Bradford	   1976)	   was	   carried	   out	   to	  
determine	  the	  protein	  concentration	  of	  the	  cell	  lysate	  supernatants	  (SN)	  using	  bovine	  
serum	  albumin	  (BSA)	  as	  a	  standard.	  In	  a	  96	  well	  plate,	  1	  µl	  of	  each	  sample	  was	  added	  
into	  the	  wells	   in	  triplicate	  and	  200	  µl	  Bradford	  reagent	  was	  added	  onto	  this.	  Samples	  
were	  shaken	  and	  left	  at	  room	  temperature	  for	  5	  min	  before	  the	  absorbance	  shift	  of	  the	  
Coomassie	   dye	   towards	   the	   blue	   spectrum	   following	   the	   binding	   of	   protein	   was	  
measured	  at	  595	  nm	  on	  a	  Tecan	  X	  Fluor	  4	  plate	  reader.	  The	  absorbance	  of	  each	  sample	  
was	  compared	  to	  a	  standard	  curve	  of	  BSA	  of	  known	  concentrations,	  constructed	  on	  the	  
same	  plate	  as	  the	  experimental	  samples.	  From	  this,	  the	  volume	  of	  the	  lysate	  required	  
for	  45	  µg	  of	  protein	  on	  the	  SDS	  page	  gel	  derived,	  and	  this	  quantity	  of	  sample	  was	  then	  
removed	   to	   another	   eppendorf	   tube.	   To	   these	   samples,	   an	   equal	   volume	   of	   sample	  
buffer	  (2%	  SDS,	  10%	  glycerol,	  2.5%	  β-­‐mercaptoethanol,	  125	  mM	  Tris/HCL	  (pH	  6.8)	  and	  
a	  few	  bromophenol	  blue	  crystals)	  was	  added	  to	  denature	  the	  protein,	  and	  aid	  loading	  
and	  visualisation	  of	  the	  gel	  front.	  Samples	  were	  then	  boiled	  for	  5	  min	  before	  loading.	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2.2.15.3	  Sodium	  Dodecyl	  Sulphate	  Polyacrylamide	  Gel	  Electrophoresis	  
Cell	   lysate	   protein	  was	   separated	   on	   Sodium	  Dodecyl	   Sulphate	   Polyacrylamide	  
Gel	   Electrophoresis	   (SDS-­‐PAGE)	   gels	   using	   a	   minigel	   apparatus	   (Biorad),	   with	   10%	  
resolver	  and	  4%	  stacking	  gels.	  The	  resolver	  gel	  contained	  3.33	  ml	  30%	  polyacrylamide,	  
2.5	  ml	  resolver	  buffer	  (pH	  8.8)	  (18.1	  g	  Tris/HCL,	  1	  ml	  10%	  SDS),	  4.17	  ml	  H20,	  50	  μl	  10%	  
APS	  (fresh)	  and	  5	  μl	   tetramethylethylenediamine	  (TEMED).	  The	  stacker	  gel	  contained	  
1.33ml	  30%	  polyacrylamide,	  2.5	  ml	  stacker	  buffer	  (pH	  6.8)	  (6.05	  g	  Tris/HCL,	  1	  ml	  10%	  
SDS),	  6.17	  ml	  H20,	  50	  μl	  10%	  Ammonium	  persulfate	  	  (APS)	  and	  5	  μl	  TEMED.	  The	  TEMED	  
and	   APS	  were	   added	   last	   to	   aid	   in	   the	   setting	   of	   the	   gels.	   After	   the	   addition	   of	   the	  
stacker	   gel	   a	   comb	  was	   placed	   in	   the	   top	   of	   the	   plate	   to	   form	  wells.	   The	   gels	  were	  
placed	  in	  their	  holder	  into	  the	  tank	  and	  the	  wells	  were	  filled	  with	  running	  buffer	  (125	  
mM	  Tris/HCl,	  1	  M	  glycine,	  0.01%	  SDS).	  The	  samples	  were	  loaded	  into	  the	  well	  based	  on	  
the	   amount	   of	   sample	   containing	   45	   µg	   of	   protein	   as	   determined	   by	   the	   Bradford	  
assay.	   Prior	   to	   loading	   the	   samples	  were	   diluted	   1:1	   in	   sample	   buffer	   (2%	   SDS,	   10%	  
glycerol,	  2.5%	  mercaptoethanol,	  125	  mM	  Tris/HCl	  pH	  6.8	  and	  a	  few	  bromophenol	  blue	  
crystals)	   and	   were	   boiled	   for	   4	   min	   to	   denature	   the	   protein.	   The	   molecular	   weight	  
marker	  and	  samples	  were	  carefully	  added	   into	  the	  wells	  and	  the	  tank	  was	  filled	  with	  
running	  buffer.	  The	  gels	  were	   run	  at	  160V	   (constant	  voltage)	  until	   the	  dye	   front	  was	  
near	  the	  end	  of	  the	  gel.	  
Following	   the	   separation	   of	   the	   proteins	   the	   gel	  was	   carefully	   removed	   from	  
the	  glass	  plates	  and	  equilibrated	   for	  20	  minutes	   in	   cold	   transfer	  buffer	   (25	  mM	  Tris,	  
192	  mM	  glycine,	  20%	  methanol,	  0.01%	  SDS).	  While	  the	  gel	  was	  equilibrating,	  a	  piece	  of	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polyvinylidene	  difluoride	  (PVDF)	  membrane	  (Immobilon	  P)	  cut	  to	  the	  same	  size	  as	  the	  
gel	  was	  activated	  in	  ice-­‐cold	  methanol	  for	  1	  min.	  This	  was	  followed	  by	  5	  min	  in	  distilled	  
water	   and	  approximately	   20	  min	   in	   cold	   transfer	  buffer.	   Two	  pieces	  of	  wadding	   and	  
3MM	  paper	  also	  cut	  to	  the	  size	  of	  the	  gel	  were	  pre-­‐soaked	  in	  cold	  transfer	  buffer.	  After	  
equilibration	  the	  gel	  was	  transferred	  to	  a	  cassette.	  The	  order	  of	  placement	  within	  the	  
cassette	  was	  wadding,	  3MM	  paper,	   gel,	   PVDF	  membrane,	  3MM	  paper	  and	  wadding.	  
The	   cassette	   was	   slotted	   into	   its	   holder	   and	   placed	   into	   the	   tank	   filled	   with	   cold	  
transfer	   buffer,	   next	   to	   an	   ice	   pack.	   The	   transfer	   was	   run	   at	   80V	   for	   1	   h	   to	   allow	  
proteins	   to	   transfer	   onto	   the	   membrane.	   The	   proteins	   migrated	   from	   the	   negative	  
anode	   to	   the	   positive	   cathode,	   and	   attached	   to	   the	   positively	   charged	   membrane.	  
Following	  transfer,	  membranes	  were	  washed	  in	  Tween-­‐20	  Tris	  buffer	  saline	  (TTBS:	  10	  
mM	  Tris	  HCL,	  150	  mM	  NaCl,	  0.5%	  Tween-­‐20,	  pH	  7.4)	  for	  10	  min,	  and	  membranes	  were	  
then	  blocked	  in	  5%	  non-­‐fat	  milk	  solution	  in	  TTBS	  for	  1	  h	  to	  prevent	  non-­‐specific	  binding	  
of	  the	  antibody.	  The	  membranes	  were	  then	  ready	  for	  immunoblotting.	  
	  
2.2.15.4	  Immunoblotting	  
After	  blocking	  with	  5%	  non-­‐fat	  milk	   solution,	  membranes	  were	   incubated	  with	  
the	   primary	   antibody	   diluted	   in	   5%	   non-­‐fat	   milk	   as	   shown	   in	   Table	   2.3.	   Typically	  














Rabbit	  anti	  mouse	  
iNOS	  	  
(BD	  transduction	  lab	  
610333)	  
1:5000	  2	  h	  room	  
temp	  
Goat	  anti-­‐rabbit	  IgG	  
peroxidise	  
	  (Sigma	  A-­‐0545)	  
1:2000	  	  
1	  h	  room	  temp	  
Anti-­‐CD35	  (E11)	  
(Abcam	  ab25)	  
1:500	  overnight	  at	  
4°C	  
Rabbit	  anti-­‐mouse	  
IgG	  HRP	  	  
(Santa	  Cruz	  358914)	  
1:1000	  




1:100	  overnight	  at	  
4°C	  
Rabbit	  anti-­‐mouse	  
IgG	  HRP	  	  
(Santa	  Cruz	  358914)	  
1:1000	  
1h	  room	  temp	  
Mouse	  anti	  rabbit	  
beta	  actin	  	  
(Sigma	  A2066)	  
1:2000	  2	  h	  room	  
temp	  
Rabbit	  anti-­‐mouse	  
IgG	  HRP	  	  
(Santa	  Cruz	  358914)	  
1:1000	  	  
1	  h	  room	  temp	  
Table	  2.3.	  List	  of	  primary	  and	  secondary	  antibodies	  used	  for	  Western	  blotting.	  
	  
Following	   incubation	  with	   the	  primary	  antibodies	   (Table	  2.3),	   the	  membranes	  
were	  washed	  three	  times	  with	  TTBS	  and	  then	  incubated	  with	  secondary	  antibodies	  as	  
shown	  in	  Table	  2.3	  for	  1	  h	  at	  room	  temperature	  on	  an	  orbital	  shaker.	  The	  membranes	  
were	  then	  washed	  a	  further	  three	  times	  with	  TTBS	  and	  were	  exposed	  using	  enhanced	  
chemiluminescence	  (ECL).	  Membranes	  were	  drained	  and	  placed	  in	  a	  tray	  containing	  an	  
equal	   volume	  of	   each	  ECL	   solution	   and	  were	   incubated	   for	   1	  min.	  Membranes	  were	  
then	  blotted	  on	  filter	  paper	  to	  remove	  excess	  ECL	  solution,	  and	  were	  wrapped	  in	  saran	  
wrap	  and	   fixed	   in	   an	  X-­‐ray	   cassette.	   In	   the	  dark,	   a	  piece	  of	  Amersham	  photographic	  
film	  (GE	  Healthcare,	  UK)	  was	  placed	  onto	  the	  membranes	  to	  expose	  the	  protein	  bands.	  
Photographic	  paper	  was	  then	  developed	  in	  developing	  solution	  and	  immersed	  in	  fixing	  
solution	  before	  finally	  being	  rinsed	  in	  water.	  The	  films	  were	  dried	  and	  analysed	  and	  the	  
80	  
	  
expression	  of	  each	  protein	  was	  quantified	  using	  densitometry	  (Image	  J).	  Western	  blots	  
were	  performed	  three	  times	  and	  those	  presented	  here	  are	  representative.	  Blots	  were	  
routinely	  re-­‐probed	  for	  β-­‐actin	  as	  a	  loading	  control	  to	  ensure	  equal	  loading	  of	  protein,	  
which	  was	  also	  used	  for	  densitometry.	  
	  
2.2.16	  Immunohistochemistry	  
Human	   post-­‐mortem	   tissue	   was	   collected	   in	   accordance	   with	   Institutional	  
Review	  Board-­‐approved	  guidelines	  at	  Brigham	  and	  Women’s	  hospital.	  Blocks	  of	  brain	  
tissue	  were	  fixed	  for	  ∼2	  h	   in	  10%	  neutral	  buffered	  formalin.	  After	   fixation,	   the	  tissue	  
was	  dehydrated	  and	  embedded	  in	  paraffin.	  10-­‐micron	  serial	  sections	  were	  cut,	  dried,	  
and	  baked	  at	  60°C	  for	  1.5	  h.	  
Sections	  were	  deparaffinized	  in	  two	  changes	  of	  Histoclear	  (National	  Diagnostics,	  
Atlanta,	   GA)	   and	   rehydrated	   in	   graded	   ethanol	   solutions.	   Endogenous	   peroxidase	  
activity	  was	  quenched	  by	  incubation	  of	  these	  sections	  in	  0.3%	  hydrogen	  peroxidase	  in	  
methanol	  for	  10	  min	  at	  room	  temperature.	  The	  sections	  were	  washed	  in	  water	  twice	  at	  
5	   min	   each.	   Pretreatment	   and	   dilution	   testing	   was	   performed	   for	   each	   primary	  
antibody	   and	   the	   experiment	   continued	  with	   the	   suitable	   combination,	   as	   shown	   in	  
Table	  2.4.	  Formic	  acid	  pretreatment	  consisted	  of	  the	  application	  of	  88%	  formic	  acid	  to	  
sections	   for	   10	   min	   at	   room	   temperature,	   followed	   by	   a	   10	   min	   water	   wash.	   Heat	  
mediated	  antigen	  retrieval	  pretreatment	  consisted	  of	  heating	  sections	  in	  citrate	  buffer	  
in	  a	  microwave	  (BioGenex,	  San	  Ramon,	  CA)	  until	  the	  solution	  came	  to	  a	  boil.	  The	  heat	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level	  was	  then	  reduced	  to	  provide	  gentle	  cyclic	  boiling	  for	  an	  additional	  5	  min.	  Sections	  
were	   cooled	   to	   room	   temperature	   and	  washed	   in	  water.	  After	   the	  pretreatment,	   all	  
sections	   were	   blocked	   for	   20	   min	   in	   10%	   horse	   serum	   in	   TBS	   (for	   CR1	   antibodies).	  
Sections	  were	  incubated	  with	  primary	  antibody	  in	  TBS	  overnight	  at	  4°C.	  Following	  a	  10	  
min	   wash	   in	   TBS,	   the	   horseradish	   peroxidase	   avidin-­‐biotin	   complex	   system	   (ABC)	  
(mouse	  Elite	  ABC	  kit;	  Vector	  Laboratories,	  Burlingame,	  CA)	  and	  diaminobenzine	  (DAB)	  
(Sigma	  Immunochemicals,	  St.	  Louis,	  MO)	  were	  used	  to	  visualize	  the	  bound	  antibodies.	  
The	  ABC	  staining	  allows	  for	  an	  improved	  sensitivity	  to	  the	  antibody	  through	  increasing	  
the	  amount	  of	  enzyme	  molecules	  bound	  to	  the	  target	  antigen	  thereby	  amplifying	  the	  
signal.	  
Sections	  were	  counterstained	  with	  hematoxylin,	  differentiated	  with	  acid	  alcohol,	  
dehydrated,	   cleared	   in	  Histoclear,	   and	  mounted	  on	   coverslips	  with	  Permount	   (Fisher	  








Antibody	   Target	   Stock	  conc	  
(mg/ml)	  




6B1	   CR1	  -­‐	  LHR-­‐D	   0.465	   1:100	   Heat-­‐
mediated	  
543	   CR1	  -­‐	  LHR-­‐C,	  D	   0.6	   1:100	   Heat-­‐
mediated	  
CR1	  Rabbit	  pAb	   CR1	  -­‐	  multi-­‐
epitope	  
3	   1:100	   Heat-­‐
mediated	  
YZ1	   CR1	  -­‐	  SCRs	  
5,6,7,	  of	  LHR-­‐
A,B,C	  
3	   1:100	   Heat-­‐
mediated	  
IC7	   CR1	   0.8	   1:100	   Heat-­‐
mediated	  















IgG1	   1	   -­‐	   -­‐	   abcam	  
3A1	   Aβ1-­‐15,	  Aβ1-­‐
40	  
0.685	   1:100	   -­‐	   Dr	  Brian	  
O’Nuallian	  
R1282	   Aβ1-­‐40	   -­‐	   1:1000	   FA	   Dr	  Dennis	  
Selkoe	  
Table	  2.4.	  List	  of	  primary	  antibodies	  used	  for	  Immunohistochemistry	  and	  flow	  cytometry.	  
For	   Immunofluorescence	   staining	   with	   6B1,	   543	   and	   CR1	   Rabbit	   pAb’s,	   tissue	  
sections	   or	   blood	   smears	   underwent	   heat-­‐mediated/formic	   acid/methanol	  
pretreatment	   as	   indicated	   in	   chapter	   5.	   The	   sections/smears	   were	   pretreated	   with	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0.1M	  Tris	   solution	  and	   then	  blocked	   in	  2%	  goat	  serum	   in	  0.1M	  Tris	  buffer	   for	  5	  min.	  
The	  sections/smears	  were	  incubated	  with	  the	  primary	  antibodies	  at	  dilutions	  indicated	  
in	   Table	   2.4	   overnight	   at	   4°C.	   Following	   a	   rinse	   with	   0.1M	   Tris	   buffer,	   the	  
sections/smears	  were	   immersed	   in	  2%	  goat	   serum	   in	  0.1M	  Tris	  buffer	   for	  5min.	   The	  
sections/smears	  were	  incubated	  with	  the	  secondary	  antibody	  (1:1000)	  for	  2	  hr	  at	  room	  
temperature	  in	  a	  moist	  chamber.	  The	  sections/smears	  were	  washed	  twice	  in	  0.1M	  Tris	  
buffer	   for	   20	  min	   and	   tissue	   sections	   were	   immersed	   in	   Sudan	   Black	   B	   for	   10	  min.	  
Immersion	   with	   Sudan	   Black	   B	   reduces	   the	   autofluorescence	   background	   without	  
interfering	   with	   the	   integrity	   of	   the	   brain	   tissue	   (Oliveira	   et	   al.	   2010).	   	   Following	  
washing	  steps	  in	  TBS	  the	  sections	  and	  smears	  were	  washed	  in	  water	  for	  5	  min,	  fixed	  in	  
10%	  formalin	  for	  1	  h	  at	  room	  temperature,	  washed	  in	  water	  for	  20	  min	  and	  mounted	  
on	  coverslips	  with	  Vectashield	  with	  DAPI	  as	  a	  counterstain	  (Vector,	  Burlingame,	  CA).	  To	  
quantify	   immunoreactivity,	   acquisition	   of	   images	   was	   performed	   in	   a	   single	   session	  
using	  a	  QICAM	  camera	  (Q-­‐imaging)	  mounted	  on	  an	  Olympus	  BX50	  microscope.	  	  
	  
2.2.17	  Flow	  Cytometry	  
Flow	   cytometry	   is	   a	   technology	   used	   for	   the	   measurement	   and	   analysis	   of	  
multiple	   characteristics	   of	   single	   cells,	   by	   passing	   thousands	   of	   cells	   per	   second	  
through	  a	  laser	  beam	  and	  capturing	  the	  light	  that	  emerges	  from	  each	  cell	  as	  it	  passes	  
through.	  This	  method	  is	  used	  for	  a	  range	  of	  applications	  including	  immunophenotyping	  
and	   cell	   counting.	   The	   data	   gathered	   can	   be	   statistically	   analyzed	   using	   software	   to	  
measure	  cellular	  characteristics	  such	  as	  size	  (by	  measuring	  forward	  scatter),	  phenotype	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(by	  measuring	   fluorescence	  of	   bound	  antibodies)	   and	   complexity	   (by	  measuring	   side	  
scatter).	  In	  this	  thesis	  flow	  cytometry	  was	  used	  to	  measure	  fluorescence	  to	  determine	  
presence	   of	   CR1	   and	  Aβ	   on	   red	   blood	   cells	   (RBCs).	   Fluorescence	   is	   described	   as	   the	  
excitation	   of	   a	   fluorophore	   to	   a	   higher	   energy	   level	   followed	   by	   the	   return	   of	   that	  
fluorophore	  to	   its	  ground	  state	  with	  the	  emitting	  of	   light.	  The	  energy	  of	   this	  emitted	  
light	  is	  dependent	  on	  the	  energy	  level	  to	  which	  the	  fluorophore	  is	  excited.	  
The	   method	   used	   is	   this	   study	   was	   adapted	   from	   previously	   published	   work	  
(Ghiran	  et	  al.	  2008b).	  Briefly,	  50	  μl	  of	  whole	  blood	  cells	  were	  mixed	  with	  500μl	  Hank’s	  
balanced	   salt	   solution	   (HBSS)	   followed	   by	   centrifugation	   at	   65	   g	   for	   2	  minutes.	   The	  
washing	  step	  was	  repeated	  one	  time.	  2μl	  of	  packed	  RBCs	  were	  mixed	  with	  500	  μl	  HBSS	  
containing	   specific	   antibodies	   to	   CR1,	   Aβ	   or	   an	   IgG	   isotype	   control	   (Table	   2.4)	   at	   a	  
concentration	  of	  5	  μg/mL.	  The	  mixture	  was	  incubated	  for	  5	  mins	  at	  room	  temperature.	  
This	  was	  followed	  by	  two	  washes	  with	  200	  μl	  HBSS	  followed	  by	  incubation	  with	  Alexa	  
Fluor	   488-­‐congugated	   secondary	   antibodies	   specific	   for	   each	   primary	   antibody	   at	   a	  
dilution	  of	  1:1000	  in	  HBSS.	  After	  incubation	  with	  secondary	  antibodies	  for	  10	  min,	  RBCs	  
were	   washed	   once,	   resuspended	   in	   400	   μl	   HBSS,	   transferred	   to	   polystyrene	   round	  
bottom	  FACS	  tubes	  and	  analyzed	  using	  a	  FACSCalibur	  flow	  cytometer	  (BD	  Biosciences).	  
For	   each	   sample,	   10,000	   events	   were	   counted	   and	   analyzed	   using	   FlowJo	   software	  
(version	  10.0.6),	  which	  then	  provided	  the	  number	  of	  positive	  cells	  after	  gating	  on	  the	  




2.2.18	  Statistical	  analysis	  
To	  assess	  statistical	  significance,	  experiments	  were	  performed	  in	  triplicate	  using	  
three	  separate	  cell	  preparations.	  In	  imaging	  experiments,	  three	  coverslips	  were	  imaged	  
per	   condition,	   and	   a	   minimum	   of	   six	   fields	   of	   view	   per	   coverslip	   were	   imaged	   and	  
analysed.	  Where	   percentages	  were	   calculated,	   statistical	   analysis	  was	   performed	   on	  
transformed	   data.	   Statistical	   analysis	   was	   performed	   using	   the	   GraphPad	   Prism	  
software.	  Data	  was	   analysed	  using	  one-­‐way	  ANOVA	  with	  Tukey	  multiple	   comparison	  
post-­‐hoc	  analysis	  whereby	  post-­‐hoc	  comparisons	  were	  made	  between	  control,	  LPS	  and	  
Aβ1-­‐42	   and	   between	   the	   same	   conditions	   following	   the	   treatment	   of	   CR1	   blocking	  
antibody	  (i.e.	  CR1	  block,	  LPS	  with	  CR1	  blocking	  antibody	  and	  Aβ1-­‐42	  with	  CR1	  blocking	  
antibody)	  and	  also	  between	  LPS	  and	  LPS	  with	  CR1	  blocking	  antibody	  and	  between	  Aβ1-­‐
42	  and	  Aβ1-­‐42	  with	  CR1	  blocking	  antibody.	  Significance	  was	  stated	  as	  *p<0.5,	  **p<0.001,	  
































3. The	  role	  of	  CR1	  in	  modulating	  microglial	  phenotypes	  
3.1	  Introduction	  and	  Summary	  of	  results	  
The	  association	  observed	  between	  the	  CR1	  loci	  and	  age-­‐related	  cognitive	  decline	  
and	   plaque	   burden	   has	   been	   implicated	   in	   impaired	   clearance	   of	   Aβ	   plaques	   in	   the	  
brain	  of	  AD	  patients	  (Chibnik	  et	  al.	  2011).	  Although	  the	  recruitment	  of	  phagocytes	  and	  
inflammatory	  mediators	  are	  intended	  to	  be	  beneficial,	  under	  certain	  conditions,	  these	  
processes	  can	  prove	  harmful	   instead.	  Classical	  markers	  of	   immune-­‐mediated	  damage	  
have	   been	   identified	   in	   AD	   brains	   including	   MHC-­‐I	   and	   MHC-­‐II	   positive	   microglia	  
(McGeer	  et	  al.	  1987;	  Tooyama	  1990;	  Perlmutter	  et	  al.	  1992).	  	  
In	  normal	  brain,	  microglia	  become	  reactive,	  surround	  damaged	  or	  dead	  cells	  and	  
clear	   cellular	   waste	   from	   the	   area	   to	   promote	   regeneration	   and	   repair	   (Fetler	   &	  
Amigorena	  2005).	  Microglia	  generally	  have	  beneficial	  effects,	  but	  their	  overstimulation	  
can	   promote	   neurotoxicity	   due	   to	   pathogenic	   signals,	   including	   Aβ,	   resulting	   in	   the	  
excess	   of	   free	   radicals,	   pro-­‐inflammatory	   cytokines,	   complement	   proteins	   and	  
glutamate	  (Morales	  et	  al.	  2010).	  	  In	  AD,	  microglia	  display	  an	  early	  reactive	  phenotype	  
(Lautner	  et	  al.	  2011),	  and	  changes	  in	  the	  immune	  response	  are	  another	  risk	  marker	  for	  
the	  development	  of	  AD	  (Jones	  et	  al.	  2010).	  	  
Exposure	  of	  microglia	  to	  extrinsic	  C1q	  complement	  protein	  demonstrated	  a	  shift	  
towards	   a	   pro-­‐inflammatory	   phenotype,	   similar	   to	   that	   seen	   after	   the	   exposure	   of	  
microglia	  to	  LPS,	  with	  a	  release	  in	  IL-­‐6,	  TNFα,	  NO	  and	  an	  oxidative	  burst	  (Färber	  et	  al.	  
2009).	   This	   chapter	   investigates	   how	   modulation	   of	   CR1	   signalling	   influenced	   the	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microglial	  phenotype	  during	  exposure	  of	  activators	  complicit	  in	  microglial	  responses	  in	  
AD.	  	  
This	  chapter	  provides	  evidence	  that	  microglial	  CR1	  can	  elicit	  a	  neurotoxic	  effect	  
which	  correlated	  with	  enhanced	  cytokine	  and	  superoxide	  production,	  but	  that	  blocking	  
CR1	  does	  not	  contribute	  a	  protective	  response	  by	  triggering	  glutathionine	  production	  
or	   inhibiting	   iNOS	   induction.	   The	   data	   shows	   an	   increased	   ability	   of	   Aβ1-­‐42	   treated	  
microglia	   to	   phagocytose	   dextran	   beads	   following	   antibody	   blockage	   of	   CR1	   but	   a	  














3.2.1	  CR1	  expression	  is	  increased	  after	  microglial	  activation;	  and	  antibody	  blockage	  
of	  CR1	  modulated	  microglial	  phagocytosis	  
β-­‐amyloid	   is	   hypothesized	   to	   accumulate	   in	   late-­‐onset	   AD	   at	   a	   normal	   rate	  
however	   it’s	   clearance	   is	   impaired	   (Mawuenyega	   et	   al.	   2010).	   This	   dysregulated	  
clearance	   and	   subsequent	   amyloid	   accumulation	   initiates	   the	   activation	   of	   the	  
complement	  system	  (Rogers	  et	  al.	  1992).	  The	  complement	  system	  acts	   in	  a	  number	  of	  
ways	  to	  support	  host	  defence,	  including	  opsonisation	  of	  pathogens	  through	  phagocytes	  
expressing	  complement	  receptors	  such	  as	  microglia	  (Tohyama	  &	  Yamamura	  2006).	  With	  
recent	   associations	   between	   the	   CR1	   polymorphism	   and	   poor	   cognitive	   performance	  
(Mengel-­‐From	  et	  al.	  2010)	  and	  MRI	  characteristics	   in	  AD	   (Biffi	  et	  al.	  2010),	   it	   could	  be	  
suggested	   that	   microglia	   mediate	   their	   phagocytic	   ability	   to	   clear	   Aβ	   through	   this	  
receptor,	  which	  was	   therefore	   investigated	  here.	   Since	   there	   is	   controversy	  about	   the	  
ability	  of	  microglia	  to	  express	  CR1,	  two	  different	  anti-­‐CR1	  antibodies	  were	  firstly	  tested	  
on	   lysates	   from	   primary	   cultures	   of	   rat	   microglia	   through	   Western	   blotting.	   These	  






Fig.	   3.2a	   shows	   the	   resultant	   Western	   blot	   incubated	   with	   anti-­‐CD35	   (E11)	  
antibody	   and	   Fig	   3.2b	   shows	   the	   resultant	   Western	   blot	   incubated	   with	   anti-­‐CD35	  
(31R)	   antibody.	   In	   each	   case	   human	   lymphoblast	   cells,	   a	   kind	   gift	   from	   Dr	   Victoria	  
Burchell,	  UCL,	  were	  also	  analysed	  as	  a	  positive	  control	  for	  each	  antibody	  due	  to	  their	  
known	  CR1	  expression	   (Rødgaard	   et	   al.	   1991).	   In	   order	   to	   assess	   how	  CR1	   signalling	  
influences	   the	   pro-­‐inflammatory	   phenotype	   associated	   with	   microglial	   responses	   in	  
AD,	   the	  effects	  of	  activators	   such	  as	  LPS	  or	  Aβ1-­‐42	  on	  microglial	  CR1	  expression	  were	  
investigated	  (Fig.	  3.2).	  There	  was	  trend	  towards	  an	  increase	  in	  CR1	  protein	  expression	  
following	   activation	   of	   primary	   rat	  microglia	  with	   either	   LPS	   (1	  µg/mL)	   or	   Aβ1-­‐42	   (20	  
nM)	  for	  24	  h.	  	  
Figure	   3.1:	   Microglia	   stained	   with	  
Isolectin	  B4	  (green)	  and	  DAPI	  (blue).	  
To	   confirm	   the	   purity	   of	   the	  microglial	  
culture,	   cells	   were	   stained	   with	  
microglial	   marker,	   Isolectin	   B4	   (2	  








In	   order	   to	   determine	   the	   functional	   consequences	   of	   CR1	   up-­‐regulation	   in	  
microglia	   following	  LPS	  or	  Aβ1-­‐42	  stimulation,	  a	  microglial	  phagocytic	  assay	  measuring	  
uptake	  of	  dextran	  beads	  was	  performed.	  Exposure	  of	  primary	   rat	  microglia	   to	  either	  
LPS	  (1	  µg/mL)	  or	  Aβ1-­‐42	  (20	  nM)	  for	  24	  h,	  decreased	  dextran	  bead	  uptake	  (Fig.	  3.3a	  and	  
3.3c)	  following	  bead	  incubation	  for	  2	  h.	  In	  the	  case	  of	  LPS	  treatment,	  phagocytosis	  of	  
beads	  was	  not	  reversed	  by	  24	  h	  co-­‐incubation	  with	  CR1	  blocking	  antibody	  (1	  mg/mL)	  
and	  LPS	  (1	  µg/mL).	  However,	  blocking	  CR1	  reversed	  the	  observed	  Aβ1-­‐42	  suppression	  of	  
dextran	  bead	  phagocytosis	   back	   to	   control	   levels.	   Phagocytosis	   is	   a	   dynamic	  process	  
Figure	  3.2:	  CR1	  expression	  is	  increased	  in	  primary	  rat	  microglia	  (45	  μg)	  treated	  with	  microglial	  
activators	  LPS	  (1	  μg/mL)	  and	  Aβ1–42	  (20	  nM).	  	  
Western	   blot	   with	   (a)	   antibody	   CD35	   (E11)	   from	   Abcam	   and	   (b)	   with	   antibody	   CD35	   (31R)	   from	  
Hycult	  biotech.	  In	  each	  case	  a	  standard	  of	  human	  lymphoblasts	  (45	  μg)	  was	  also	  analysed	  for	  each	  
antibody	  as	  a	  positive	  control.	  Densitometry	  of	  expression	   relative	   to	   the	   loading	  control,	  β-­‐actin	  
and	  against	  control	  CR1	  expression	  was	  performed	  on	  three	  separate	  blots.	  Data	  were	  analysed	  by	  




requiring	   energy	   (Kvarstein	   1969;	   Peterson	   et	   al.	   1977;	   Pratten	   &	   Lloyd	   1984)	   and	  
phagocytosis	  of	  dextran	  beads	  was	   significantly	   reduced	  when	   the	  assay	  was	   carried	  
out	  at	  4°C,	  thus	  eliminating	  binding	  or	  a	  superficial	  cell-­‐association	  as	  an	  explanation	  
for	   the	   results	   observed	   (Fig.	   3.3b).	   The	   experiment	   was	   repeated	   measuring	  
phagocytosis	  of	  HiLyte	  FluorTM	  488-­‐labeled	  Aβ1-­‐42	   (Fig.	  3.4a	  and	  3.4b)	  and	   the	   results	  
exhibited	   a	   differential	   response	   compared	   with	   phagocytosis	   of	   dextran	   beads.	  
Following	  antibody	  blockade	  of	  CR1	   in	  microglia	  treated	  with	  LPS	  (1	  µg/mL)	  or	  Aβ1-­‐42	  
(20	  nM),	  there	  was	  a	  significant	  reduction	  in	  fluorescent	  Aβ1-­‐42	  phagocytosis	  compared	  
with	   LPS	   or	   Aβ1-­‐42	   treatment	   alone.	   	   Again,	   conduction	   of	   the	   experiments	   at	   4°C	  





Figure	  3.3:	  CR1	  functional	  blocking	  antibody	  modulates	  microglial	  phagocytosis	  following	  treatment	  
with	  Aβ	  or	  LPS.	  	  
Quantification	   and	   images	   of	   primary	   microglial	   phagocytosis	   of	   dextran	   beads	   (a,c)	   after	   direct	  
treatment	   of	   microglia	   with	   Aβ1-­‐42	   (20	   nM)	   or	   LPS	   (1	   μg/mL)	   in	   the	   presence	   or	   absence	   of	   CR1	  
blocking	  antibody	  (1	  mg/mL)	  for	  24	  h.	  (b)	  Quantification	  of	  primary	  microglial	  phagocytosis	  carried	  out	  
as	   in	   (a)	   at	   4	   °C.	   Phagocytosis	   was	   measured	   as	   a	   percentage	   of	   the	   number	   of	   cells	   with	   a	  
fluorescence	  signal	  to	  total	  microglial	  cell	  number/field	  of	  view	  from	  3	  fields	  per	  coverslip,	  3	  coverslips	  
per	  condition,	  from	  3	  separate	  experiments.	  Data	  were	  analysed	  by	  one-­‐way	  ANOVA	  (ρ	  <	  0.0001)	  and	  








Figure	   3.4:	   CR1	   functional	   blocking	   antibody	   modulates	   microglial	   phagocytosis	   following	  
treatment	  with	  Aβ	  or	  LPS.	  	  
(a)	   Quantification	   and	   (b)	   images	   of	   primary	  microglial	   phagocytosis	   of	   fluorescently	   tagged	   Aβ1-­‐42	  
after	  direct	  treatment	  of	  microglia	  with	  Aβ1-­‐42	  (20	  nM)	  or	  LPS	  (1	  μg/mL)	  in	  the	  presence	  or	  absence	  of	  
CR1	   blocking	   antibody	   (1	   mg/mL)	   for	   24	   h.	   Phagocytosis	   was	   measured	   as	   a	   percentage	   of	   the	  
number	  of	  cells	  with	  a	  fluorescence	  signal	  to	  total	  microglial	  cell	  number/field	  of	  view	  from	  3	  fields	  
per	  coverslip,	  3	  coverslips	  per	  condition,	  from	  3	  separate	  experiments.	  Data	  were	  analysed	  by	  one-­‐
way	  ANOVA	  (ρ	  <	  0.0001)	  and	  Tukey	  post-­‐hoc	  tests,	  	  ***ρ	  <	  0.001	  and	  *ρ	  <	  0.05.	  Data	  are	  shown	  as	  




3.2.2	  CR1	  modulation	  has	  an	  effect	  on	  and	  TNFα	  and	  IL-­‐1β 	  secretion	  from	  microglia	  
Production	   of	   cytokines	   and	   complement	   activation	   are	   important	   microglial	  
responses	  to	  CNS	   injury,	  particularly	   in	  AD	  (Smith	  et	  al.	  2012;	  Di	  Bona	  et	  al.	  2008;	  Di	  
Bona	  et	  al.	  2009).	   In	  vitro	  microglial	  activation	  with	  Aβ1-­‐42	   leads	  to	  an	   increase	   in	  the	  
production	   of	   a	   number	   pro-­‐inflammatory	   cytokines	   including	   IL-­‐1β,	   IL-­‐6	   and	   TNFα	  
(Rogers	  &	  Lue	  2001;	  Lue	  et	  al.	  2001).	  Levels	  of	  the	  soluble	  neurotoxins,	  TNFα,	  IL-­‐6	  and	  
IL-­‐1β	  were	  measured	   in	  MGCM	   following	   24	   hr	   treatment	  with	  microglial	   activators	  
and	  CR1	  blocking	   antibody	   (Fig.	   3.5).	   There	  was	   an	   increase	   in	   TNFα	   in	  MGCM	   from	  
microglia	  treated	  with	  LPS	  (1	  µg/mL)	  compared	  with	  control	  MGCM	  (Fig.	  3.5a).	  TNFα	  
levels	  were	  significantly	  reduced	  in	  MGCM	  from	  microglia	  co-­‐treated	  with	  CR1	  blocking	  
antibody	  and	  LPS.	  No	  difference	  was	  seen	  in	  MGCM	  from	  microglia	  treated	  with	  Aβ1-­‐42	  
(20	  nM)	  or	  with	  MGCM	  from	  microglia	  treated	  with	  Aβ1-­‐42	  and	  CR1	  blocking	  antibody	  
compared	   with	   control.	   Although	   an	   increase	   in	   IL-­‐6	   production	   was	   observed	   in	  
MGCM	   from	   primary	   microglia	   treated	   with	   LPS	   (1	   µg/mL)	   there	   was	   no	   change	  
detected	   in	  microglia-­‐co-­‐treated	  with	   CR1	   blocking	   antibody	   (Fig.	   3.5b).	   As	   in	   figure	  
3.5a,	  no	  difference	  was	  observed	   in	  MGCM	   from	  microglial	   co-­‐treatment	  with	  Aβ1-­‐42	  
and	  CR1	  blocking	  antibody	  and	  Aβ1-­‐42	  alone	  (Fig.	  3.5b).	  Fig.	  3.5c	  shows	  that	  there	  was	  a	  
decrease	  in	  IL-­‐1β	  levels	  in	  MGCM	  from	  microglia	  co-­‐treated	  with	  CR1	  blocking	  antibody	  
plus	   Aβ1-­‐42	   compared	   with	   Aβ1-­‐42	   activator	   alone.	   No	   significant	   release	   of	   IL-­‐1β	   or	  
regulation	   by	   CR1	   block	  was	   seen	   following	   LPS	   stimulation	   (Fig.	   3.5c).	   IL-­‐10	   release	  














Figure	   3.5:	   ELISA	   analysis	   of	   (a)	   TNFα,	   (b)	   IL-­‐6	   and	   (c)	   IL-­‐1β	   secretion	   from	  primary	   cultured	   rat	  
microglia	  following	  treatment	  with	  LPS	  (1	  μg/mL),	  Aβ1–42	  (20	  nM)	  and	  CR1	  blocking	  antibody	  (1	  
mg/mL),	  alone	  and	  in	  combination,	  for	  24	  h.	  	  
(a)	   Reduced	   TNFα	   secretion	   following	   LPS	   treatment	   in	   microglia	   pre-­‐treated	   with	   CR1	   blocking	  
antibody.	   (b)	   A	   trend	   towards	   a	   decrease	   in	   IL-­‐6	   secretion	   and	   a	   significant	   decrease	   in	   IL-­‐1β	  
secretion	  (c)	  was	  observed	  in	  microglia	  pre-­‐treated	  with	  CR1	  blocking	  antibody	  compared	  with	  Aβ1–
42	   treatment	   alone.	   Data	   are	   the	   mean	   of	   supernatant	   values	   performed	   in	   duplicate	   from	   3	  
separate	  coverslips	  per	  condition	  taken	  from	  3	  independent	  experiments	  and	  values	  were	  analysed	  
by	  one-­‐way	  ANOVA	  (TNFα	  ρ	  <	  0.0001;	  IL-­‐6	  ρ	  <	  0.0001;	  IL-­‐1β	  ρ	  <	  0.0078)	  and	  Tukey	  post-­‐hoc	  tests,	  	  




3.2.3	  CR1	  block	  down-­‐regulates	  iNOS	  expression	  in	  primary	  rodent	  microglia	  as	  
measured	  by	  ICC	  
Microglial	   iNOS	   expression	   at	   high	   levels	   can	  mediate	   pathogenic	   effects	   with	  
complement	   having	   a	   possible	   role	   (Montalto	   et	   al.	   2003).	   Reactive	   oxygen	   species	  
(ROS)	  and	  reactive	  nitrogen	  species	  (RNS)	  produced	  by	  microglia	  can	  react	  to	  form	  the	  
highly	  toxic	  peroxynitrite	  in	  response	  to	  LPS	  or	  Aβ	  stimulation	  (Kim	  et	  al.	  2009;	  Neher	  
et	  al.	  2011).	  The	  possibility	  of	  CR1	  playing	  a	  role	  on	  iNOS	  expression	  was	  investigated.	  
ICC	  data	  showed	  that	  LPS	  induced	  a	  significant	  increase	  in	  iNOS	  expression	  in	  microglia	  
(Fig.	   3.6a	   and	   3.6b),	   which	   was	   attenuated	   by	   pre-­‐treatment	   with	   CR1	   functional	  
blocking	  antibody.	  A	  similar	  trend	  was	  observed	  with	  the	  Aβ1-­‐42	  –treated	  microglia	  (Fig	  
3.6a	  and	  3.6b).	  Fig	  3.6c	  shows	  the	  resultant	  Western	  blot	  data	  with	  a	   representative	  
image	   of	   primary	   microglia	   treated	   with	   LPS	   (1μg/mL),	   Aβ1-­‐42	   (20nM)	   and	   in	   some	  
cultures	  co-­‐incubation	  with	  CR1	  blocking	  antibody	  (2μg/mL)	  and	   incubated	  with	  anti-­‐
iNOS	   antibody.	   A	   trend	   was	   observed	   showing	   a	   reduction	   in	   iNOS	   expression	   in	  
microglia	  with	  co-­‐treatment	  with	  CR1	  blocking	  antibody	  compared	  with	  LPS	  treatment	  









3.2.4	  CR1	  block	  inhibits	  O2
.-­‐	  production	  in	  microglia	  
The	  immune	  system	  can	  battle	  against	  invading	  pathogens	  through	  a	  respiratory	  
burst	  which	  is	  a	  rapid	  release	  of	  ROS	  from,	  in	  this	  case,	  microglia.	  Previously,	  there	  has	  
been	  a	  positive	  correlation	  between	  an	  increase	  in	  respiratory	  burst	  and	  expression	  of	  
C3b,	   the	  binding	  of	  which	   to	   its	   corresponding	   receptor,	  CR1,	  promotes	   signalling	   to	  
Figure	   3.6	   Immunocytochemistry,	   western	   blot	   and	   densitometric	   analysis	   of	   iNOS	   expression	   in	  
primary	   rat	   microglia	   after	   treatment	   with	   Aβ1-­‐42	   (20	   nM)	   or	   LPS	   (1	   μg/mL)	   in	   the	   presence	   or	  
absence	  of	  CR1	  blocking	  antibody	  (1	  mg/mL)	  for	  24	  h.	  	  
(b)	  Quantification	  of	  the	  presence	  of	  microglia	  staining	  positive	  for	  iNOS	  after	  treatments	  given	  in	  (a).	  
(c)	  is	  a	  representative	  Western	  blot	  probing	  for	  the	  expression	  of	  iNOS	  from	  primary	  microglia	  
following	  24h	  treatment.	  ICC	  data	  analyses	  were	  carried	  out	  as	  a	  percentage	  of	  the	  number	  of	  cells	  
with	  a	  fluorescence	  signal	  to	  total	  microglial	  cell	  number/field	  of	  view	  from	  3	  fields	  per	  coverslip,	  3	  
coverslips	  per	  condition,	  from	  3	  separate	  experiments	  and	  western	  blot	  data	  were	  analysed	  from	  three	  
separate	  blots	  from	  three	  independent	  experiments	  and	  compared	  by	  ANOVA	  (ρ	  <	  0.0001)	  and	  Tukey	  
post-­‐hoc	  tests,	  	  ***ρ	  <	  0.001,	  **ρ	  <	  0.01	  and	  *ρ	  <	  0.05.	  Data	  are	  shown	  as	  mean	  ±	  SEM.	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NADPH	  oxidase	   to	  produce	   superoxide	   (Hoogerwerf	   et	   al.	   1990;	  Gessler	  &	  Dahinden	  
2003).	   Superoxide	   production	   was	   measured	   by	   DHE	   staining,	   and	   here,	   primary	  
microglia	  treated	  with	  LPS	  (1	  μg/mL)	  for	  24	  h	  showed	  a	  significantly	  higher	  intracellular	  
O2
.-­‐	  production	  compared	  with	  control,	  which	  was	  attenuated	  by	   functional	  antibody	  
CR1	   block	   (Fig.	   3.7a	   and	   3.7b).	   A	   similar	   significant	   reduction	   in	  O2
.-­‐	   production	  was	  
observed	   in	   primary	   microglia	   treated	   for	   24	   h	   with	   Aβ1-­‐42	   (20	   nM)	   and	   CR1	   block	  
compared	  with	   Aβ1-­‐42	   treatment	   alone.	   Primary	  microglia	   were	   also	   co-­‐treated	  with	  
apocynin	   (10μM),	   an	   inhibitor	   of	   NADPH	   oxidase	   which	   prevents	   superoxide	  
production	   through	   inhibiting	   the	   translocation	   and	   assembly	   of	   the	   active	   NADPH	  
oxidase	  complex	  (Stefanska	  &	  Pawliczak	  2008;	  Mead	  et	  al.	  2012b)	  and	  O2
.-­‐	  production	  
was	  inhibited	  on	  these	  cells.	  Similar	  O2
.-­‐	  	  production	  was	  observed	  in	  BV2	  microglia	  (Fig.	  
3.8a	   and	   3.8b).	   Levels	   of	   O2
.-­‐	   were	   significantly	   reduced	   in	   BV2	  microglia	   co-­‐treated	  
with	  CR1	  blocking	  antibody	  compared	  with	  LPS	  alone	  and	  a	  trend	  towards	  a	  reduction	  
compared	   to	   Aβ1-­‐42	   treatment	   alone.	   O2
.-­‐	   production	   was	   also	   measured	   in	   BV2	  
microglia	   transfected	  with	   Crry	   siRNA,	   the	  murine	   ortholog	   of	   the	   human	   CR1	   gene	  
(Killick	  et	  al.	  2012).	  LPS	  or	  Aβ1-­‐42	  treated	  BV2	  microglia	  displayed	  significantly	  increased	  
O2
.-­‐	  production	  compared	  with	  control	  and	  this	  was	  reduced	   in	  cells	  transfected	  with	  
Crry	  siRNA	  prior	  to	  LPS	  and	  Aβ1-­‐42	  treatment	  (Fig.	  3.9a	  and	  3.9b).	  BV2	  cells	  transfected	  
with	  cyclophilin	  B	  control	  siRNA	  prior	  to	  treatment	  with	  LPS	  demonstrated	  similar	  O2
.-­‐	  
production	   to	   control.	   Although	   a	   trend	   can	   be	   observed,	   there	   was	   no	   significant	  
decrease	   in	   O2
.-­‐	   production	   between	   LPS	   treatment	   alone	   and	   LPS	   following	   control	  
siRNA	   transfection.	   In	   addition,	   there	   was	   a	   significant	   decrease	   in	   O2
.-­‐	   production	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between	   LPS	   and	   Crry	   siRNA	   treated/transfected	   cells	   versus	   LPS	   and	   control	   siRNA	  
treatment/transfection	   suggesting	   that	   Crry	   may	   have	   a	   role	   in	   O2
.-­‐	   production.	  
Additional	   controls	   would	   be	   needed	   to	   confirm	   this	   finding	   such	   as	   confirming	  
knockdown	   of	   Crry	   by	  measuring	   Crry	   expression,	   therefore	   these	   data	   only	   show	   a	  
preliminary	   look	   into	   the	   effect	   of	   Crry	   on	  O2
.-­‐	   production.	  O2
.-­‐	   positive	   fluorescence	  
was	   also	   inhibited	   in	   BV2	   microglia	   pre-­‐treated	   with	   the	   NADPH	   oxidase	   inhibitor,	  
apocynin,	  prior	  to	  LPS	  or	  Aβ1-­‐42	  treatment.	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Figure	  3.7:	  CR1	  functional	  blocking	  antibody	  modulates	  intracellular	  superoxide	  (O2	  •−)	  production	  in	  
primary	  rat	  microglia.	  	  
(a)	   Live	   cell	   imaging	   of	  O2	   •−	   generation	  monitored	  with	   dihydroethidium	   (DHE,	   pink	   fluorescence)	   in	  
cells	   producing	   intracellular	   O2	   •−	   in	   primary	  microglia,	   after	   treatment	   with	   Aβ1-­‐42	   (20	   nM),	   phorbol	  
myristate	  acetate	  (PMA,	  10	  ng/mL)	  or	  LPS	  (1	  μg/mL)	  in	  the	  presence	  or	  absence	  of	  CR1	  blocking	  antibody	  
(1	  mg/mL)	  for	  24	  h	  or	  apocynin	  (Apo)	  (10	  mM)	  during	  DHE	  loading,	  as	  a	  control	  for	  the	  specificity	  of	  DHE	  
fluorescence.	  (b)	  Quantification	  of	  the	  percentage	  of	  microglia	  positive	  for	  O2	  •−	  after	  treatments	  given	  
in	  (a)	  (black	  bars).	  Grey	  bars	  represent	  treatments	  with	  apocynin	  and	  were	  not	  included	  in	  the	  statistical	  
analysis.	  Data	  were	  analysed	  by	  one-­‐way	  ANOVA	  ((ρ	  <	  0.0001)	  and	  Tukey	  post-­‐hoc	  tests,	  	  ***ρ	  <	  0.001,	  




	   	   	  
Figure	  3.8:	  CR1	  functional	  blocking	  antibody	  modulates	  intracellular	  superoxide	  (O2	  •−)	  production	  in	  
BV2	  murine	  microglia.	  	  
(a)	   Live	   cell	   imaging	   of	  O2	   •−	   generation	  monitored	  with	   dihydroethidium	   (DHE,	   pink	   fluorescence)	   in	  
cells	   producing	   intracellular	   O2	   •−	   in	   BV2	   microglia,	   after	   treatment	   with	   Aβ1-­‐42	   (20	   nM),	   phorbol	  
myristate	  acetate	  (PMA,	  10	  ng/mL)	  or	  LPS	  (1	  μg/mL)	  in	  the	  presence	  or	  absence	  of	  CR1	  blocking	  antibody	  
(1	  mg/mL)	  for	  24	  h	  or	  apocynin	  (Apo)	  (10	  mM)	  during	  DHE	  loading,	  as	  a	  control	  for	  the	  specificity	  of	  DHE	  
fluorescence.	  (b)	  Quantification	  of	  the	  percentage	  of	  microglia	  positive	  for	  O2	  •−	  after	  treatments	  given	  
in	  (a)	  (black	  bars).	  Grey	  bars	  represent	  treatments	  with	  apocynin	  and	  were	  not	  included	  in	  the	  statistical	  
analysis.	  Data	  were	  analysed	  by	  one-­‐way	  ANOVA	  (ρ	  <	  0.0001)	  and	  Tukey	  post-­‐hoc	  tests,	  **ρ	  <	  0.01	  and	  









Figure	   3.9:	   Quantification	   of	   the	   percentage	   of	   microglia	   positive	   for	   O2	   •−	   after	   siRNA	  
knockdown	  of	  Crry,	  the	  mouse	  homologue	  to	  CR1.	  	  
(a)	  and	  (b)	  Quantification	  was	  carried	  out	  following	  treatment	  with	  microglial	  activators,	  Aβ1-­‐42	  (20	  
nM)	  and	  LPS	  (1	  μg/mL)	  or	  apocynin	  (10	  mM)	  during	  DHE	  loading,	  as	  a	  control	  for	  the	  specificity	  of	  
DHE	   fluorescence.	   siRNA	   knockdown	   of	   Crry	   results	   in	   a	   modulation	   of	   O2	   •−	   production	   after	  
treatment	  with	  Aβ1–42	  (20	  nM)	  or	  LPS	  (1	  μg/mL)	  for	  24	  h.	  Data	  were	  analysed	  by	  one-­‐way	  ANOVA	  




NBT	  analysis	   to	  measure	   superoxide	  production	  was	  performed	   to	   support	   the	  
DHE	  fluorescence	  data	  (Fig.	  3.10).	  This	  experiment	  was	  carried	  out	  at	  4	  h	  and	  24	  h	  and	  
it	  appeared	   that	  NBT	   reduction	  had	  a	   similar	   trend	  at	  both	   time-­‐points.	  A	   significant	  
increase	   in	  NBT	   reduction	   compared	   to	  basal	   levels	   (NBT	   treatment	  alone)	  was	   seen	  
following	   treatment	   with	   the	   positive	   control,	   PMA	   (10	   ng/mL).	   This	   increase	   in	  
reduction	  of	  NBT	  was	  also	  observed	  in	  BV2	  cells	  treated	  with	  LPS	  (1	  μg/mL)	  and	  Aβ1-­‐42	  
(20	  nM)	  alone	  for	  24	  h.	  Co-­‐treatment	  with	  CR1	  blocking	  antibody	  (1	  mg/mL)	  resulted	  in	  
a	   significant	  decrease	   in	  NBT	   reduction.	   	   It	  was	   important	   to	  determine	  whether	   the	  
LPS	   and	   Aβ1-­‐42	   induced	   superoxide	   production,	   as	   shown	   by	   NBT	   production	   in	   BV2	  
microglia,	  was	  a	  consequence	  of	  NADPH	  oxidase	  activity.	  BV2	  microglia	  were	  treated	  
with	  LPS	  and	  Aβ1-­‐42	   in	  the	  presence	  of	  the	  specific	  NADPH	  oxidase	   inhibitor	  apocynin	  
(10	  μM),	  and	  superoxide	  production	  was	  assessed	  by	  NBT	  reduction	  following	  4	  h	  and	  






3.2.5	  CR1	  block	  does	  not	  alter	  glutathione	  production	  in	  LPS	  and	  Aβ1-­‐42	  treated	  
microglia	  
As	   CR1	   blockade	   was	   shown	   to	   attenuate	   LPS	   and	   Aβ1-­‐42	   induced	   superoxide	  
production	   in	   microglia,	   the	   mechanisms	   behind	   this	   were	   investigated	   further.	  
Glutathione	  is	  an	  antioxidant	  produced	  by	  glial	  cells	  (Keelan	  et	  al.	  2001),	  and	  as	  such	  
plays	   a	   role	   in	   the	   defence	   system	   (Perricone	   et	   al.	   2011).	   Microglial	   cells	   produce	  
glutathione	   for	   defence	   against	   ROS	   produced	   by	   microglia	   or	   other	   cells	   such	   as	  
astrocytes	  in	  the	  brain	  (Hirrlinger	  et	  al.	  2000).	  Glutathione	  production	  was	  investigated	  
Figure	  3.10:	  NBT	  assay	  showing	  reduction	  of	  superoxide	  production	  by	  CR1	  blocking	  antibody.	  BV2	  
cells	  were	  treated	  with	  LPS	  (1	  μg/mL),	  Aβ1-­‐42	  (20	  nM)	  and	  CR1	  blocking	  antibody	  (1	  mg/mL)	  in	  the	  
presence	  of	  NBT	  for	  4	  h	  and	  24	  h.	  	  
To	  determine	  whether	  NBT	  reduction	  following	  treatment	  with	  LPS	  and	  Aβ1-­‐42	  was	  as	  a	  consequence	  of	  
the	   NADPH	   oxidase,	   BV2	   microglia	   were	   co-­‐treated	   with	   LPS	   (1	   μg/mL)	   and	   Aβ1-­‐42	   (20	   nM)	   in	   the	  
presence	   of	   the	  NADPH	   oxidase	   inhibitor	   apocynin	   (Apo)	   (10	  mM).	   Data	  were	   analysed	   by	   one-­‐way	  
ANOVA	  (ρ	  <	  0.0001)	  and	  Tukey	  post-­‐hoc	  tests,	  ***ρ	  <	  0.001	  and	  **ρ	  <	  0.01.	  Data	  compared	  with	  Ctrl	  
and	  with	  NBT	  alone	  were	  marked	  with	  #	  and	  represent	  ###ρ	  <	  0.001.	  Data	  are	  shown	  as	  mean	  ±	  SEM.	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using	  the	  MCB	  assay	  following	  treatment	  of	  microglia	  with	  CR1	  blocking	  antibody	  and	  
microglial	   activators.	   There	   was	   no	   change	   in	   mean	   MCB	   fluorescence	   per	   cell	  
following	   incubation	  with	  CR1	  blocking	  antibody	  (1	  mg/mL),	  LPS	  (1	  μg/mL)	  and	  Aβ1-­‐42	  
(20	   nM)	   for	   24	   h	   (Fig.	   3.11).	   Grey	   bars	   represent	   microglia	   pre-­‐incubated	   with	  
ethacrynic	  acid	  (EA)	  (1	  mM)	  a	  potent	  inhibitor	  of	  glutathione	  S-­‐transferases	  for	  10	  min	  
prior	  to	  additional	  treatment	  (Ploemen	  et	  al.	  1993)	  to	  confirm	  fluorescence	  was	  due	  to	  









Figure	  3.11:	  CR1	  functional	  blocking	  antibody	  does	  not	  alter	  glutathione	  production	  in	  microglia.	  CR1	  
functional	   blocking	   antibody	   does	   not	   alter	   glutathione	   production	   in	   primary	   rat	   microglia	  
investigated	  by	  live	  cell	  imaging	  of	  monochlorobimane	  (MCB)	  fluorescence.	  	  
Quantification	  of	  mean	  MCB	  fluorescence	  per	  microglial	  cell	  after	  treatment	  with	  Aβ1-­‐42	  (20	  nM)	  or	  LPS	  (1	  
μg/mL)	   in	   the	   presence	   or	   absence	   of	   CR1	   blocking	   antibody	   (1	  mg/mL)	   for	   24	   h	   (white	   bars)	   and	   co-­‐
treatment	  with	   ethacrynic	   acid	   (1	  mM)	   as	   a	   control	   for	  MCB	   fluorescence	   (grey	  bars).	   Treatment	  with	  
ethacrynic	   acid	   was	   not	   included	   in	   the	   statistical	   analysis.	   Data	   are	   the	   mean	   ±	   SEM	   of	   cellular	  
fluorescence	  in	  approximately	  50	  cells	  per	  field,	  3	  fields	  per	  coverslip,	  3	  coverslips	  per	  condition	  from	  3	  
independent	   experiments	   analysed	   with	   ImageJ	   software.	   Data	   were	   analysed	   by	   one-­‐way	   ANOVA	  





It	  is	  hypothesized	  that	  in	  LOAD,	  it	  is	  not	  the	  rate	  at	  which	  Aβ	  is	  accumulated	  that	  
is	  impaired	  but	  its	  clearance	  (Mawuenyega	  et	  al.	  2010).	  CR1	  is	  known	  to	  be	  involved	  in	  
immune	  clearance	  of	  opsonised	  pathogens	  on	  erythrocytes	  (Kavai	  2008;	  Li	  et	  al.	  2010),	  
and	  so	  it	   is	  thought	  that	  this	  receptor,	  shown	  here	  to	  be	  expressed	  in	  microglia,	  may	  
provide	   a	   role	   in	   the	   clearance	   of	   Aβ	   or	   lack	   thereof	   in	   the	   AD	   brain.	   In	   healthy	  
conditions,	   C3b,	   the	   ligand	   for	   CR1,	   is	   spontaneously	   produced	   and	   destroyed.	  
However,	  in	  the	  presence	  of	  a	  pathogen,	  or	  in	  this	  instance	  a	  dextran	  bead,	  C3b	  binds	  
to	  the	  bead	  and	  through	  the	  action	  of	  cofactors	  B	  and	  D	  develops	  into	  C3	  convertase	  
(Tohyama	  &	  Yamamura	  2006).	  C3b	  is	  then	  cleaved	  to	  C3bi,	  which	  surrounds	  the	  bead	  
and	   results	   in	   the	   capture	   of	   the	   bead	   by	   the	   phagocyte,	   which	   expresses	   CR3,	   the	  
receptor	  for	  C3bi.	  When	  CR1	  is	  blocked,	  it	  prevents	  the	  cleavage	  of	  C3b	  at	  two	  sites	  to	  
produce	  C3bi,	  therefore	  preventing	  phagocytosis.	  	  
Microglia	   activated	   with	   LPS	   have	   been	   demonstrated	   to	   be	   a	   good	   cellular	  
model	  to	  study	  neuroinflammation,	  and	  Toll-­‐like	  receptors	  (TLRs)	  have	  been	  identified	  
as	  important	  mediators	  of	  neuroinflammation	  (Le	  et	  al.	  2001;	  Sheng	  et	  al.	  2003;	  Arroyo	  
et	   al.	   2011).	   In	   order	   to	   examine	   the	   phagocytic	   capability	   of	   microglia	   in	   a	  
proinflammatory	  environment,	  the	  cells	  were	  treated	  with	  LPS,	  of	  which	  the	  resulting	  
activation	  is	  mediated	  by	  TLR-­‐4	  (Chow	  1999;	  Lien	  et	  al.	  2000).	  A	  significant	  reduction	  in	  
phagocytosis	   of	   dextran	  beads	  was	  observed	   in	  microglia	   treated	  with	   LPS.	   This	  was	  
not	   reversed	   by	   LPS	   and	   CR1	   blocking	   antibody	   compared	  with	   control	   at	   37°C	   (Fig.	  
3.3a	   and	   3.3c),	   suggesting	   that	   CR1	   does	   not	   play	   a	   role	   in	   a	   general	   phagocytosis	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promoted	   by	   activation	   of	   microglia	   through	   the	   TLR-­‐4	   signalling	   pathway.	   Dextran	  
bead	   phagocytosis	   of	   microglia	   previously	   exposed	   to	   Aβ1-­‐42	   was	   also	   significantly	  
lower	  than	  in	  control	  cells	  (Fig	  3.3a).	  However,	  an	  increase	  in	  phagocytosis	  of	  dextran	  
beads	   was	   observed	   in	   microglia	   treated	   with	   Aβ1-­‐42	   and	   CR1	   blocking	   antibody	  
compared	   with	   Aβ1-­‐42	   alone	   (Fig.	   3.3a	   and	   3.3c).	   The	   ability	   of	   Aβ	   binding	   to	  
erythrocyte	  CR1	  as	  previously	  mentioned,	  may	  extend	  to	  microglial	  CR1,	  and	  as	  such	  
could	  contribute	  to	  a	  reduction	  in	  phagocytosis	  due	  to	  direct	  binding	  to	  the	  receptor.	  
With	   the	   reduction	   of	   CR1	   receptors	   available	   for	   binding	   this	  may	   contribute	   to	   an	  
increased	   microglial	   activation	   response,	   through	   binding	   to	   components	   of	   the	  
microglial	   cell	   surface	   receptor	   system	  resulting	   in	   increased	  phagocytosis.	  Microglial	  
cells	  exposed	  to	  Aβ	  undergo	  phagocytosis	  through	  a	  different	  receptor-­‐linked	  pathway	  
to	  that	  induced	  by	  LPS.	  Microglia	  interact	  with	  fAβ	  through	  an	  Aβ	  cell	  surface	  receptor	  
CD36,	   α6β	   integrin	   and	   CD47	   (Koenigsknecht	   &	   Landreth	   2004)	   as	   well	   as	   to	   the	  
Receptor	   for	   Advanced	   Glycation	   End-­‐product	   (RAGE)	   (Yan	   et	   al.	   1996;	   Fang	   et	   al.	  
2010).	  	  Microglial	  phagocytosis	  of	  fluorescently	  tagged	  Aβ1-­‐42	  following	  LPS	  or	  cold	  Aβ1-­‐
42	  stimulation	  was	  prevented	  by	  CR1	  block,	  suggesting	  that	  CR1	  block	  may	  have	  distinct	  
consequences	   for	   different	   phagocytotic	   pathways	   in	   microglia.	   This	   may	   reflect	  
changes	   in	   ongoing	   phagocytosis	   versus	   pinocytosis	   (Pratten	   &	   Lloyd	   1984).	   The	  
decreased	   uptake	   of	   fluorescently	   tagged	   Aβ1-­‐42	   in	  microglia	   treated	  with	   Aβ1-­‐42	   and	  
CR1	   block	   may	   be	   associated	   with	   a	   reduction	   in	   IL-­‐1β	   induced	   phagocytosis.	   An	  
increase	   in	   IL-­‐1β	   has	   been	   described	   to	   stimulate	   microglial	   motility	   (Ferreira	   et	   al.	  
2011),	  which	   correlates	  with	   the	   findings	   in	   Figure	  3.5c	   showing	  a	   reduction	   in	   IL-­‐1β	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release	   in	   primary	   microglia	   treated	   with	   Aβ1-­‐42	   and	   CR1	   block	   compared	   to	   Aβ1-­‐42	  
alone.	   This	   reduction	   in	   IL-­‐1β	   expression	   following	   treatment	   with	   CR1	   block	   may	  
consequently	   contribute	   to	   a	   reduced	   phagocytic	   effect.	   The	   exposure	   of	   2	   µM	  
fluorescently-­‐labelled	  Aβ42	  to	  microglia	  for	  2	  hrs	  prior	  to	  imaging	  may	  have	  also	  had	  an	  
effect	   on	   microglial	   phagocytosis.	   Although	   it	   has	   been	   previously	   shown	   that	  
oligomeric	  and	  fibrillar	  Aβ42	  do	  not	  lessen	  primary	  microglial	  cell	  viability	  until	  used	  at	  
concentrations	  of	  over	  5	  µM	  and	  10	  µM	  respectively	  (Pan	  et	  al.	  2011),	  addition	  of	  the	  2	  
µM	  fluorescently-­‐labelled	  Aβ42	  to	  the	  culture	  for	  2	  hrs	  may	  contribute	  to	  the	  microglial	  
activation	  state,	   thus	  possibly	  amplifying	  the	  phagocytic	  response.	   If	   this	  additional	  2	  
hr	   exposure	   to	   a	   higher	   concentration	   of	   Aβ42	   did	   have	   an	   effect	   on	   microglial	  
phagocytosis,	   it	  may	  contribute	   to	   the	  differences	   in	   levels	  of	  phagocytosis	  observed	  
between	   both	   the	   experiments	   measuring	   uptake	   of	   latex	   beads	   and	   uptake	   of	  
fluorescently-­‐labelled	   Aβ42.	   A	   possible	   control	   for	   extracellular	   binding	   may	   be	   to	  
image	  the	  uptake	  experiment	  by	  confocal	  microscopy	  and	  labelling	  the	  microglia	  with	  
CD11b,	   thereby	   confirming	   that	   the	   fluorescently-­‐labelled	   Aβ42	  was	   intracellular	   and	  
not	  due	  to	  extracellular	  binding.	  
Cytokine	   production	   is	   an	   important	   microglial	   response	   to	   CNS	   injury	   and	   is	  
associated	   with	   microglial	   activation.	   This	   cytokine	   production	   can	   lead	   to	   further	  
activation	  of	  microglia	  by	  a	  positive	  feedback	  mechanism	  (Hanisch	  2002).	  As	  previously	  
noted,	   this	   proinflammatory	   cytokine	   production	   contributes	   to	   neuroinflammation	  
implicated	   in	   AD	   pathogenesis.	   The	   proinflammatory	   cytokine,	   TNFα,	   is	   exorbitantly	  
expressed	  coinciding	  with	   increased	   levels	  of	  Aβ	  plaque	  deposition	   (Fillit	  et	  al.	  1991;	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Paganelli	  et	  al.	  2002).	  Additionally,	   three	  TNFα	  polymorphisms	  have	  been	   implicated	  
with	   increased	  risk	  of	  LOAD,	  two	  of	  which	  are	  associated	  with	  higher	  TNFα	  secretion	  
(Collins	  et	  al.	  2000)	  further	  implicating	  this	  cytokine	  in	  the	  neuroinflammatory	  role	  in	  
AD.	  A	  number	  of	  animal	  studies	  have	  shown	  an	  upregulation	  of	  TNFα	  production	  in	  AD	  
mouse	  models	  which	  correlated	  with	  microgliosis	  (Janelsins	  et	  al.	  2005;	  Janelsins	  et	  al.	  
2008)	   and	   further	  down-­‐regulation	  of	   this	   cytokine	   in	  AD	   correlating	  with	   significant	  
modulation	   of	   amyloid	   and	   tau	   related	   pathologies	   (Montgomery	   et	   al.	   2013).	  
Activation	   in	   a	   number	   of	   cell	   types	   have	   shown	   LPS	   to	   induce	   activation	   of	  
extracellular-­‐signal-­‐regulated	  kinase-­‐1	  (ERK1)	  and	  ERK2,	  c-­‐Jun	  N-­‐terminal	  kinases	  (JNKs)	  
and	   p38	   of	  which	   all	   have	   been	   shown	   to	   be	   involved	   in	   either	   TNFα	   production	   or	  
translation	   (Liu	  et	  al.	  1994;	  Arditi	  et	  al.	  1995;	  Hambleton	  et	  al.	  1996;	  Sanghera	  et	  al.	  
1996;	   Nijenhuis	   et	   al.	   1999).	   A	   significant	   increase	   in	   TNFα	   secretion	   was	   observed	  
following	   treatment	   of	   primary	   rat	   microglia	   with	   LPS	   however	   this	   increase	   in	  
secretion	  was	  not	  replicated	  following	  activation	  with	  Aβ1-­‐42	  (Fig.	  3.5a).	  This	  correlates	  
with	   data	   from	   neuronal-­‐glial	   mixed	   cultures	   showing	   that	   low	   doses	   of	   Aβ	   did	   not	  
increase	   levels	   of	   TNFα	   secretion	   but	   the	   toxicity	   was	   thought	   to	   arise	   from	   ROS	  
production	  (Qin	  et	  al.	  2002).	  TNFα	  and	  IL-­‐1β	  stimulate	  an	  upregulation	  of	  C3	  and	  factor	  
B	   biosynthesis,	  which	   are	   activator	   proteins	   of	   the	   alternative	   complement	   pathway	  
(refer	  to	  fig.	  1.5)	  in	  umbilical	  cord	  endothelial	  cells	  (Kawakami	  et	  al.	  1997).	  This	  could	  
suggest	   that	   the	   already	   continuously	   activated	   innate	   immune	   response	   pathway	  
contributes	  to	  an	  increased	  C3b	  deposition.	  However,	  TNFα	  and	  IL-­‐1	  have	  been	  found	  
on	  neutrophils	  to	  upregulate	  CR1	  expression	  (Ogle	  et	  al.	  1990),	  which	  could	  bind	  the	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excess	  C3b.	  The	  reduction	  in	  TNFα	  secretion	  shown	  in	  figure	  3.5a	  could	  be	  as	  a	  result	  
of	  low	  expression	  of	  TNFα	  cleavage	  proteins	  such	  as	  TNFα	  converting	  enzyme	  (TACE	  or	  
ADAM17).	   TACE	   is	   responsible	   for	   cleavage	  of	   the	  membrane-­‐bound	  precursor	  TNFα	  
(mTNFα)	   to	   its	   mature	   soluble	   TNFα	   (sTNFα)	   form	   which	   is	   secreted	   from	   the	  
membrane	  into	  the	  extracellular	  compartment	  (Black	  et	  al.	  1997;	  Mohan	  et	  al.	  2002).	  
TACE	  requires	  certain	  conditions	  for	  the	  cleavage	  of	  mTNFα	  and	  subsequent	  release	  of	  
sTNFα,	  which	  may	  be	   affected	  by	  blocking	  CR1.	   Further	   investigation	   into	   a	   possible	  
interaction	  would	  need	  to	  be	  addressed.	  
The	   proinflammatory	   cytokine,	   IL-­‐6	   is	   also	   thought	   to	   play	   a	   role	   in	   the	  
pathogenesis	  of	  AD	  with	  studies	  reporting	  increased	  serum	  levels	  of	  this	  cytokine	  in	  AD	  
patients	   compared	  with	   control	   (Cojocaru	  et	   al.	   2011)	   and	   immunostaining	  detected	  
around	   senile	   plaques	   and	   large	   cortical	   neurons	   of	   AD	   brains	   (Strauss	   et	   al.	   1992).	  
Furthermore	   a	   genetic	   polymorphism	   of	   the	   IL-­‐6	   gene	   has	   been	   associated	   with	  
increased	   risk	   for	   the	   development	   of	   AD	   and	   modulation	   of	   time	   of	   onset	  
(Papassotiropoulos	  et	  al.	  1999;	  Bagli	  et	  al.	  2000).	  Figure	  3.5b	  shows	  an	  increase	  in	  IL-­‐6	  
secretion	   from	   primary	   rodent	   microglia	   following	   24	   h	   hour	   stimulation	   with	   LPS	  
which	   is	   consistent	  with	   known	  LPS	  activation	  data	   (Minogue	  et	   al.	   2012).	   In	  human	  
skin	  fibroblasts	  IL-­‐6	  has	  been	  shown	  to	  increase	  the	  rate	  of	  synthesis	  of	  C3	  and	  factor	  B	  
(Katz	   et	   al.	   1989).	   This	   pathway	   is	   further	   accelerated	   by	   IL-­‐6,	   contributing	   to	   the	  
protection	  of	  the	  body	  by	  mediating	  an	  inflammatory	  response,	  pathogen	  opsonization	  
and	  stimulating	  phagocytosis.	  Blocking	  CR1	  may	  result	  in	  an	  accumulation	  of	  C3b	  due	  
to	   reduced	   binding	   and	   subsequent	   removal	   from	   circulation.	   Excess	   C3b	   deposition	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results	   in	   red	   cell	   deposition	   of	   which	   CR1	   binding	   can	   have	   a	   protective	   effect	  
(Odhiambo	  et	  al.	  2008).	  Although	  there	  is	  an	  increase	  in	  rodent	  microglia	  IL-­‐6	  secretion	  
observed	   following	  LPS	  activation,	  pre-­‐treatment	  with	  CR1	  blocking	  antibody	  did	  not	  
appear	  to	  have	  any	  effect	  on	  IL-­‐6	  secretion	  (Fig.	  3.5b).	  One	  of	  the	  components	  of	  the	  
MAC	   complex,	   C5b,	   has	   also	   been	   hypothesized	   to	   contribute	   to	   IL-­‐6	   expression	  
through	   the	  activation	  of	   transcription	   factors	  NFkB	  and	  AP-­‐1	   in	   smooth	  muscle	   cells	  
(Viedt	   et	   al.	   2000),	   implicating	   a	   positive	   feedback	   mechanism	   is	   at	   play.	   This	   may	  
attribute	   to	   the	   continuous	   secretion	   of	   IL-­‐6	   observed	   following	   increased	   C3b	  
deposition.	  
IL-­‐1β	   is	   another	   pro-­‐inflammatory	   cytokine	   that	   has	   been	   indicated	   to	   be	  
associated	  with	  the	  pathogenesis	  of	  AD.	  	  Both	  genetic	  data	  linking	  polymorphisms	  in	  IL-­‐
1β	   to	   increased	  AD	   risk	   (Licastro	  et	  al.	   2004)	  and	   studies	   investigating	   IL-­‐1β	   levels	   in	  
post-­‐mortem	  brain	  tissue	  and	  in	  CSF	  have	  found	  a	  significantly	  higher	  concentration	  of	  
this	   cytokine	   in	   AD	   patients	   versus	   aged-­‐matched	   controls	   (Cacabelos	   et	   al.	   1991;	  
Cacabelos	  et	  al.	  1994).	  In	  vitro	  data	  demonstrate	  that	  microglia	  are	  the	  primary	  source	  
of	   IL-­‐1β	   in	   the	   brain	   (Chauvet	   et	   al.	   2001).	   Figure	   5.3c	   does	   not	   show	   an	   increased	  
secretion	   of	   IL-­‐1β	   following	   microglial	   activation	   with	   LPS	   as	   seen	   with	   the	   other	  
cytokine	   ELISA	   measurements.	   It	   has	   been	   reported	   that	   IL-­‐6	   can	   act	   as	   an	   anti-­‐
inflammatory	   under	   certain	   conditions,	   and	   a	   study	   investigating	   the	   impact	   of	   IL-­‐6	  
secretion	  on	   LPS	   release	  of	   IL-­‐1β	   from	  glial	   cells	   found	   that	   co-­‐treatment	  of	   LPS	  and	  
recombinant	  IL-­‐6	  demonstrated	  a	  partially	  attenuated	  release	  of	  IL-­‐1β	  (Minogue	  et	  al.	  
2012).	  Minogue	  and	  colleagues	  also	  postulated	  that	   it	  could	  be	  due	  to	  an	   increase	   in	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the	   anti-­‐inflammatory	   cytokine	   IL-­‐10.	   However	   this	   study	   saw	   no	   change	   in	   IL-­‐10	  
secretion	  between	  treatments	  (data	  not	  shown).	  Figure	  3.5c	  does	  show	  an	  increase	  in	  
IL-­‐1β	   secretion	   following	   activation	   of	   primary	   rodent	  microglia	   with	   Aβ1-­‐42,	   a	   result	  
shown	  to	  correlate	  with	  data	  investigating	  oligomeric	  and	  fibrillar	  Aβ1-­‐42	  effects	  on	  glial	  
cultures	   (White	   et	   al.	   2005).	   Prior	   to	   IL-­‐1β	   secretion	   from	   microglia,	   biologically	  
inactive	  pro-­‐IL-­‐1β	  is	  cleaved	  by	  caspase-­‐1	  to	  generate	  the	  mature,	  biologically	  active	  IL-­‐
1β	  (Eder	  2009).	  The	  first	  protein	  of	  the	  complement	  cascade,	  C1q,	  is	  able	  to	  suppress	  
pro-­‐caspase	  1	  and	  pro-­‐IL-­‐1β	  cleavage	  and	  therefore	  reducing	  IL-­‐1β	  secretion	  (Benoit	  et	  
al.	   2012).	   Perhaps	   by	   blocking	   a	   complement	   regulatory	   protein	   such	   as	   CR1	   could	  
contribute	  to	  the	  mechanism	  by	  which	  C1q	  attenuates	   the	  cleavage	  of	   these	   factors.	  
Increased	  binding	  of	  IL-­‐1β	  to	  C3b	  following	  human	  serum	  activation	  (Borth	  et	  al.	  1990),	  
may	  suggest	  a	  possible	  reason	  for	  a	  decrease	  in	  IL-­‐1β	  release	  from	  Aβ1-­‐42	  and	  CR1	  block	  
treated	  cells	  compared	  to	  Aβ1-­‐42	  alone.	  Binding	  to	  the	  increased	  C3b	  available	  through	  








iNOS	  expression	  has	  been	  detected	  in	  the	  AD	  brain	  and	  associated	  with	  senile	  
plaques	  and	  neurofibrillary	  tangles	  (Lee	  et	  al.	  1999)	  and	  in	  figure	  3.6a	  and	  3.6b,	  there	  
is	   an	   observed	   increase	   in	   expression	   following	   treatment	   with	   neuroinflammatory	  
activator	  markers,	  LPS	  and	  Aβ1-­‐42.	  The	  increase	  observed	  through	  immunofluorescence	  
was	  reduced	  in	  primary	  microglia	  co-­‐treated	  with	  LPS	  and	  CR1	  blocking	  antibody	  and	  a	  
Figure	   3.12:	   Possible	   interactions	   within	   the	   complement	   system	   following	   modulation	   of	   CR1	   in	  
neuroinflammation.	  
Microglial	  activation	  increases	  secretion	  of	  IL-­‐6,	  TNFα	  and	  IL-­‐1β	  which	  could	  upregulate	  C3	  and	  Factor	  B	  of	  
the	   alternative	   pathway.	   This	   may	   then	   contribute	   to	   increased	   C3b	   expression	   which	   could	   lead	   to	  
increased	  cell	  lysis	  and	  increased	  O2
.-­‐	  through	  activation	  of	  C3.	  Blocking	  CR1	  could	  lead	  to	  less	  production	  
of	  iC3b	  which	  may	  reduce	  O2




trend	  towards	  a	  decrease	  in	  expression	  observed	  in	  Aβ1-­‐42	  and	  CR1	  blocking	  antibody	  
co-­‐treatment	   (Fig.	   3.6a	   and	   3.6b)	   proposing	   that	   CR1	   may	   play	   a	   role	   in	   iNOS	  
expression	   in	  microglia.	  The	  Western	  blotting	  data	  also	  showed	  a	   trend	  towards	  CR1	  
blockade	  decreasing	  LPS	  and	  Aβ1-­‐42	  induced	  iNOS	  expression,	  however	  these	  data	  were	  
not	  significant.	  
	   iNOS	  is	  involved	  in	  mediating	  the	  production	  of	  NO,	  which	  when	  it	  interacts	  with	  
O2
.-­‐	   is	   known	   to	   have	   detrimental	   consequences	   to	   cells	   through	   the	   production	   of	  
peroxynirtite.	  Superoxide	  production	  via	  NADPH	  oxidase	  has	  been	  previously	  shown	  to	  
play	  a	  role	  in	  AD	  (Shimohama	  et	  al.	  2000;	  Ansari	  &	  Scheff	  2011).	  This	  study	  sought	  to	  
investigate	   if	   CR1	  was	   involved	   in	   this	   toxic	   role.	   TNFα,	   IL-­‐6	   and	   IL-­‐1β	  upregulate	  C3	  
and	   Factor	   B	   leading	   to	   the	   increased	   expression	   of	   C3b,	  which	   has	   been	  previously	  
mentioned	   to	   have	   a	   positive	   correlation	   with	   increased	   respiratory	   burst	   in	  
neutrophils	   (Hoogerwerf	  et	  al.	  1990).	  Figures	  3.7	  and	  3.8	  appear	   to	  complement	  this	  
finding	  demonstrating	  an	   increase	   in	  O2
.-­‐	  expression	   in	  primary	  rat	  microglia	  and	  BV2	  
microglia	   respectively.	   An	   increase	   that	   can	   be	   attributed	   to	   NADPH	   oxidase	  
production	   of	   O2
.-­‐	   due	   to	   the	   coinciding	   co-­‐treatments	   with	   the	   NADPH	   oxidase	  
inhibitor,	  apocynin,	  demonstrating	  an	  almost	  complete	  absence	  of	  O2
.-­‐	  expression.	  	  In	  
leukocytes,	   CR3,	   the	   receptor	   for	   iC3b,	   mediates	   the	   activation	   of	   protein	   tyrosine	  
kinases	   (PTKs).	   PTKs	   in	   turn	   stimulate	   the	   phos-­‐phoinositide	   3-­‐kinase	   (PI-­‐3K)	   activity	  
and	  these	  function	  as	  src-­‐homology	  2	  (SH2)	  docking	  sites.	  This	  leads	  to	  the	  activation	  
of	  RAC2,	  which	  as	  part	  of	  the	  granulocyte	  NADPH	  oxidase	  complex	  ultimately	  leads	  to	  
a	   respiratory	   burst	   (Wymann	   et	   al.	   2000).	   Blocking	   CR1	   would	   result	   in	   reduced	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cleavage	  of	  C3b	  to	  C3bi,	  and	  as	  a	  consequence	  reduced	  binding	  to	  CR3	  and	  subsequent	  
reduced	  O2
.-­‐	  expression	   (Fig.	  3.7	  and	  3.8).	  This	   result	  was	   replicated	   in	  BV2	  microglia	  
using	  Crry	  siRNA	  (Fig.	  9),	  however	  further	  controls	  need	  to	  be	  done	  in	  this	  experiment	  
to	   help	   reinforce	   the	   data	   indicating	   that	   blocking	   CR1	   inhibits	   O2
.-­‐	   expression	   in	  
microglia.	   Superoxide	   production	  was	   also	  measured	   by	   a	  NBT	   assay	   to	   confirm	   the	  
findings.	   The	   data	   from	   this	   experiment	   replicates	   the	   decrease	   in	   superoxide	  
production	   following	   blocking	   CR1	   that	   was	   observed	   by	   DHE	   fluorescence	  
measurement	   (Fig.	  3.10).	  Figure	  3.7,	  3.8,	  3.9	  and	  3.10	  provide	  data	   that	   suggest	  CR1	  
may	  play	  a	  role	  in	  the	  superoxide	  production	  via	  NADPH	  oxidase	  activity.	  
	   Oxidative	   stress	   is	   an	   imbalance	   between	   ROS	   and	   its	   removal	   by	   antioxidant	  
systems.	  Microglia	  produce	  glutathione	  for	  the	  defence	  of	  ROS	  (Hirrlinger	  et	  al.	  2000)	  
and	   a	   decline	   in	   glutathione	   concentration	   is	   seen	   in	   blood	   from	  male	   AD	   patients	  
compared	   to	   controls	   (H	   Liu	   et	   al.	   2004).	   Perhaps	   the	   oxidative	   stress	   observed	  
following	  blocking	  CR1	  is	  not	  only	  exclusively	  due	  to	  an	  increase	  in	  ROS	  such	  as	  O2
.-­‐	  but	  
also	   through	   a	   change	   in	   glutathione	   to	   counteract	   this	   toxicity.	   However,	   following	  
investigations	  as	  to	  whether	  CR1	  played	  a	  role	  in	  microglial	  release	  of	  glutathione,	  the	  
results	   demonstrated	   no	   change	   in	   production	   (Fig.	   11)	   implying	   that	   CR1’s	  
contribution	   to	   the	   oxidative	   stress	   balance	   remains	   likely	   to	   be	   solely	   through	   ROS	  
production.	   However,	   further	   investigation	   measuring	   other	   anti-­‐oxidant	   systems	  





These	   results	   possibly	   demonstrate	   that	   CR1	   plays	   a	   role	   in	   microglial	  
phagocytosis,	   particularly	   when	   triggered	   by	   Aβ.	   This	  modulation	   is	   interesting	   as	   it	  
revealed	   CR1	   to	   enhance	   dextran	   phagocytosis	   but	   reduce	   Aβ	   phagocytosis.	   Thus,	  
taken	   together,	   GWAS	   studies	  mutations	   in	   CR1	  may	   lead	   to	   loss	   of	   function	   and	   a	  
decrease	  in	  Aβ	  clearance,	  which	  correlates	  with	  the	  data	  presented	  here.	  What	  is	  also	  
clear	   here	   is	   the	   proinflammatory	   influence	   CR1	   has	   on	   neurotoxicity,	   and	   our	   data	  
suggest	  this	  is	  via	  actions	  of	  microglial	  O2
.-­‐	  and	  cytokine	  production.	  Mice	  express	  the	  
Cr1-­‐related	  protein	  Y	  (Crry)	  which	  is	  more	  similar	  to	  human	  Cr1	  in	  its	  protein	  sequence	  
and	   function	   than	   murine	   Cr1	   and	   deletion	   of	   Crry	   has	   been	   recently	   shown	   to	  
influence	   tau	   phosphorylation	   and	   complement	   production	   (Jacobson	   &	  Weis	   2008;	  
Killick	  et	  al.	  2012).	  In	  this	  study,	  results	  for	  Crry	  knockdown	  in	  murine	  BV2	  microglia	  are	  
the	  same	  as	  those	  using	  the	  CR1	  blocking	  antibody	  in	  rat	  microglia,	  suggesting	  similar	  
downstream	   pathways.	   It	   should	   be	   noted	   that	   further	   experiments	   also	   using	   IgG	  
control	  and	  a	  Fc	  receptor	  blocker	  would	  need	  to	  be	  carried	  out	  to	  control	  for	  the	  CR1	  
blocking	  antibody.	  Considering	  the	  recent	  data	  demonstrating	  a	  genetic	   link	  between	  
CR1	   and	   LOAD,	   it	   is	   crucial	   to	   determine	   what	   impact	   this	   has	   on	   the	   cellular	   and	  
molecular	   ramifications	   of	   CR1	   activation	   on	   neuronal	   survival	   and	   consequences	   of	  

























4. Ramifications	  of	  CR1	  activation	  on	  neuronal	  survival	  
4.1	  Introduction	  and	  summary	  of	  results	  
In	  the	  previous	  chapter,	  blocking	  microglial	  CR1	  was	  shown	  to	  reduce	  a	  number	  
of	   responses	   from	  microglia	   that	  are	  potentially	  neurotoxic	   such	  as	   iNOS	  expression,	  
superoxide	  production	  and	   secretion	  of	   cytokines	   such	  as	   TNFα.	   It	  was	   important	   to	  
investigate	  the	  ramifications	  of	  microglial	  CR1	  modulation	  on	  neuronal	  survival,	  which	  
may	  have	  important	  consequences	  for	  future	  AD	  therapies.	  
Survival	   of	   cerebellar	   granule	   neuronal	   cells	   (CGCs)	   was	   examined	   following	  
direct	   treatment	  with	   LPS	  and	  Aβ1-­‐42	   alone	  and	  also	   in	   the	  presence	  of	  CR1	  blocking	  
antibody.	   Neuronal	   death	   was	   also	   investigated	   following	   treatment	   with	   microglial	  
conditioned	   medium	   (MGCM)	   from	   microglia	   incubated	   with	   LPS,	   Aβ1-­‐42	   and	   CR1	  
blocking	  antibody.	  Modulating	  CR1	  was	  found	  to	  have	  an	  effect	  on	  neuronal	  death.	  
Following	  on	  from	  the	  observed	  microglial	  TNFα	  secretion	  and	  iNOS	  expression,	  
this	  study	  also	  aimed	  to	  determine	  if	  these	  microglial	  mediators	  of	  neurotoxicity,	  were	  
causative	   factors	   in	   the	   observed	   neuronal	   death.	   It	   was	   observed	   that	  
pharmacologically	  inhibiting	  microglial	  iNOS	  and	  TNFα	  did	  not	  have	  a	  protective	  effect	  







4.2.1	  CR1	  modulation	  has	  an	  effect	  on	  neuronal	  death	  
Evidence	   suggests	   that	   apoptosis	   can	   stimulate	   the	   complement	   system,	   and	  
such	   activation	   contributes	   to	   the	   phagocytosis	   of	   subsequent	   apoptotic	   cells	   (Köhl	  
2006).	   Figure	  4.1	   shows	   the	   results	   following	  measuring	  percentage	  of	   cell	   death,	   as	  
assessed	   by	   as	   assessed	   by	   fluorescence	  microscopy	   using	   PI,	   which	   is	   a	  marker	   for	  
necrosis	   and	   late	   apoptosis	   and	  Hoechst	   33342,	   a	   nuclear	   stain	  which	   stains	   smaller	  
brighter	  apoptotic	  nuclei.	  Percentage	  of	  cell	  death	  was	  measured	  following	  either	  48	  h	  
treatment	  of	  CGC	  cultures	  directly	  with	  LPS	  (1	  μg/mL),	  Aβ1-­‐42	  (20	  nM)	  and	  CR1	  blocking	  
antibody	  (2	  	  µg/mL)	  (Fig.	  4.1a)	  or	  48	  h	  treatment	  with	  MGCM	  from	  microglial	  cultures	  
treated	  for	  24	  h	  with	  LPS,	  Aβ1-­‐42	  and	  CR1	  blocking	  antibody	  (Fig.	  4.1c).	  	  
Direct	  treatment	  of	  CGC	  cultures	  with	  LPS	  (1	  μg/mL)	  or	  addition	  of	  MGCM	  from	  
LPS-­‐treated	   microglia	   for	   24	   h	   induced	   significant	   cell	   death	   (Fig.	   4.1a	   and	   4.1c),	  
suggesting	  the	  neurotoxin(s)	  responsible	  was	  soluble	  and	  stable.	  No	  death	  was	  induced	  
when	  CGC	  cultures	  were	  directly	   treated	  with	  Aβ1-­‐42	   (20	  nM)	   for	  48	  h	   (Fig.	  4.1a)	  but	  
significant	   death	   was	   observed	   when	   CGC	   cultures	   were	   treated	   with	   conditioned	  
medium	  from	  microglia	   treated	  with	  Aβ1-­‐42	   	   (Fig.	  4.1c),	   suggesting	   that	  Aβ1-­‐42	   -­‐MGCM	  
contains	  stable	  neurotoxins	  which	  may	  not	  be	  potent	  in	  mixed	  neuronal-­‐glial	  cultures.	  
It	   may,	   however,	   be	   as	   a	   consequence	   of	   a	   dampening	   of	   the	   response	   due	   to	   Aβ	  
activated	  astrocytes	  in	  the	  CGC	  culture	  mediating	  extracellular	  signal-­‐regulated	  kinase	  
(ERK)	   dependent	   neuroprotection	   (Abe	   et	   al.	   2003;	   Yamamuro	   et	   al.	   2003).	   A	  
significant	   reduction	   in	   death	   was	   observed	   in	   CGCs	   directly	   pre-­‐treated	   with	   CR1	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functional	   blocking	   antibody	   compared	  with	  CGCs	   treated	  with	   LPS	   alone	   (Fig.	   4.1a).	  	  
Also	   data	   presented	   in	   Fig.	   4.1b	   indicate	   that	   the	   total	   cell	   number	   did	   not	   vary	  
between	  treatments	  reducing	  the	  possibility	  of	  the	  decrease	  in	  apoptosis	  being	  due	  to	  
an	   increase	   in	   phagocytosis	   of	   the	   apoptotic	   cells	   or	   floating	   off	   of	   dead	   cells.	   No	  
difference	   in	  CGC	   levels	  of	  death	  were	  seen	   following	  direct	   treatment	   for	  48	  h	  with	  
Aβ1-­‐42	  with	  or	  without	  the	  presence	  of	  CR1	  blocking	  antibody	  (Fig	  4.1a).	  Data	  presented	  
in	   Fig.	   4.1c	   indicated	   that	   neuronal	   death	   was	   enhanced	   after	   treatment	   of	   CGC	  
cultures	  with	  MGCM	   from	  microglia	   treated	  with	   LPS	   or	   Aβ1-­‐42.	   This	   neuronal	   death	  
was	  reduced	  when	  the	  CGC	  cultures	  were	  treated	  with	  MGCM	  from	  primary	  microglia	  
treated	  with	  Aβ1-­‐42	  and	  CR1	  blocking	  antibody.	  	  
In	  order	  to	  investigate	  the	  potential	  protective	  effect	  of	  blocking	  CR1	  in	  one	  of	  
the	   regions	   in	   which	   neurodegeneration	   is	   known	   to	   occur	   early	   on	   in	   AD,	   the	  
hippocampus,	   a	   live	   cell	   assay	   was	   performed	   on	   hippocampal	   neurons.	   Similar	  
findings	   were	   observed	   with	   these	   neurons	   compared	   with	   CGCs	   (Fig.	   4.1e).	  
Calculation	  of	  NeuN	  positively	  stained	  neurons	  was	  carried	  out	  to	  determine	  neuronal	  
viability	  (Fig.	  4.1e).	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Figure	   4.1:	   CR1	   functional	   blocking	   antibody	   protects	   against	   microglial-­‐evoked	   neurotoxicity	   following	  
direct	   and	   indirect	   treatment	   with	   Aβ1-­‐42	   (20	   nM)	   or	   LPS	   (1	   μg/mL)	   in	   the	   presence	   or	   absence	   of	   CR1	  
blocking	  antibody	  (1	  mg/mL).	  	  
(a)	   Live–dead	   cell	   staining	   of	   CGC	  neuronal	   cultures	  with	  Hoechst	   33342	   (white	   bars)	   and	   propidium	   iodide	  
(grey	  bars)	  after	  48	  h	  direct	  treatment.	  (b)	  Total	  cell	  number	  per	  condition.	  (c)	  Live–dead	  cell	  staining	  of	  CGC	  
cultures	   treated	   with	   MGCM	   from	   microglia	   treated	   with	   the	   conditions	   in	   (a)	   for	   48	   h	   with	   +ve	   Ctrl	  
representing	  cells	  with	  no	  treatment	  of	  MGCM.	  (d)	  Total	  cell	  number	  per	  condition	  after	  MGCM	  treatment	  of	  
CGCs.	   (e)	  Hippocampal	  neuronal	  protection	  under	  the	  same	  conditions	  monitored	  by	  NeuN	  staining.	   In	  all	  of	  
the	   experiments	   data	   are	   the	   mean	   of	   3	   fields	   per	   coverslip,	   3	   coverslips	   per	   condition	   from	   3	   separate	  
experiments.	  Data	  were	  analysed	  by	  one-­‐way	  ANOVA	  (ρ	  <	  0.0001	  for	  a,c	  and	  e)	  and	  Tukey	  post-­‐hoc	  tests,	  ***ρ	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Following	  the	  findings	  that	  CR1	  block	  conferred	  neuronal	  protection	  against	  LPS	  
and	   Aβ1-­‐42	   treatment,	   the	   mechanisms	   of	   this	   protection	   were	   investigated	   further.	  
Activation	  of	   the	  caspase-­‐3	  pathway,	  which	   is	  a	  hallmark	  of	  apoptosis	   (Thornberry	  &	  
Lazebnik	  1998),	  was	  investigated	  to	  determine	  whether	  blocking	  CR1	  down-­‐regulated	  
this	   cell	   death	   cascade	   (Fig.	   4.2).	   Treated	   and	   PFA	   fixed	   CGCs	   showed	   a	   significant	  
increase	   in	   cleaved	   caspase-­‐3	   immunoreactivity	   following	   treatment	   with	   LPS	  
compared	  to	  control.	  This	  in	  turn	  was	  significantly	  reduced	  in	  CGCs	  co-­‐treated	  with	  LPS	  
and	   CR1	   blocking	   antibody	   (Fig.	   4.2b).	   There	   was	   no	   change	   in	   cleaved	   caspase-­‐3	  
immunoreactivity	  following	  CGC	  treatment	  with	  Aβ1-­‐42	  and	  also	  with	  co-­‐treatment	  with	  
CR1	  blocking	  antibody.	  These	   results	  are	   in	   line	  with	   the	  CGC	   live	   fluorescence	  assay	  







Figure	   4.2:	   Cleaved	   caspase-­‐3	   cleavage	   can	   be	   attenuated	   by	   CR1	   functional	   blocking	   antibody	  
following	  activation	  of	  CGCs.	  	  
(a)	   Quantification	   and	   (b)	   images	   of	   localization	   of	   caspase-­‐3	   expression	   in	   CGC	   cultures	   performed	  
using	   ICC	   after	   treatment	   with	   Aβ1-­‐42	   (20	   nM)	   or	   LPS	   (1	   μg/mL)	   in	   the	   presence	   or	   absence	   of	   CR1	  
blocking	   antibody	   (1	  mg/mL).	   After	   treatment	   for	   48h,	   cultures	   were	   fixed	   and	   incubated	  with	   anti-­‐
NeuN	  (green)	  for	  neuronal	  identification	  and	  anti-­‐cleaved	  caspase-­‐3	  (red).	  Data	  were	  analysed	  by	  one-­‐
way	  ANOVA	  (ρ	  <	  0.0001)	  and	  Tukey	  post-­‐hoc	  tests,	  ***ρ	  <	  0.001,	  **ρ	  <	  0.01	  and	  *ρ	  <	  0.05.	  Data	  are	  





To	   ascertain	   whether	   the	   cell-­‐death	   was	   due	   to	   microglia	   present	   in	   the	   CGC	  
culture,	   microglia	   were	   selectively	   depleted	   using	   LME	   (25	   mM)	   and	   CGC	   live	  
fluorescence	   assay	   was	   carried	   out	   to	   measure	   cell	   death.	   Firstly,	   to	   confirm	   the	  
optimum	   concentration	   to	   deplete	   microglia	   without	   increasing	   neuronal	   death,	   25	  
mM	  LME	   for	  1	  h	  which	  was	  previously	  optimized	   in	   this	   lab,	  was	   tested	   in	  CGCs	  and	  




Figure	  4.3:	  Initial	  characterization	  of	  LME	  treatment	  of	  CGCs.	  	  
(a)	  Representative	  images	  of	  ICC	  experiments	  performed	  on	  CGC	  cultures	  after	  treatment	  with	  
25	  mM	  LME	  for	  1	  h.	  ICC	  was	  performed	  with	  DAPI	  (blue)	  for	  quantification	  of	  total	  cell	  number	  
and	  those	  displaying	  apoptotic	  morphology	  and	  Isolectin	  B4	  (green)	  for	  microglial	  identification	  
and	   quantification.	   (b)	   Quantification	   of	   microglial	   number,	   as	   percentage	   of	   control	   levels.	  





Following	   experimental	   confirmation	   that	   25	   mM	   successfully	   depleted	  
microglial	   cell	   number	   in	   CGC	   cultures,	   live	   fluorescence	   assays	  were	   carried	   out	   to	  
investigate	  whether	   the	  neuronal	  death	  observed	   in	   figures	  4.1	  and	  4.2	  were	  due	   to	  
the	  microglia	   present	   in	   the	   CGC	   cultures.	   Figure	   4.4a	   displays	   the	   results	   from	   this	  
experiment	  which	  have	  been	  separated	  into	  graphs	  separately	  showing	  apoptosis	  (Fig.	  
4.4b)	  and	  necrosis	  (Fig.	  4.4c)	  for	  more	  a	  straightforward	  observation.	  Apoptosis	  levels	  
were	   comparable	   between	   CGC	   cultures	   directly	   treated	   with	   control,	   CR1	   blocking	  
antibody	  (1	  mg/mL),	  LPS	  and	  CR1	  blocking	  antibody	  and	  Aβ1-­‐42	  (20	  nM)	  and	  Aβ1-­‐42	  and	  
CR1	   blocking	   antibody	   and	   those	   that	   were	   also	   pre-­‐treated	   with	   LME	   (Fig.	   4.4b).	  
However	  a	  similar	  trend	  was	  not	  observed	  in	  CGC	  cultures	  treated	  with	  LPS	  compared	  
to	  the	  same	  treatment	  in	  LME	  pre-­‐treated	  cultures.	  A	  higher	  percentage	  of	  apoptosis	  
was	  observed	  in	  LPS	  	  treated	  CGCs	  minus	  LME	  (i.e.	  containing	  microglia).	  Measurement	  
of	  necrosis	  by	  PI	  also	  demonstrated	  a	  similar	  result	  (Fig.	  4.4c),	  showing	  a	  trend	  towards	  
a	   decrease	   in	   cell	   death	   in	   LME	   pre-­‐treated	   CGC	   cultures	   compared	   with	   non-­‐LME	  
treated	   cells	   following	   activation.	   This	   result	   showed	   a	   trend	   towards	   a	   higher	  
percentage	  of	  cell	  death	  in	  non-­‐microglia	  depleted	  cultures	  treated	  with	  Aβ1-­‐42	  thereby	  









Figure	  4.4:	  CGC	  neurotoxicity	   can	  be	  down-­‐regulated	  by	  CR1	   in	   the	  presence	  of	  microglia.	  Hoechst	  33342	  
and	  PI	  staining	  of	  live	  CGC	  cultures	  for	  the	  quantification	  of	  apoptotic	  nuclear	  morphology	  and	  necrosis.	  
Some	  cultures	  were	  depleted	  of	  microglia	  prior	  to	  treatment	  with	  LME.	  Cultures	  were	  treated	  with	  Aβ1-­‐42	  (20	  
nM)	  or	  LPS	  (1	  μg/mL)	  in	  the	  presence	  or	  absence	  of	  CR1	  blocking	  antibody	  (1	  mg/mL).	  (a)	  Graph	  showing	  all	  
treatments	   and	   apoptosis	   and	   necrosis	  measurements.	   (a)	   Apoptosis	  measurement	   of	   CGC	   treatments.	   (b)	  




4.2.2	  Inhibition	  of	  microglial	  iNOS	  and	  TNFα	  result	  in	  a	  different	  neuronal	  response	  
which	  may	  not	  mediated	  by	  CR1	  
Following	   on	   from	   the	   findings	   that	  microglial	   depletion	  was	   protective	   in	   LPS	  
activated	   CGCs,	   and	   from	   findings	   in	   the	   previous	   chapter	   that	  microglial	   treatment	  
induced	  the	  release	  of	  iNOS	  and	  TNFα	  in	  a	  CR1	  dependent	  manner,	  it	  was	  important	  to	  
investigate	   the	   contribution	   of	   these	   released	   factors	   to	   neuronal	   cell	   death.	   As	  
previously	  shown	  by	   ICC,	  CR1	  block	  alters	   iNOS	  expression	  by	  LPS	  activated	  microglia	  
(Fig.	  3.6),	  and	  this	  chapter	  has	  shown	  that	  blocking	  CR1	  in	  LPS	  activated	  CGC	  cultures	  
confers	  protection	  by	  reducing	  neuronal	  death.	  It	  was	  therefore	  important	  to	  evaluate	  
if	   it	   was	   iNOS	   that	   was	   responsible	   for	   having	   the	   effect	   on	   the	   neuronal	   death	  
observed.	  CGCs	  were	   incubated	  with	  1400W	  dihydrochloride	   (1400W)	  at	  100	  μM,	  as	  
used	   in	   previously	   published	  work	   (Yuan	   et	   al.	   2012)	   to	   inhibit	   iNOS	   activity	   30	  min	  
prior	   to	   treatment	  with	   LPS	   (1	   μg/mL),	   Aβ1-­‐42	   (20	   nM)	   and	  CR1	   blocking	   antibody	   (1	  
mg/mL)	   for	   48	   h	   (Fig.	   4.6a).	   	   The	   data	   in	   this	   study	   also	   demonstrated	   that	   this	  
concentration	  was	  not	  neurotoxic	  at	  this	  concentration	  (Fig.	  4.5).	  
	  
	  
Figure	   4.5:	   Percentage	   apoptosis	   of	   total	  
cell	  number	  in	  control	  CGCs	  in	  the	  presence	  
and	   absence	   of	   1400W	   dihydrochloride	  
(1400W)	   (100	   μM)	   for	   48	   h	   demonstrates	  
concentration	  is	  not	  neurotoxic.	  	  
In	  all	  of	  the	  experiments	  data	  are	  the	  mean	  
of	   3	   fields	   per	   coverslip,	   3	   coverslips	   per	  
condition	   from	   3	   separate	   experiments.	  
Data	  were	  analysed	  by	  student’s	  t-­‐test.	  Data	  






Statistical	   analysis	   of	   this	   data	   was	   carried	   out	   comparing	   the	   percentage	   of	  
apoptotic	  nuclei	   in	  CGCs	   from	  each	   treatment	   to	   their	   respective	   controls	   (i.e.	   LPS	   v	  
Ctrl	  or	  LPS	  +	  CR1	  block	  v	  CR1	  block)	  and	  also	  comparing	  the	  percentage	  of	  apoptosis	  in	  
each	   treatment	   in	   the	   presence	   and	   absence	   of	   1400W	   pre-­‐incubation.	   Direct	  
treatment	  of	   CGCs	  with	   LPS	   (1	  μg/mL),	  Aβ1-­‐42	   (20	  nM)	   and	  CR1	  blocking	   antibody	   (1	  
mg/mL)	  for	  48	  h	  showed	  a	  significant	  decrease	  in	  apoptosis	  in	  LPS	  activated	  cells	  pre-­‐
incubated	   with	   1400W.	   A	   similar	   significant	   result	   of	   decreased	   apoptosis	   was	   also	  
observed	   in	   LPS	   and	   CR1	   blocking	   antibody	   treated	   CGCs.	   There	   was	   however,	   no	  
change	  in	  the	  Aβ1-­‐42	  treated	  cells	  following	  pre-­‐treatment	  with	  1400W.	  The	  experiment	  
was	  also	  repeated	  treating	  CGC	  cultures	  for	  48h	  with	  MGCM	  from	  microglia	  previously	  





Figure	   4.6:	   Direct	   1400W	   dihydrochloride	   treatment	   and	   indirect	   1400W	   dihydrochloride	   (1400W)	  
treatment	  through	  MGCM	  of	  CGCs	  shows	  modulation	  of	  apoptosis.	  	  
Hoechst	   33342	   staining	   of	   live	   CGC	   cultures	   for	   the	   quantification	   of	   apoptotic	   nuclear	   morphology.	  
Some	  CGC	  cultures	  were	   (a)	  directly	  pre-­‐treated	  with	  1400W	  30	  min	  prior	   to	  activation	  with	  Aβ1-­‐42	   (20	  
nM)	  or	  LPS	  (1	  μg/mL)	  in	  the	  presence	  or	  absence	  of	  CR1	  blocking	  antibody	  (1	  mg/mL).	  CGC	  cultures	  were	  
also	  (b)	  treated	  with	  MGCM	  from	  microglia	  pre-­‐treated	  with	  1400W	  prior	  to	  activation	  with	  conditions	  as	  
in	  (a).	  +ve	  Ctrl	  represents	  absence	  of	  MGCM.	  	  In	  all	  of	  the	  experiments	  data	  are	  the	  mean	  of	  3	  fields	  per	  
coverslip,	   3	   coverslips	   per	   condition	   from	   3	   separate	   experiments.	   Data	   were	   analysed	   by	   one-­‐way	  
ANOVA	  (ρ	  <	  0.0001	  for	  a	  and	  b)	  and	  Tukey	  post-­‐hoc	  tests,	  ***ρ	  <	  0.001,	  **ρ	  <	  0.01	  and	  *ρ	  <	  0.05.	  Data	  
compared	  with	   respective	  controls	   (Ctrl	  or	  CR1	  block)	  were	  marked	  with	  #	  and	   represent	   ###ρ	  <	  0.001.	  





The	  results	  from	  this	  experiment	  showed	  an	  increase	  in	  apoptosis	  from	  the	  CGCs	  treated	  with	  
the	  MGCM	   from	   the	  microglia	  pre-­‐incubated	  with	  1400W	   in	   all	   conditions	  except	  Aβ1-­‐42	   (Fig.	  
4.6b).	  	  
TNFα	   secretion	   was	   also	   previously	   shown	   by	   ELISA	   to	   be	   increased	   in	   LPS	   treated	  
microglia	   and	   further	   decreased	   with	   CR1	   blocking	   antibody	   co-­‐treatment	   (Fig.	   3.5)	   which	  
coincided	  with	  data	  from	  this	  chapter	  showing	  a	  reduction	  in	  LPS	  activated	  neuronal	  death	  (Fig.	  
4.1a)	  and	  a	  trend	  towards	  a	  decrease	  in	  neuronal	  death	  following	  MGCM	  exposure	  (Fig.	  4.1c).	  
Investigation	  into	  whether	  TNFα	  played	  a	  role	  in	  this	  reduction	  of	  neuronal	  death	  was	  carried	  
out	   through	   pharmacological	   inhibition	   of	   TNFα	   synthesis.	   To	   confirm	   that	   Thalidomide	   was	  
sufficiently	   inhibiting	   TNFα	   synthesis	   at	   the	   concentration	   used,	   an	   ELISA	   to	   measure	   TNFα	  
secretion	   in	   MGCM	   from	   microglia	   pre-­‐incubated	   with	   Thalidomide	   was	   carried	   out.	  
Thalidomide	   (10	   μg/mL)	   appeared	   to	   sufficiently	   inhibit	   TNFα	   secretion	   in	   primary	  microglia	  
(Fig.	  4.7).	  
	  
Figure	   4.7:	   ELISA	   analysis	   of	   TNFα	  
secretion	   from	   primary	   cultured	   rat	  
microglia.	  	  
Analysis	   after	   treatment	   with	   LPS	   (1	  
μg/mL),	  Aβ1–42	  (20	  nM)	  and	  CR1	  blocking	  
antibody	  (1	  μg/mL)	  for	  24	  h,	  following	  1	  h	  
pre-­‐treatment	   with	   Thalidomide	   (10	  
μg/mL).	  Reduced	  TNFα	  secretion	  following	  




CGC	  cultures	  were	  pre-­‐incubated	  with	  Thalidomide	  at	  10	  μg/mL,	  previously	  recognised	  
as	  optimum	  concentration	  to	   inhibit	  TNFα	  (Mohty	  et	  al.	  2002),	   for	  1	  h	  before	  treatment	  with	  
LPS	   (1	   μg/mL),	   Aβ1-­‐42	   (20	   nM)	   and	   CR1	   blocking	   antibody	   (1	   mg/mL)	   for	   48	   h	   (Fig.	   4.8a).	  
Statistical	  analysis	  of	  this	  data	  was	  carried	  out	  similar	  to	  the	  previous	  experiment	  with	  1400W,	  
comparing	  the	  percentage	  of	  apoptotic	  nuclei	  in	  CGCs	  from	  each	  treatment	  to	  their	  respective	  
controls	   (i.e.	   LPS	   v	   Ctrl	   or	   LPS	   +	   CR1	   block	   v	   CR1	   block).	   Comparison	   of	   the	   percentage	   of	  
apoptosis	   in	   each	   treatment	   in	   the	  presence	   and	   absence	  of	   thalidomide	  pre-­‐incubation	  was	  
also	  carried	  out.	  Significant	  reduction	  in	  apoptosis	  was	  only	  observed	  in	  CGCs	  treated	  with	  LPS	  
and	   LPS	   with	   CR1	   blocking	   antibody.	   When	   the	   neuronal	   apoptotic	   effect	   was	   investigated	  
following	  microglial	   TNFα	   inhibition,	   an	   increase	   in	   apoptosis	  was	  measured	   in	   CGCs	   treated	  





Figure	  4.8:	  Direct	  thalidomide	  treatment	  and	  indirect	  thalidomide	  treatment	  through	  MGCM	  of	  CGCs	  
shows	  modulation	  of	  apoptosis.	  	  
Hoechst	   33342	   staining	   of	   live	   CGC	   cultures	   for	   the	   quantification	   of	   apoptotic	   nuclear	  morphology.	  
Some	  cultures	  were	  (a)	  directly	  pre-­‐treated	  with	  Thalidomide	  1	  h	  prior	  to	  activation	  with	  Aβ1-­‐42	  (20	  nM)	  
or	  LPS	   (1	  μg/mL)	   in	   the	  presence	  or	  absence	  of	  CR1	  blocking	  antibody	   (1	  mg/mL).	  CGC	  cultures	  were	  
also	   (b)	   treated	   with	   MGCM	   from	   microglia	   pre-­‐treated	   with	   Thalidomide	   prior	   to	   activation	   with	  
conditions	  as	   in	  (a).	   In	  all	  of	  the	  experiments	  data	  are	  the	  mean	  of	  3	  fields	  per	  coverslip,	  3	  coverslips	  
per	  condition	  from	  3	  separate	  experiments.	  Data	  were	  analysed	  by	  one-­‐way	  ANOVA	  (ρ	  <	  0.0001)	  and	  
Tukey	  post-­‐hoc	  tests,	  ***ρ	  <	  0.001,	  **ρ	  <	  0.01	  and	  *ρ	  <	  0.05.	  Data	  compared	  with	  respective	  controls	  
(Ctrl	  or	  CR1	  block)	  were	  marked	  with	  #	  and	  represent	  ###ρ	  <	  0.001.	  Data	  are	  shown	  as	  mean	  ±	  SEM.	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4.3	  Discussion	  	  
Exploring	  the	  consequences	  of	  blocking	  CR1	  on	  microglial-­‐neuronal	  interactions	  
by	  48	  h	  treatment	  with	  MGCM	  from	  microglia	  treated	  with	  CR1	  blocking	  antibody,	  LPS	  
or	   Aβ1-­‐42,	   and	   after	   direct	   treatment	   with	   these	   activators	   demonstrated	   that	  
modulating	  CR1	  has	  an	  effect	  on	  neuronal	  survival.	  Direct	  treatment	  with	  LPS	  resulted	  
in	  increased	  neuronal	  death	  (Fig.	  4.1a)	  and	  this	  death	  was	  decreased	  in	  cells	  co-­‐treated	  
with	   CR1	   blocking	   antibody	   (Fig.	   4.1a).	   LPS	   is	   capable	   of	   activating	   the	   complement	  
system	   in	  macrophages	  as	  measured	  by	   iC3b	  ELISA	   (Sladowski	  et	  al.	  2001)	  ultimately	  
leading	   to	   cell	   lysis.	   Blocking	   CR1,	   of	   which	   binding	   to	   C3b	   is	   necessary	   for	   the	  
opsonization	  of	   pathogens,	  may	   therefore	   lead	   to	   a	   reduction	   in	   neuronal	   apoptosis	  
and	  necrosis.	  This	  result	  is	  also	  in	  line	  with	  data	  from	  the	  previous	  chapter	  showing	  an	  
increase	   in	   TNFα	   secretion	   following	   LPS	   activation,	   together	   with	   a	   decline	   in	  
secretion	  observed	  upon	  co-­‐treatment	  with	  CR1	  blocking	  antibody	  (Fig.	  3.5a).	  This	  link	  
was	  further	  investigated	  and	  will	  be	  discussed	  in	  greater	  detail	  later.	  
A	   similar	   result	   to	   direct	   LPS	   treatment	   of	   CGCs	   was	   found	   with	   microglial-­‐
neuronal	   interactions,	   showing	   an	   increase	   in	   neuronal	   death	   following	   LPS	   MGCM	  
incubation	  (Fig.	  4.1c),	  however	  this	  was	  not	  modulated	  by	  the	  co-­‐treatment	  with	  CR1	  
blocking	  antibody	  as	  it	  was	  with	  direct	  neuronal	  treatment.	  Microglial	  release	  of	  TNFα	  
is	  very	  fast	  and	  a	  time-­‐course	  analysis	  after	  the	  addition	  of	  1	  μg/mL	  LPS	  has	  shown	  6	  h	  
to	   be	   the	   peak	   of	   TNFα	   release	   after	  which	   it	   gradually	   decreases	   (Nakamura	   et	   al.	  
1999;	  Pinteaux-­‐Jones	  et	  al.	  2008).	  MGCM	  for	  this	  experiment	  was	  collected	  following	  
24	  h	  LPS	  treatment	  and	  as	  such	  the	  levels	  of	  TNFα	  present	  in	  the	  MGCM	  would	  have	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been	   lower,	   possibly	   contributing	   to	   the	   lower	   amount	   of	   neuronal	   death	  measured	  
compared	  with	  direct	  treatment	  with	  LPS.	  However	  TNFα	  is	  not	  the	  only	  inflammatory	  
factor	   important	   for	   determining	   the	   outcome	   of	   neuronal	   survival.	   A	   significant	  
amount	  of	  NO,	  matching	  the	  peak	  production	  of	  TNFα,	  was	  released	  at	  24	  h	  following	  
LPS	  treatment	  (Nakamura	  et	  al.	  1999)	  which	  may	  also	  reflect	  the	  increase	  in	  neuronal	  
death	  (Fig.	  4.1c).	  	  
The	  rescuing	  effect	  observed	  with	  direct	  treatment	  of	  CGCs	  with	  CR1	  blocking	  
antibody	  together	  with	  LPS	  was	  not	  replicated	   in	  neurons	  directly	  treated	  with	  Aβ1-­‐42	  
(Fig.4.1a).	  This	  may	  be	  due	  to	  the	  low	  nanomolar	  concentration	  of	  Aβ1-­‐42	  used	  (20	  nM)	  
which	  may	  not	  produce	  a	  direct	  toxic	  effect	  to	  neurons,	  but	  can	  have	  damaging	  effects	  
on	  neurons	  through	  the	  inflammatory	  role	  of	  glia	  (Neniskyte	  et	  al.	  2011).	  The	  increased	  
apoptosis	   of	   CGCs	   treated	   with	   Aβ1-­‐42	   MGCM	   for	   48	   h	   (Fig.	   4.1c)	   was	   significantly	  
decreased	  when	  the	  neurons	  were	  exposed	  to	  MGCM	  from	  microglia	  treated	  with	  CR1	  
blocking	  antibody	  together	  with	  Aβ1-­‐42.	  Binding	  of	  Aβ1-­‐42	  to	  the	  receptor	  for	  advanced	  
glycation	   end	   products	   (RAGE)	   can	   induce	   a	   microglial	   mediated	   inflammatory	   and	  
neurotoxic	  response	  (Yan	  et	  al.	  1996)	  and	  Aβ	  oligomers,	  fibrils	  and	  aggregates	  can	  all	  
bind	   to	   this	   receptor	   (Sturchler	   et	   al.	   2008).	   This	   behavior	   creates	   a	   harmful	   cellular	  
environment,	   in	  which	   the	  persistent	   activation	  of	  microglia	   causes	   them	   to	  adopt	  a	  
predominantly	   neurotoxic	   phenotype,	   resulting	   in	   neuronal	   cell	   death	   (Fang	   et	   al.	  
2010).	   The	   decrease	   in	   apoptosis	   seen	   in	   CGCs	   treated	   with	  MGCM	   from	  microglia	  
treated	  with	  Aβ1-­‐42	   and	  CR1	  blocking	   antibody	   suggests	   that	  manipulating	  CR1	  has	   a	  
positive	  effect	  on	  neuronal	  survival	  (Fig.	  4.1c.).	  Total	  cell	  number	  was	  also	  measured	  to	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eliminate	   the	   possibility	   that	   a	   reduction	   in	   neuronal	   death	   was	   a	   consequence	   of	  
changes	   in	  cell	  number	  (Fig.	  4.1b	  and	  4.1d).	  These	  results	  appeared	  to	  correlate	  with	  
hippocampal	  neuronal	  viability	  data	  (Fig.	  4.1e).	  
Caspase-­‐3	   is	   one	   of	   the	   proteases	   that	   serves	   as	   a	   primary	   mediator	   for	  
apoptosis	  (Thornberry	  &	  Lazebnik	  1998)	  therefore	  to	  further	  support	  the	  live	  cell	  assay	  
with	  direct	  treatment	  of	  CGCs	  from	  figure	  4.1a,	  ICC	  probing	  for	  cleaved	  caspase-­‐3	  and	  
NeuN	  was	  carried	  out	  (Fig.	  4.2).	  This	  experiment	  demonstrated	  an	  increase	  in	  cleaved	  
caspase-­‐3	   expression	   after	   CGC	   treatment	   with	   LPS,	   which	   was	   then	   shown	   to	   be	  
significantly	  decreased	  in	  the	  presence	  of	  CR1	  blocking	  antibody	  (Fig.	  4.2).	  These	  data	  
show	  the	  same	  result	  and	  are	  in	  line	  with	  the	  live	  assay,	  thus	  strengthening	  the	  finding	  
that	  inhibiting	  CR1	  may	  have	  a	  protective	  role	  on	  neurons.	  	  
A	   small	   number	   of	  microglia,	   ~5%,	   are	   also	   present	   in	   CGC	   cultures	   (despite	  
Ara-­‐C	   treatment)	   (Fig.	   4.3)	   and	   so	   it	   is	   was	   important	   to	   investigate	   whether	   the	  
microglia	   present	   in	   the	   culture	   contribute	   to	   neuronal	   death.	   After	   successfully	  
confirming	  that	  25	  mM	  LME	  was	  sufficient	  to	  deplete	  a	  CGC	  culture	  of	  microglia	  (Fig.	  
4.3),	   all	   conditions	   previously	   used	   in	   the	   live	   assay	  were	   added	   to	   the	   LME	   treated	  
CGCs.	   Depletion	   of	   all	  microglia	   from	   the	   CGC	   culture	   resulted	   in	   a	   trend	   towards	   a	  
reduction	  in	  apoptosis	  (Fig.4.4b)	  and	  necrosis	  (Fig.	  4.4c)	  in	  LPS	  treated	  cells,	  suggesting	  
that	  microglia	   influenced	   the	   neuronal	   death	   observed.	  Microglia	   release	   neurotoxic	  
factors	  upon	  activation	  with	  pro-­‐inflammatory	  stimuli	  such	  as	  LPS	  resulting	  in	  neuronal	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death	  (Block	  et	  al.	  2007)	  explaining	  the	  reduction	  in	  neuronal	  death	  in	  CGC	  cultures	  in	  
absence	  of	  microglia.	  	  
iNOS	  expression	  as	  measured	  by	   ICC	   in	  chapter	  3	  demonstrated	   the	  ability	  of	  
blocking	  CR1	  on	  reducing	  the	  expression	  of	  iNOS	  from	  LPS	  and	  Aβ1-­‐42	  treated	  microglia	  
(Fig.	   3.6a	   and	   3.6b),	   which	   is	   a	   somewhat	   similar	   trend	   to	   the	   neuronal	   loss	   data	  
measured	   in	   this	   study	   (Fig.	   4.1	   and	   4.2).	   To	   confirm	   the	   involvement	   of	   increased	  
microglial	   iNOS	  with	   neuronal	   death,	   the	   enzyme	  was	   inhibited	   before	   activation	   of	  
microglia	   and	   the	   MGCM	   was	   incubated	   with	   the	   CGCs	   (Fig.4.6b).	   The	   contrasting	  
results	   of	   the	   MGCM	   treated	   CGCs	   to	   the	   directly	   treated	   CGCs	   (Fig.	   4.6a)	   pose	   a	  
question	  of	  whether	  iNOS	  works	  alone	  to	  bring	  about	  neurotoxicity	  and	  if	  so,	  whether	  
disrupting	   this	   combination	   will	   cause	   an	   imbalance	   and	   subsequent	   increased	  
neurtoxicity.	   However,	   control	   and	   CR1	   block	   MGCM	   had	   a	   significantly	   increased	  
amount	   of	   neuronal	   death	   when	   iNOS	   was	   inhibited	   indicating	   that	   this	   is	   not	   an	  
activation	  specific	  response.	  Further	  investigation	  into	  the	  cause	  of	  this	  increase	  death	  
would	  need	  to	  be	  carried	  out,	  perhaps	  by	  evaluating	  the	  soluble	  factors	  present	  in	  the	  
MGCM.	  
As	   previously	   shown	   in	   chapter	   3,	   LPS	   increases	   the	   secretion	   of	   the	   pro-­‐
inflammatory	  cytokine	  TNFα	  (Fig.	  3.5a),	  which	  is	  able	  to	  activate	  the	  extrinsic	  pathway	  
of	   caspase	   activation	   through	   binding	   to	   cell	   surface	   receptor,	   TNFR1,	   followed	   by	  
oligomerization	  and	  cleavage	  of	  pro-­‐caspase-­‐8	  and	  -­‐10	  ultimately	  resulting	  in	  apoptosis	  
(Micheau	  &	  Tschopp	  2003).	  This	  was	  in	  line	  with	  results	  in	  this	  study	  that	  were	  able	  to	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demonstrate	   an	   increase	   in	   neuronal	   apoptosis	   following	   direct	   LPS	   treatment	   and	  
incubation	  with	  MGCM	  from	  LPS	  treated	  microglia	  (Fig.	  4.1a	  and	  4.1c).	  	  
A	   similar	   correlation	   between	   TNFα	   secretion	   and	   neuronal	   death	   was	   also	  
observed	  between	  reduced	  TNFα	  secretion	  from	  microglia	  by	  ELISA	  analysis	  following	  
co-­‐treatment	  with	  CR1	  blocking	  antibody	  (Fig.	  3.5a)	  and	  a	  trend	  towards	  a	  reduction	  in	  
neuronal	  death	   in	  CR1	  co-­‐treated	  MGCM	  (Fig.	  4.1c).	  To	  ascertain	   the	   involvement	  of	  
TNFα	  secretion	  as	  a	  contributing	  element	  to	  the	  neuronal	  apoptosis,	  pharmacological	  
inhibition	  of	  TNFα	  was	  performed	  (Fig.	  4.7).	   	  Data	   from	  direct	  CGC	  treatment,	  shows	  
that	  apoptosis	  was	  significantly	  reduced	  in	  LPS	  treated	  cells	  where	  TNFα	  was	  inhibited	  
prior	   to	   incubation	   suggesting	   that	   this	   pro-­‐inflammatory	   cytokine	   was	   in	   fact	   a	  
contributor	   to	   the	  neuronal	  death.	  Therefore,	   the	   reduced	  TNFα	  secretion	  measured	  
following	  co-­‐treatment	  with	  CR1	  blocking	  antibody	  may	  then	  be	  a	  tenable	  mechanism	  
for	  reduced	  neuronal	  death	  following	  CR1	  inhibition.	  However	  this	  measurement	  was	  
in	   the	   neuronal	   culture	   and	   does	   not	   reflect	   the	   microglial	   TNFα	   measurements	  
reported	  in	  chapter	  3.	  Inhibition	  of	  microglial	  TNFα	  secretion	  did	  not	  appear	  to	  reduce	  
apoptosis	   in	  the	  Aβ1-­‐42	  MGCM	  treated	  CGCs	  (Fig.	  4.8b)	  perhaps	  suggesting	  that	  TNFα	  
may	  work	  in	  concert	  with	  another	  toxic	  mediator	  to	  contribute	  to	  neuronal	  death.	  This	  
could	   be	   examined	   further	   by	   a	   more	   comprehensive	   cytokine	   array	   or	   by	   mass	  
spectrometry.	  TNFα	  was	  decreased	  in	  the	  MGCM	  added	  to	  the	  CGCs	  as	  shown	  by	  ELISA	  
(Fig.	   4.7)	   therefore	   it	   is	   unlikely	   that	   this	   increase	   was	   due	   to	   unsuccessful	   TNFα	  
inhibition.	  It	  is	  important	  to	  note	  that	  TNFα	  does	  not	  solely	  play	  a	  neurotoxic	  role.	  It’s	  
pleiotropic	   characteristic	   means	   it	   can	   also	   exert	   protective	   effects	   by	   binding	   to	  
137	  
	  
different	   TNFRs	   (Sriram	   &	   O’Callaghan	   2007).	   Microglia	   are	   have	   been	   shown	   to	  
express	  both	  TNFR1	  and	  TNFR2	  and	  it	   is	  thought	  that	  the	  patterns	  of	  these	  receptors	  
on	  microglia	   influence	  the	  outcome	  of	  TNFα	  binding	  (Dopp	  et	  al.	  1997;	  Dziewulska	  &	  
Mossakowski	  2003).	  It	  may	  be	  possible	  that	  Aβ1-­‐42	  has	  an	  effect	  on	  the	  distribution	  of	  
TNFRs	  whereby	  increasing	  the	  expression	  of	  TNFR1	  which	  could	  lead	  to	  an	  increase	  in	  
neuronal	   apoptosis	   following	   Aβ1-­‐42	  MGCM	   treatment	   (Fig.	   4.1c	  &	   4.8b)	   despite	   low	  
levels	  of	  microglial	  TNFα	  secretion	  by	  microglia	  (Fig.	  3.5a).	  Therefore	  it	  may	  have	  been	  
interesting,	   to	   carry	   out	  Western	   blot	   experiments	   to	   investigate	   TNFR1	   and	   TNFR2	  
protein	  level	  differences	  between	  treated	  cells.	  It	  is	  important	  to	  note	  that	  thalidomide	  
has	  also	  been	  thought	  to	  inhibit	  other	  cytokines	  such	  as	  IL-­‐6,	  IL-­‐12	  and	  IL-­‐10	  and	  also	  
have	   an	   stimulatory	   effect	   on	   the	  production	  of	   IL-­‐2,	   IL-­‐4	   and	   IL-­‐5	   (Singhal	  &	  Mehta	  
2002),	  therefore	  possibly	  effecting	  the	  cell	  survival	  of	  the	  neurons.	  
	  
4.4	  Conclusions	  
The	  aim	  of	  the	  research	  presented	  in	  this	  chapter	  was	  to	  investigate	  the	  effect	  of	  
CR1	  activation	  on	  neuronal	  survival	  and	  the	  results	  provide	  indications	  of	  how	  CR1	  may	  
play	   a	   role	   in	   neuronal	   cell	   death	   in	   neurodegeneration.	   Taken	   together	   with	   the	  
results	   from	   chapter	   3,	   it	   was	   interesting	   to	   find	   that	   CR1	  modulation	   of	   microglial	  
TNFα	   and	   iNOS	  may	   not	   be	   the	  main	   contributors	   to	   the	   neuronal	   death	   observed,	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5. Preliminary	  investigation	  into	  CR1	  expression	  in	  Alzheimer’s	  disease	  
post-­‐mortem	  brain	  tissue	  and	  control	  red	  blood	  cell	  CR1	  levels	  
5.1 Introduction	  and	  summary	  of	  results	  
	  
The	   studies	   performed	   in	   the	   previous	   chapters	   have	   demonstrated	   that	   CR1	  
plays	   an	   important	   role	   in	   modulating	   microglial	   activation,	   phagocytosis	   and	  
subsequent	  neuronal	  survival	   in	  vitro,	  and	  here,	  human	  post-­‐mortem	  tissue	  was	  used	  
to	  determine	  whether	  CR1	  is	  up-­‐regulated	  in	  the	  AD	  brain.	  It	  was	  hoped	  that	  this	  may	  
provide	  evidence	  that	  CR1	  may	  play	  an	  important	  role	  in	  in	  vivo	  as	  well	  as	  in	  vitro.	  The	  
Aβ	  protein	  is	  transported	  in	  both	  directions	  across	  the	  blood	  brain	  barrier	  (Deane	  et	  al.	  
2009)	  which	  thereby	  maintains	  an	  equilibrium	  between	  soluble	  Aβ	  levels	   in	  the	  brain	  
and	  blood.	  CR1	  is	  expressed	  on	  human	  red	  blood	  cells	  (Dobson	  et	  al.	  1981).	  Peripheral	  
Aβ42	   clearance	   in	   the	   blood	   has	   been	   shown	   to	   occur	   through	   a	   C3b-­‐dependent	  
adherence	  to	  CR1	  on	  red	  blood	  cells	  (RBCs)	  (Rogers	  et	  al.	  2006).	  Therefore	  individuals	  
who	  express	   low	   levels	  of	  CR1	  on	  RBCs	  might	  be	   less	  efficient	  at	   immune-­‐adherence	  
mechanisms	  of	  Aβ	  removal,	  resulting	  in	  possible	  gradual	  accumulation	  of	  Aβ	  protein	  in	  
the	  brain	  with	  aging	  and	  increased	  risk	  of	  AD.	  
To	  date	  conflicting	  reports	  exist	  as	  to	  whether	  and	  where	  CR1	  is	  expressed	  in	  the	  
brain	   (Singhrao	  et	   al.	   1999;	   Singhrao	  et	   al.	   2000;	   van	  Beek	  et	   al.	   2005),	   therefore	   in	  
order	   to	   investigate	   CR1	   expression	   in	   the	   brain,	   paraffin	   sections	   from	   different	  
regions	  of	   the	  human	  brain	  were	   immunostained.	  Aβ	  plaque	  burden,	  CR1	  expression	  
and	   cellular	   localization	   in	   frontal,	   temporal,	   hippocampal	   and	   parietal	   tissue	   of	   AD	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patients	   and	   age-­‐matched	   controls	   (AMC)	   was	   determined.	   A	   number	   of	   CR1	  
antibodies	  generated	  by	  collaborators,	  Dr	  Anne	  Nicholson-­‐Weller	  and	  Dr	  Ionita	  Ghiran,	  
targeting	   different	   epitopes,	   were	   tested	   and	   optimized	   for	   this	   use	   by	   IHC.	   Flow	  
cytometry	  to	  quantify	  the	  levels	  of	  CR1	  on	  RBCs	  isolated	  from	  fresh	  blood	  drawn	  from	  
control	   individuals	  was	  also	  carried	  out	  to	  determine	  differences	  in	  RBC	  CR1	  quantity	  
among	  individuals	  and	  to	  investigate	  any	  inverse	  correlation	  with	  circulating	  Aβ	  levels	  
in	  the	  blood.	  	  
Data	   presented	   in	   this	   chapter	   provide	   evidence	   for	   the	   presence	   of	   CR1	   in	  
human	  AD	  and	   control	   brain	   and	   indicate	  differences	   in	  CR1	   coverage	  between	   four	  
brain	  regions	  in	  areas	  with	  high	  and	  low	  plaque	  burden.	  The	  findings	  of	  this	  study	  also	  












5.2.1	  Optimization	  of	  CR1	  antibodies	  indicates	  anti-­‐CR1	  6B1	  is	  appropriate	  for	  
investigation	  into	  CR1	  expression	  in	  post-­‐mortem	  brain	  tissue	  
There	   is	   very	   little	   published	   literature	   describing	   immunoreactivity	   of	   any	  
commercially	  available	  CR1	  antibody	  in	  human	  brain	  tissue.	  Therefore	  a	  great	  deal	  of	  
optimization	   was	   required	   to	   begin	   investigation	   of	   CR1	   expression	   in	   brain	   tissue	  
through	  IHC	  using	  the	  range	  of	  antibodies	  available	  for	  this	  project.	  This	  study	  began	  
by	  determining	  the	  optimal	  concentration	  and	  IHC	  pre-­‐treatment	  procedures.	  Formalin	  
or	  other	  aldehyde	  fixation	  treatments	  form	  protein	  cross-­‐links	  that	  mask	  the	  antigenic	  
sites	   in	   the	   tissue	   which	   can	   lead	   to	   weak	   staining	   or	   even	   false	   negative	   staining.	  
There	  are	  a	  number	  of	  treatments	  that	  can	  be	  carried	  out	  to	  break	  these	  protein	  cross-­‐
links,	   thus	   unmasking	   the	   antigens	   and	   epiptopes	   in	   formalin-­‐fixed	   and	   paraffin	  
embedded	   tissue	   sections	   leading	   to	   enhanced	   staining	   intensity.	   Formic	   acid	   is	   a	  
solution	  that	  is	  capable	  of	  breaking	  these	  protein	  cross-­‐links	  and	  successfully	  works	  as	  
a	  pre-­‐treatment	  for	  IHC	  working	  especially	  well	  with	  Aβ	  antibody	  staining	  (Kitamoto	  et	  
al.	   1987).	   Heat-­‐mediated	   antigen	   retrieval	   with	   citrate	   buffer	   in	   conjunction	   with	   a	  
microwave	   treatment	   (citrate/mw)	   is	   another	  method	  of	   breaking	   the	  protein	   cross-­‐
links	  to	  enhance	  staining	  intensity	  and	  is	  suitable	  for	  most	  antibody	  applications	  (Shi	  et	  
al.	  1991).	  Immunoreactivity	  detected	  by	  6	  different	  CR1	  antibodies	  was	  investigated	  in	  
parietal	   tissue:	   anti-­‐CR1	  mAb	   543,	   anti-­‐CR1	   pAb,	   anti-­‐CR1	  mAb	   3C10,	   anti-­‐CR1	  mAb	  
IC7,	  anti-­‐CR1	  mAb	  YZ1	  and	  anti-­‐CR1	  mAb	  6B1	  (Fig.	  5.1).	  In	  this	  study,	  immunoreactivity	  
is	  only	  shown	  in	  parietal	  tissue	  with	  the	  anti-­‐CR1	  mAb	  6B1	  which	  targets	  LHR-­‐D.	  Heat-­‐
mediated	  antigen	  retrieval	  was	  considered	  the	  optimum	  pre-­‐treatment	  as	  it	  produced	  
142	  
	  
less	  damage	  to	  the	  tissue	  and	  4.6	  μg/mL	  was	  chosen	  as	  the	  optimum	  concentration	  of	  























Figure	   5.1:	   Optimization	   of	   immunohistochemistry	   in	   human	   post-­‐mortem	   brain	   tissue	   using	   anti-­‐CR1	  
antibodies	  at	  varying	  pretreatments	  and	  concentrations.	  
(a)	   anti-­‐CR1	   mAb	   543	   (stock:	   0.6mg/ml),	   (b)	   anti-­‐CR1	   pAb	   (stock:	   3mg/ml),	   (c)	   anti-­‐CR1	   mAb	   3C10	   (stock:	  
0.2mg/ml),	  (d)	  anti-­‐CR1	  mAb	  IC7	  (stock:	  0.8mg/ml),	  (e)	  anti-­‐CR1	  mAb	  YZ1	  (stock:	  3mg/ml)	  and	  (f)	  anti-­‐CR1	  mAb	  
6B1	   (stock:	  0.465mg/ml)	  were	  tested	  on	  paraffin-­‐embedded	  parietal	  cortex	   tissue	   from	  an	  84yr	  old	  male	  AD	  




Anti-­‐CR1	  mAb	  6B1	  was	  further	  investigated	  at	  a	  higher	  magnification	  using	  a	  40x	  
objective	  on	  an	  Olympus	  BX50	  microscope	  (Fig.5.2).	  The	  tissue	  was	  also	  stained	  with	  
the	   nuclear	   stain,	   hematoxylin,	   and	   it	   was	   found	   that	   CR1	   immunoreactivity	   was	  
colocalized	  to	  cells	  positively	  stained	  with	  hematoxylin.	  	  
	  
	  
Figure	  5.2:	  Immunohistochemistry	  in	  paraffin-­‐embedded	  parietal	  cortex	  tissue	  from	  84yr	  old	  
male	  AD	  patient	  using	  anti-­‐CR1	  6B1	  antibody.	  




Another	   CR1	   antibody	   that	  was	   commercially	   available	   and	   described	   to	  work	  
well	  on	  paraffin-­‐embedded	  tissue,	  anti-­‐CR1	  E11,	  was	  used	  for	  CR1	  detection	  through	  





In	  the	  periphery,	  CR1	  aids	  in	  the	  removal	  of	  complement-­‐opsonized	  particles	  by	  
their	   transfer	   to	  macrophages	   in	   the	   liver	   and	   spleen	   (Ghiran	   et	   al.	   2008b),	   and	   so	  
immunoreactivity	  of	  these	  antibodies	  was	  tested	  in	  spleen	  tissue	  as	  a	  positive	  control	  
(Fig.	  5.4).	  
Figure	   5.3:	   Immunohistochemistry	   in	   paraffin-­‐embedded	   parietal	   cortex	   tissue	   from	  81yr	  
old	  female	  AD	  patient	  using	  anti-­‐CR1	  E11	  antibody	  (5	  μg/ml)	  compared	  with	  IgG	  control.	  
Pretreatment	   for	   antigen	   retrieval	   was	   heat	   mediated	   with	   citrate	   buffer	   (citrate/MV).	  







Figure	  5.4:	  CR1	  antibody	  optimization	  on	  spleen	  tissue.	  
Immunohistochemistry	   in	   paraffin-­‐embedded,	   briefly	   fixed	   spleen	   tissue	   from	   77yr	   old	  
female	  AD	  patient	  using	  the	  range	  of	  CR1	  antibodies	  targeting	  different	  CR1	  LHR	  domains	  




The	  results	   in	  Fig.	  5.4	  were	  able	  to	  show	  that	  there	  was	   immunoreactivity	  with	  
anti-­‐CR1	  mAb-­‐	  E11	  (5	  μg/ml),	  -­‐6B1	  (4.6	  μg/ml),	  -­‐543	  (6	  μg/ml)	  and	  YZ1	  (30	  μg/ml).	  Anti-­‐
CR1	  pAb	  (50	  μg/ml)	  appeared	  to	  have	  a	  high	  background	  which	  may	  be	  due	  to	  tissue	  
quality	  and	  anti-­‐CR1	  mAb	  IC7	  (8	  μg/ml)	  did	  not	  appear	  to	  show	  any	  immunoreactivity	  
in	  the	  control	  spleen	  tissue.	  Immunofluorescence	  (IF)	  staining	  using	  the	  range	  of	  anti-­‐
CR1	   antibodies	   was	   performed	   however	   the	   experiment	   was	   unsuccessful	   after	   a	  
number	   of	   optimizations	   with	   most	   antibodies.	   Anti-­‐CR1	   mAb	   E11	   was	   the	   only	  




The	  washing	  steps	  in	  IHC	  commonly	  use	  TBS	  as	  a	  rinse	  buffer	  for	  the	  removal	  of	  
antibodies	  unbound	  and	  weakly	  bound	  to	  non-­‐specific	  sites.	  It	  is	  also	  used	  as	  a	  buffer	  
for	   antibody	   incubation.	   	   The	   addition	   of	   the	   detergent	   Tween	   20	   to	   TBS	   (TBS-­‐T)	   is	  
capable	   of	   aiding	   in	  more	   effective	   rinsing	   and	   assisting	   in	   uniform	   spreading	   of	   the	  
antibody.	  Therefore	  IHC	  was	  also	  carried	  out	  replacing	  TBS	  with	  TBS-­‐T	  in	  the	  washing	  
and	  incubation	  steps	  and	  probing	  with	  the	  range	  of	  anti-­‐CR1	  543,	  3C10,	  YZ1,	  pAb	  and	  
Figure	   5.5:	   CR1	   immunofluorescence	  
on	  spleen	  tissue.	  
Immunofluorescence	   of	   paraffin-­‐
embedded,	   briefly	   fixed	   spleen	   tissue	  
from	  77yr	  old	  female	  AD	  patient	  using	  
(a,b)	  anti-­‐CR1	  mAb	  E11	  (5	  μg/ml)	  (red)	  
and	   (c)	   control	   IgG	   (5	   μg/ml).	  




IC7.	  The	  results	  from	  this	  proved	  unsuccessful	  as	  there	  no	  immunoreactivity	  observed	  
(data	  not	  shown).	  	  
Tissue	   fixation	   chemically	   cross-­‐links	  proteins	  and	   can	   reduce	  protein	   solubility	  
which	   can	   mask	   target	   antigens	   thus	   hindering	   IHC	   immunoreactivity	   (Otali	   et	   al.	  
2009).	   To	   test	   if	   the	   2	   h	   formalin	   fixation	   of	   the	   post-­‐mortem	   brain	   tissue	   was	  
responsible	   for	   the	  absence	  of	   immunoreactivity	  of	  a	  number	  of	   the	  CR1	  antibodies,	  
RBCs	  were	  fixed	  with	  10%	  formalin	  and	  the	  sensitivity	  of	  the	  anti-­‐CR1	  antibodies	  was	  
measured	  by	  flow	  cytometry.	  	  
Flow	  cytometry	  works	  on	  the	  basis	  of	  the	  movement	  of	  cells	  in	  suspension	  past	  a	  
detector,	  which	  for	  the	  measurement	  of	  fluorescence	  requires	  fluorescence	  markers	  to	  
be	  used.	   The	  prepared	   sample	   in	   suspension	   is	   taken	  up	   from	  a	   round	  bottom	  FACS	  
tube	  under	  pressure	  and	  transported	  to	  the	  flow	  cell,	  where	  the	  sample	  combines	  with	  
a	   faster	   flowing	   sheath	   fluid	   which	   transports	   the	   sample	   to	   a	   light	   source	   for	  
excitation,	  where	  fluorescence	   is	  captured	  and	  detected	  by	  photodetectors.	  The	  flow	  
cytometer	  is	  able	  to	  count	  single	  cell	  events	  by	  passing	  the	  cell	  suspension	  through	  a	  
narrow	  tube	  at	  high	  pressure,	  which	   forces	   the	  cell	   suspension	   to	  pass	   the	   laser	  and	  
detector	  in	  a	  stream	  of	  particles.	  To	  count	  the	  events,	  the	  flow	  cytometer	  relied	  in	  this	  
experiment	  on	  the	  ability	  of	  cells	  to	  emit	  light	  when	  tagged	  with	  a	  fluorescent	  probe.	  
Flow	  cytometry	  was	  used	  to	  fluorescently	  measure	  CR1	  on	  both	  fixed	  and	  fresh	  RBCs	  
to	   determine	   whether	   the	   fixation	   method	   affected	   the	   immunoreactivity	   with	   the	  
range	  of	  CR1	  antibodies	  (Fig.	  5.6).	  The	  flow	  cytometry	  data	  demonstrated	  that	  anti-­‐CR1	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3C10	  and	  anti-­‐CR1	  pAb	  were	  both	  fixation	  sensitive	  (Fig.	  5.6f	  and	  5.6h)	  as	  measured	  by	  
mean	   fluorescence	   comparable	   to	   IgG	   isotype	   control.	   The	   remaining	   antibodies	   did	  












Figure	  5.6:	  Flow	  cytometry	  analysis	  of	  fixed	  and	  fresh	  red	  blood	  cells	  using	  CR1	  antibodies.	  
RBCs	   were	   fixed	   in	   10%	   formalin	   for	   2	   h	   prior	   to	   analysis.	   The	   histograms	   show	   a	   shift	   in	  
fluorescence	   compared	   to	   IgG	   isotype	   control	  with	   (c)	   anti-­‐CR1	  mAb	  543,	   (d)	   anti-­‐CR1	  mAb	  
YZ1,	   (e)	   anti-­‐CR1	   mAb	   E11,	   (g)	   anti-­‐CR1	   6B1	   and	   (i)	   anti-­‐CR1	   mAb	   IC7,	   which	   is	   also	  
represented	   on	   the	   corresponding	   graphs.	   (f)	   anti-­‐CR1	   pAb	   and	   (h)	   anti-­‐CR1	   mAb	   3C10	  




5.2.2	  Higher	  CR1	  expression	  is	  regionally	  present	  in	  low	  Aβ	  plaque	  areas	  of	  AD	  tissue,	  
however	  increased	  CR1	  presence	  overall	  is	  higher	  compared	  to	  low	  plaque	  areas	  
	  
Following	   the	   optimization	   experiments,	   it	   was	   decided	   that	   the	   anti-­‐CR1	   6B1	  
antibody	   should	   be	   used	   for	   all	   further	   experiments.	   As	   such,	   CR1	   immunoreactivity	  
using	  6B1	  antibody	  was	  measured	   in	  areas	  of	  high	  and	   low	  Aβ	  plaque	  density	  within	  
four	  regions	  of	  human	  AD	  and	  control	  brains	  (Fig.	  5.7).	  The	  age-­‐matched	  control	  (AMC)	  
tissue	  were	  from	  donors	  who	  were	  not	  reported	  to	  have	  dementia,	  and	  were	  of	  similar	  
age	  to	  the	  AD	  tissue	  donors	  at	  time	  of	  death.	  Aβ	  deposition	  was	  measured	  using	  R1282	  
antibody	  at	  dilution	  1:1000.	  R1282	   is	   a	   general	  Aβ	   rabbit	  polyclonal	   antibody,	   (a	   gift	  
from	   Dr.	   Dennis	   Selkoe,	   Center	   for	   Neurologic	   Diseases,	   Boston,	   MA),	   was	   raised	  
against	  synthetic	  Aβ1-­‐40	  peptide	  and	  recognizes	  multiple	  epitopes	  and	  conformations.	  
Figure	   5.7a(iii-­‐vi)	   and	   5.7b	   showing	   this	   investigation	   in	   the	   parietal	   cortex	  
demonstrated	   that	   in	   areas	   of	   high	   plaque	   load	   there	   was	   similar	   level	   of	   CR1	  
immunoreactivity.	  In	  areas	  with	  low	  volume	  of	  Aβ	  plaques,	  there	  was	  a	  comparatively	  
higher	  ratio	  of	  CR1	  present	  (Fig.	  5.7c),	  however	  this	  still	  remained	  lower	  than	  the	  CR1	  
present	  in	  higher	  plaque	  areas.	  When	  this	  was	  investigated	  in	  the	  frontal	  cortex	  it	  was	  
found	   that	   there	  was	  a	   trend	   towards	   lower	  CR1	  present	   in	  areas	  of	  high	  Aβ	  plaque	  
load	  (Fig.	  5.7d(iii-­‐vi)	  and	  5.7e),	  which	  appeared	  to	  show	  an	  opposite	  trend	  in	  areas	  of	  
low	  plaque	   load	   (Fig.	   5.7c).	  Again,	   this	  percentage	  of	  CR1	   in	   low	  plaque	  areas	   is	   still	  
lower	  compared	  to	  that	  present	  in	  high	  plaque	  density.	  The	  Aβ	  plaque	  and	  CR1	  ratio	  in	  
the	   hippocampus	   was	   similar	   to	   that	   observed	   in	   the	   parietal	   cortex	   with	   similar	  
immunoreactivity	  of	  Aβ	  plaques	  and	  CR1	  in	  areas	  of	  high	  plaque	  density	  (Fig.	  5.7g(iii-­‐vi)	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and	  5.7h).	  Also,	  although	  lower	  than	  measured	  in	  high	  density	  plaque	  areas,	  there	  was	  
a	   trend	   towards	   an	   increase	   in	   higher	   CR1	   in	   low	  Aβ	   plaque	   areas	   (Fig.5.7i).	   Finally,	  
data	   from	   the	   temporal	   cortex	   demonstrate	   a	   similar	   trend	   observed	   in	   the	   frontal	  
cortex	   AD	   tissue	   (Fig.	   5.7d	   and	   5.7e	   and	   5.7f).	   A	   lower	   density	   of	   Aβ	   plaques	   was	  
measured	   in	   AMC	   compared	   to	   the	   corresponding	   areas	   in	   the	   AD	   brain.	  
Representative	   images	  of	   these	  areas	  corresponding	   to	  high	  plaque	   load	   fields	   in	  AD	  














Figure	  5.7:	  Immunohistochemical	  analysis	  of	  parietal,	  fronal,	  hippocampal	  and	  temporal	  cortex	  tissue	  
in	  AD	  and	  aged-­‐matched	  control	  (AMC)	  brains	  probing	  for	  Aβ	  plaques	  and	  CR1	  immunoreactivity.	  
The	  representative	  images	  show	  R1282	  (Aβ)	  and	  6B1	  (CR1)	  immunoreactivity	  in	  (i)	  and	  (ii)	  AMC,	  (iii)	  and	  
(iv)	  area	  of	  high	  plaque	  load,	  (v)	  and	  (vi)	  same	  area	  of	  high	  plaque	  load	  at	  higher	  magnification	  and	  (vii)	  
and	  (viii)	  probing	  with	  IgG	  isotype	  controls.	  Experiment	  carried	  out	  in	  3	  AD	  and	  AMC	  brains.	  Scale	  bar	  




When	  percentage	  CR1	  coverage	  was	  compared	  between	  the	  regions	  of	  the	  AD	  brain,	  a	  
trend	  was	  observed	  for	  higher	  CR1	   immunoreactivity	  with	  higher	  plaque	   load	   (Fig.	  5.8b).	  This	  
trend	   is	   not	   observed	   when	   the	   same	   regions	   are	   compared	   in	   the	   AMC	   brain	   (Fig.	   5.8a).	  
Parietal,	   frontal,	   cortex	   and	   hippocampal	   tissue	   from	   AD	   brain	   showed	   a	   trend	   towards	   a	  
reduction	   in	   CR1	   coverage	   in	   low	   Aβ	   plaque	   areas	   compared	   with	   AMC	   brains	   with	   CR1	  
coverage	  in	  hippocampal	  tissue	  demonstrating	  a	  similar	  trend	  in	  the	  high	  Aβ	  volume	  area	  also.	  
However	  the	  opposite	  was	  observed	  in	  the	  temporal	  cortex,	  which	  showed	  a	  trend	  towards	  a	  






Figure	  5.8:	  Comparison	  of	  CR1	  coverage	  in	  regions	  of	  AD	  and	  AMC	  brain	  from	  Fig.	  5.7.	  
CR1	   was	   measured	   using	   anti-­‐CR1	   mAb	   6B1	   (4.65	   μg/mL)	   and	   Aβ	   deposition	   was	   measured	   using	  
general	  Aβ	  antibody	  R1282	  (dilution	  1:1000).	  (a)	  Graph	  comparing	  percentage	  of	  CR1	  coverage	  in	  four	  
regions	   of	   the	   AMC	   brain	   in	   both	   high	   and	   low	   plaque	   areas.	   (b)	   Graph	   comparing	   CR1	   percentage	  




5.2.3	  Quantification	  of	  CR1	  on	  RBCs	  and	  comparison	  to	  circulating	  Aβ	  levels	  
The	  presence	  of	  CR1	  on	  RBCs	  in	  blood	  vessels	  in	  paraffin-­‐embedded	  brain	  tissue	  
was	   investigated	   using	   a	   range	   of	   CR1	   antibodies:	   anti-­‐CR1	  mAb	   543,	   anti-­‐CR1	   pAb,	  
anti-­‐CR1	  mAb	  3C10,	  anti-­‐CR1	  mAb	  IC7,	  anti-­‐CR1	  mAb	  YZ1	  and	  anti-­‐CR1	  mAb	  6B1	  (Fig.	  
5.9).	  CR1	  staining	  (DAB)	  was	  not	  found	  on	  the	  RBCs	   in	  this	  tissue	  (Fig.	  5.9b)	  however	  
CR1	  staining	  (DAB)	  was	  observed	  in	  blood	  smears	  that	  were	  fixed	  in	  10%	  formalin	  for	  2	  




Figure	  5.9:	  CR1	  staining	  (DAB)	  of	  RBC	  from	  blood	  smears	  and	  brain	  tissue.	  
(a)	  CR1	  is	  seen	  as	  black	  dots	  were	  visible	  on	  RBC	  ghosts	  as	  indicated	  by	  the	  arrow	  by	  
anti-­‐CR1	  mAb	  543.	  (b)	  CR1	  was	  not	  observed	  on	  the	  RBCs	  in	  the	  parraffin-­‐embedded	  




Levels	  of	  CR1	  present	  on	  RBCs	  can	  vary	  between	  individuals	  and	  this	  may	  lead	  to	  
differences	   in	   Aβ	   clearance.	   Therefore	   flow	   cytometry	   was	   used	   to	   measure	   these	  
circulating	   levels	   of	   CR1	   and	   Aβ	   in	   control	   blood	   samples	   to	   investigate	   any	   inverse	  









The	  gating	  analysis	   shows	  clearly	   that	   the	   four	  donors	  express	  CR1	  at	  different	  
levels,	  as	  measured	  by	  anti-­‐CR1	  YZ1	  antibody:	  high,	  medium	  and	  low	  (Fig.	  5.10a).	  There	  
was	  no	  obvious	   correlation	  with	  Aβ	   levels	  observed	  which	  was	  measured	  by	   two	  Aβ	  
antibodies,	   R1282	   and	   3A1.	   	   This	   data	   is	   also	   presented	   by	   mean	   fluorescence	   on	  
histograms,	   which	   can	   also	   clearly	   see	   the	   differences	   of	   CR1	   expression	   between	  
individuals	  (Fig.	  5.10b-­‐e).	  Fig.	  5.9a	  demonstrates	  a	  high	  level	  of	  mean	  fluorescence	  of	  
YZ1	   compared	   to	   that	  of	   the	  donor	  measurements	   recorded	   in	   Fig.	   5.10b	  and	  5.10c.	  
This	  high	  CR1	  level	  did	  not	  appear	  to	  have	  an	  impact	  on	  the	  Aβ	  levels	  as	  measured	  by	  
Figure	  5.10:	  Flow	  Cytometry	  analysis	  of	  four	  blood	  donors	  measuring	  CR1	  and	  Aβ	  expression.	  
(a)	  Gating	  analysis	  demonstrating	  CR1	   levels	  measured	  by	   fluorescence	  of	   YZ1	   (1	  μg/mL)	   and	  Aβ	  
levels	   measured	   by	   fluorescence	   of	   R1282	   (1	   μg/mL)	   and	   3A1	   (1	   μg/mL).	   Fluorescence	  
measurement	  of	  IgG	  isotype	  controls	  mouse	  IgG	  (1	  μg/mL)	  and	  rabbit	  (1	  μg/mL)	  and	  RBC	  alone	  also	  
carried	  out.	   (b)	  Histogram	  depicting	   the	  mean	   fluorescence	   from	   the	  CR1	  high	   donor	   in	   the	   first	  
column	   in	   (a),	   (c)	   showing	  all	   the	  mean	   fluorescence	  of	   the	  CR1	  medium	  donor	   from	   the	   second	  
column	  in	  (a),	  (d)	  showing	  the	  mean	  fluorescence	  of	  the	  CR1	  low	  donor	  from	  the	  third	  column	  in	  (a)	  
and	   (e)	   showing	   the	   mean	   fluorescence	   of	   the	   CR1	   high	   donor	   from	   the	   fourth	   column	   in	   (a).	  




R1282	  and	  3A1.	  Fig.	  5.10c	  and	  Fig.	  5.10d	  show	   individuals	  who	  would	  be	  considered	  
medium	  and	  low	  expressors	  of	  CR1	  respectively	  and	  both	  these	  donors	  did	  not	  show	  
any	   correlation	   between	   the	   CR1	   and	   Aβ	   levels	   also.	   Fig.	   5.10e	   shows	   an	   additional	  
individual	   that	  would	   be	   considered	   a	   high	   CR1	   expressor	  with	   no	   differences	   in	   Aβ	  
levels	  either.	  
It	  was	  possible	  to	  visualise	  the	  increased	  presence	  of	  CR1	  on	  RBCs	  by	  IF	  on	  fresh	  
blood	  smears	  using	  a	  number	  of	  CR1	  antibodies.	  This	  study	  investigated	  CR1	  using	  E11	  
(5	   μg/mL),	   543	   (1	   μg/mL)	   and	   6B1	   (1	   μg/mL)	   along	  with	   control	  mIgG	   (5	   μg/mL)	   on	  
blood	   smears	   from	   individuals	   already	   shown	   to	   be	   high	   and	   low	   expressors	   of	   CR1	  
through	  flow	  cytometry.	  All	  three	  CR1	  antibodies	  were	  able	  to	  show	  CR1	  presence	  on	  
RBCs	  through	  IF.	  Figure	  5.11	  shows	  representative	  images	  of	  RBC	  CR1	  IF	  using	  anti-­‐CR1	  
E11.	   The	   graph	   shows	   the	   average	   volume	  of	   CR1	   ‘dots’	   per	   donor.	   The	   experiment	  
was	  carried	  out	  by	  measuring	  CR1	  on	  a	  set	  number	  of	  RBCs	  from	  9	  fields	  of	  view	  from	  3	  
cover-­‐slipped	   blood	   smears.	   The	   results	   were	   in	   line	   with	   the	   flow	   cytometry	   data	  











Figure	   5.11:	   Immunofluorescence	   of	   RBCs	   with	   anti-­‐CR1	   mAb	   E11	   shows	   a	   difference	   in	   CR1	  
volume	  between	  control	  blood	  donors.	  
Representative	  images	  following	  probing	  with	  E11	  (5μg/mL)	  and	  mAb	  IgG	  isotype	  control	  (5	  μg/mL).	  
Graph	  shows	  average	  volume	  of	  RBC	  CR1	  ‘dots’	  per	  donor.	  Experiment	  measured	  on	  a	  set	  number	  
of	  RBCs	  from	  9	  fields	  per	  coverslip	  and	  3	  coverslips	  per	  donor.	  Data	  were	  analysed	  by	  Student's	  t-­‐





The	   association	   of	   complement	   fragments	   with	   AD	   lesions	   was	   first	   reported	  
over	  3	  decades	  ago	  (Eikelenboom	  &	  F.	  C.	  Stam	  1982;	  Ishii	  &	  Haga	  1984).	  This	  has	  been	  
further	  strengthened	  over	   the	  years	  with	   the	  development	  of	  monoclonal	  antibodies	  
for	  the	  specific	  detection	  of	  complement,	  and	  complement	  component	  knock-­‐out	  mice	  
to	   validate	   these	   (Yasojima	   et	   al.	   1999;	   Afagh	   et	   al.	   1996;	   Fonseca	   et	   al.	   2004).	   The	  
recent	  reports	  of	  CR1	  polymorphisms	  being	  associated	  with	  AD,	  suggest	  new	  roles	  for	  
complement	   (Lambert	   et	   al.	   2009;	   Hazrati	   et	   al.	   2012),	   which	   may	   provide	   a	   novel	  
approach	  in	  augmenting	  Aβ	  clearance.	  Although	  there	  is	  escalating	  evidence	  of	  blood-­‐
brain	  barrier	  disruption	  in	  AD	  (Bowman	  &	  Quinn	  2008)	  this	  is	  not	  observed	  in	  all	  cases	  
and	  there	  is	  also	  evidence	  of	  complement	  gene	  expression	  in	  the	  AD	  brain	  (Shen,	  Li,	  et	  
al.	   1997;	   Walker	   et	   al.	   1995).	   As	   previously	   mentioned	   a	   number	   of	   complement	  
components	   have	   been	   identified	   in	   the	   AD	   brain	   however	   there	   have	   been	   few	  
reports	   of	   the	   presence	   of	   CR1	   in	   the	   AD	   brain.	   This	   does	   not	   necessarily	  mean	   an	  
absence	  of	  CR1	  in	  the	  brain,	  as	   it	  may	  be	  due	  to	   lack	  of	  specific	  reagents	  used	  in	  the	  
investigation,	  such	  as	  high	  affinity	  antibodies	  that	  are	  highly	  specific	  for	  different	  LHR	  
domains	   of	   CR1	   or	   possibly	   due	   to	   tissue	   preservation	   and	   staining	   methods.	   	   The	  
present	  study	  used	  a	  range	  of	  highly	  specific	  CR1	  antibodies	  that	  target	  LHR-­‐A,	  -­‐B,	   -­‐C	  
and	  –D	  to	  investigate	  the	  presence	  of	  CR1	  in	  the	  human	  AD	  brain.	  Formalin	  fixation	  is	  
one	  of	   the	  most	  widely	  used	   fixation	  methods	  used	   in	  histology	   and	  although	   it	   can	  
provide	  excellent	  preservation	  of	  tissue	  and	  cellular	  morphology	  it	  has	  been	  implicated	  
in	   the	  masking	  or	  even	   loss	  of	  epitopes	   in	   immunohistochemistry.	   Fixation	  with	  10%	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formalin	  can	  reduce	  immunohistochemical	  activity	  through	  a	  number	  of	  ways,	  such	  as	  
blocking	  access	  of	  antibodies	  to	  the	  epitopes	  by	  protein	  cross-­‐linking,	  directly	  binding	  
to	   the	   epitope	   and	   modifying	   it	   or	   causing	   a	   change	   in	   the	   conformation	   of	   the	  
proteins	  (Dapson	  2007;	  Bogen	  et	  al.	  2009;	  O’Leary	  et	  al.	  2009).	  The	  additional	  steps	  in	  
tissue	   processing;	   dehydration	   in	   alcohols,	   establishing	   a	   hydrophobic	   environment	  
such	   as	   infiltration	  with	   xylene	   and	   the	   embedding	   of	   the	   tissue	   in	   the	   hydrophobic	  
environment,	   paraffin,	   may	   also	   contribute	   to	   altering	   of	   epitopes	   (Dapson	   2007).	  
Performing	  the	  optimum	  antigen	  retrieval	  method	  is	  important	  for	  the	  re-­‐exposure	  of	  
the	   epitope,	   which	   ultimately	   restores	   immunoreactivity.	   Heat-­‐mediated	   antigen	  
retrieval	   is	   able	   to	   reverse	   the	   formaldehyde-­‐protein	   adduct	   formation	   through	  
reducing	   the	   number	   of	   ribonuclease	   A	   molecules	   participating	   in	   the	   cross-­‐linking	  
(O’Leary	  et	  al.	  2009),	  giving	  rise	  to	  increased	  immunoreactivity.	  The	  protein	  denaturing	  
agent	   formic	   acid	   also	   functions	   to	   successfully	   retrieve	   antigens	   and	   improve	  
immunoreactivity	  (Shi	  et	  al.	  1991).	  Both	  these	  retrieval	  methods	  were	  performed	  with	  
the	  paraffin-­‐embedded	  tissue	  to	  determine	  an	  optimum	  antigen	  retrieval	  method	  for	  
CR1	   immunoreactivity.	   Immunoreactivity	  was	  only	  observed	  with	   anti-­‐CR1	  mAb	  6B1.	  
This	  was	  observed	  through	  both	  methods	  of	  retrieval	  but	  heat-­‐mediated	  pretreatment	  
by	   citrate/mw	   was	   chosen	   as	   the	   optimum	   method.	   The	   lack	   of	   immunoreactivity	  
demonstrated	  by	  the	  other	  CR1	  antibodies	  cannot	  be	  solely	  attributed	  to	   inadequate	  
antigen	   retrieval.	   The	   CR1	   antibodies	   used	   in	   this	   study	   target	   a	   variety	   of	   epitopes	  
however	  6B1	  was	  the	  only	  antibody	  to	  solely	  target	  LHR-­‐D.	  LHR-­‐D	  has	  been	  suggested	  
as	  the	  functional	  domain	  in	  the	  CR1	  protein	  with	  a	  coding	  variant	  in	  the	  LHR	  region	  of	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the	   CR1	   gene.	   This	   variant	   is	   able	   to	   alter	   the	   conformation	   of	   CR1	   (threonine	   for	  
serine	   substitution)	   influencing	   a	   decline	   of	   episodic	   memory,	   however	   this	   was	  
evaluated	  to	  be	  mediated	  by	  an	   increase	   in	  AD	  neuropathology	  (Keenan	  et	  al.	  2012).	  
Haematoxylin	   staining	  was	   positive	   for	   nuclei	   near	   CR1	   immunoreactivity	   suggesting	  
that	   CR1	   has	   cellular	   presence	   in	   the	   brain	   (Fig.	   5.2).	   Further	   investigation	   into	   the	  
tissue	  quality	  as	  a	  cause	  for	  the	  absence	  of	  immunoreactivity	  with	  the	  other	  CR1	  anti-­‐
bodies	   was	   investigated	   in	   serial	   sections	   of	   spleen	   tissue	   from	   an	   AD	   patient	   also	  
briefly	  fixed	  for	  2	  h,	  and	  the	  presence	  of	  immunoreactivity	  with	  anti-­‐CR1;	  E11,	  6B1,	  543	  
and	  YZ1	  suggested	  that	  it	  was	  not	  the	  tissue	  quality	  that	  was	  interfering	  with	  obtaining	  
a	  positive	  result	  in	  Fig.	  5.1.	  Flow	  cytometry	  analysis	  comparing	  fresh	  and	  2	  h	  formalin	  
fixed	  RBCs	  probed	  even	  further	  into	  determining	  whether	  the	  lack	  of	  immunoreactivity	  
with	  some	  antibodies	  was	  due	  to	  fixation.	  The	  outcome	  from	  this	  experiment	  indicates	  
that	   C310	   and	   pAb	   are	   fixation	   sensitive,	   which	   together	   with	   IHC	   data	   from	   the	  
spleen,	  the	  positive	  control,	   leaves	  the	  question	  open	  as	  to	  why	  YZ1,	  E11	  and	  543	  do	  
not	   show	   any	   immunoreactivity.	   All	   antibodies	   failed	   to	   produce	   IF	   in	   human	   brain	  
tissue	   sections	   and	   all	   antibodies	   except	   E11	   (Fig.	   5.5)	  were	   unable	   to	   produce	   IF	   in	  
control	   spleen	   sections	   therefore	   it	   was	   not	   possible	   to	   perform	   double	   immune	  
labelling	   to	   determine	   the	   cellular	   presence	   in	   the	   tissue	   (see	   Fig.	   5.2).	   If	   time	  
permitted	  additional	  analysis	   into	  the	  cell	   type	  could	  have	  been	  carried	  out.	  This	  will	  
be	  discussed	  further	  in	  chapter	  6.	  
The	  Aβ	  peptide	  is	  able	  to	  activate	  two	  pathways	  of	  the	  complement	  system,	  the	  
classical	  pathway	  through	  binding	  to	  C1q	  (Jiang	  et	  al.	  1994;	  Velazquez	  et	  al.	  1997)	  and	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the	  alternative	  pathway	  by	  binding	  to	  C3	  (Bradt	  et	  al.	  1998)	  and	  as	  a	  result	   initiating	  
mediators	  of	  inflammation	  and	  the	  MAC	  complex.	  These	  pathways	  would	  result	  in	  an	  
increased	  production	  of	  C3b,	  which	  is	  required	  for	  the	  cleavage	  of	  C5	  into	  C5a	  and	  one	  
of	   the	   components	   of	   the	   MAC	   complex,	   C5b.	   An	   increase	   in	   C3b	   would	   result	   in	  
increased	  binding	  of	  the	  complement	  regulatory	  protein,	  CR1,	  of	  which	  may	  be	  present	  
on	   the	   cell	   surface	  of	  microglia,	  which	   are	   known	   to	   accumulate	   around	  Aβ	  plaques	  
(Fetler	  &	  Amigorena	  2005).	  This	  would	  be	  in	   line	  with	  findings	  from	  this	  study	  where	  
there	  was	  a	  high	  volume	  of	  6B1	  immunoreactivity	  in	  areas	  of	  high	  plaque	  volume	  in	  AD	  
tissue	   (Fig	   5.7b).	   CR1	   measurement	   from	   a	   similar	   Aβ	   plaque	   deposition	   regions	   in	  
AMC’s	   were	   also	   measured	   (Fig.	   5.7a)	   and	   demonstrated	   little	   difference	   in	   CR1	  
coverage	  between	   low	  and	  high	  Aβ	  plaque	  burdened	  areas.	  As	  previously	  mentioned	  
the	  binding	   to	  CR1	   to	  C3b,	  which	   increased	   through	  complement	  pathway	  activation	  
by	  Aβ,	  will	  generate	  iC3b	  therefore	  stimulating	  phagocytosis.	  Although	  this	  pathway	  is	  
possibly	   more	   stimulated	   in	   the	   AD	   brain	   due	   to	   an	   increased	   plaque	   load,	   the	  
beneficial	   phagocytosis	   role	   may	   be	   disrupted	   in	   the	   AD	   brain	   owing	   to	   less	   CR1	  
present.	   It	  may	   be	   hypothesized	   that	   individuals	   with	   AD-­‐associated	   polymorphisms	  
have	  low	  CR1	  expression	  and	  as	  such,	  have	  less	  efficient	  clearance	  of	  Aβ	  protein.	  	  
The	   number	   of	   CR1	   molecules	   per	   RBC	   is	   genetically	   determined	   which	   is	  
typically	  characterised	  by	  100	  CR1	  per	  RBC	  for	  low	  CR1	  expressors,	  500	  CR1	  per	  RBC	  for	  
medium	  CR1	  expressors	  and	  1000	  CR1	  per	  RBC	  for	  high	  expressors	  (Wilson	  et	  al.	  1986).	  
Similarly	   as	   in	  human	   tissue	   it	  may	  be	   considered	   that	   individuals	  possessing	  an	  AD-­‐
associated	  polymorphism	  could	  result	   in	  having	  a	   reduced	  ability	   to	  adequately	  clear	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Aβ	   protein	   in	   the	   blood	   due	   to	   having	   low	   CR1	   expression	   on	   RBCs.	   This	   reduced	  
clearance	  throughout	   life	  could	  result	   in	   the	  gradual	  accumulation	  of	  Aβ	   in	   the	  brain	  
with	  aging	  and	  increased	  risk	  of	  AD.	  The	  physiological	  role	  of	  Aβ	  is	  not	  fully	  understood	  
but	  studies	  identifying	  it	  as	  a	  modulator	  of	  K+	  currents	  in	  central	  neurons	  (Plant	  et	  al.	  
2006)	  and	  its	  presence	  in	  CSF	  of	  non-­‐demented	  individuals	  (Tamaoka	  et	  al.	  1997)	  and	  
media	   from	  neuronal	   cell	   cultures	   (Haass	  et	  al.	  1992)	  point	   to	  Aβ	  having	  a	   toxic	   role	  
when	   its	   production	   and	   degradation	   are	   imbalanced.	   In	   vitro	   and	   in	   vivo	   animal	  
studies	   have	   demonstrated	   that	   Aβ	   is	   capable	   of	   binding	   to	   RBCs	   (Nakagawa	   et	   al.	  
2011)	  and	  so	  levels	  of	  both	  this	  peptide	  and	  CR1	  on	  RBCs	  were	  measured.	  Investigation	  
into	  levels	  of	  CR1	  on	  RBCs	  from	  different	  donors	  was	  able	  to	  demonstrate	  a	  difference	  
in	   CR1	   expression	   between	   these	   individuals	   however	   these	   differences	   did	   not	  
correlate	  with	  Aβ	   levels	   in	  the	  RBCs	  (Fig.	  5.10a-­‐e).	  Upon	  evaluation	  of	  this	  result	   it	   is	  
important	   to	   point	   out	   that	   the	   age	  of	   the	  donor	   individuals	   in	   this	   experiment	  was	  
24.25±4	  yrs.	  A	  study	  measuring	  a	  correlation	  between	  RBC	  and	  plasma	  Aβ40	  and	  Aβ42	  
found	   that	   levels	  were	   low	  on	  RBCs	   in	  healthy	   young	   volunteers,	   aged	  24.2±6	  but	   it	  
tended	  to	  increase	  with	  age	  as	  seen	  in	  healthy	  older	  volunteers,	  aged	  56.2±0.9	  (Kiko	  et	  
al.	  2012).	  This	  increase	  over	  time	  may	  be	  due	  to	  a	  reduced	  Aβ	  clearance	  or	  increased	  
Aβ	   production	   as	   previously	   suggested	   as	   a	   possible	   mechanism	   in	   AD.	   It	   could	   be	  
potentially	   due	   to	   changes	   in	   enzymes	   that	   are	   associated	   with	   aging	   such	   as	   Aβ	  
secretase	  enzymes	  (Nistor	  et	  al.	  2007)	  or	  Aβ	  catabolic	  enzymes	  (Apelt	  et	  al.	  2003).	   It	  
would	   have	   possibly	   been	   more	   informative	   to	   have	   also	   investigated	   an	   inverse	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correlation	  between	  CR1	  and	  Aβ	   levels	   in	  older	  healthy	  donors	  and	  this	  could	  be	  put	  
forward	  as	  a	  possible	  future	  experiment.	  
The	   number	   of	   CR1	  molecules	   per	   RBC	   has	   been	   shown	   to	   have	   a	   significant	  
functional	   impact	   including	   calcium	   (Ca++)	   influx.	  Analysis	  of	  RBC	  Ca++	   influx	  with	   the	  
use	  of	   the	   fluorescent	  Ca++	   indicator,	  Fluo-­‐4	  AM,	   found	  that	  antibody	   ligation	  of	  RBC	  
CR1	   triggered	  a	  sustained	  Ca++	   influx	  which	  was	  observed	   to	  be	  more	  pronounced	   in	  
high	   CR1	   donors	   compared	   with	   low	   RBC	   CR1	   expressors	   as	   measured	   by	   flow	  
cytometry	   (Glodek	   et	   al.	   2010).	   This	   high	   Ca++	   influx	   was	   also	   found	   to	   promote	  
phosphorylation	  of	   cytoskeletal	   proteins,	   α-­‐adducin	   and	  β-­‐spectrin,	  which	   correlated	  
with	  increased	  RBC	  membrane	  deformability,	  which	  is	  important	  for	  oxygen	  transport.	  
RBC	  morphology	  has	  been	  found	  to	  be	  more	  elongated	  in	  blood	  from	  individuals	  with	  
AD	   compared	   to	   controls	   which	   typically	   results	   in	   RBCs	   being	   less	   deformable	  
(Mohanty	   et	   al.	   2008).	   Binding	   of	   Aβ40	   and	   Aβ42	   fibrils	   to	   RBCs	   results	   in	   decreased	  
deformability	   (Jayakumar	  et	  al.	  2003)	   suggesting	   that	   the	   increased	  availability	  of	  Aβ	  
peptides	   in	   AD	   individuals	   lead	   to	   increased	   binding	   to	   RBC	   and	   as	   such	   decreased	  
deformability	   and	   passage	   through	   the	   microvasculature.	   The	   decreased	   RBC	  
membrane	  deformability	  correlating	  with	  the	  low	  Ca++	   influx	  associated	  with	  low	  RBC	  
CR1	   expressors	   may	   prove	   detrimental	   in	   the	   presence	   of	   an	   increase	   in	   Aβ	   in	   the	  
blood.	   Not	   only	   in	   terms	   of	   possible	   reduced	   clearance	   of	   Aβ	   through	   less	   CR1	  





The	  data	  presented	  here	  provide	  evidence	  for	  the	  presence	  of	  CR1	  in	  the	  human	  
brain.	  There	  has	  been	  conflicting	  data	  published	  as	  to	  whether	  CR1	  is	  expressed	  in	  the	  
brain	  however	  its	  expression	  has	  been	  observed	  in	  this	  study	  in	  four	  different	  regions	  
of	   the	   brain,	   through	   the	   use	   of	   a	   highly	   specific	   antibody	   targeting	   LHR-­‐D	   on	   CR1.	  
Extensive	   optimisation	   of	   the	   range	   of	   CR1	   antibodies	   available	   for	   this	   study	   was	  
carried	  out	  and	  a	  summary	  of	  the	  outcome	  of	  the	  use	  of	  these	  in	  paraffin-­‐embedded	  
tissue	  and	  blood	  is	  demonstrated	  in	  Table.	  5.1.	  










6B1  IgG1  LHR-­‐D  +  +  +  +  




 Multiple  -­‐  -­‐  -­‐  +  
YZ1  IgG1  SCR	  5,	  6,	  7	  
of	  LHR-­‐A,	  
B,	  C  
-­‐  +  +  +  
IC7  IgG1   -­‐  +  +  +  
3C10  IgG1   -­‐  n.d  -­‐  -­‐  
E11  IgG1  LHR-­‐C,	  D  -­‐  +  +  +  
Table.	  5.1.	  CR1	  antibody	  reactivity	  in	  tissue	  and	  blood.	  *n.d	  =	  not	  done	  	  
This	   study	  was	  able	   to	   identify	  a	   trend	   for	  higher	  CR1	  coverage	   in	   the	  areas	  of	  
the	   parietal,	   frontal,	   hippocampal	   and	   temporal	   cortex	  with	   highest	  Aβ	  plaque	   load.	  
CR1	   presence	   on	   microglia	   could	   account	   for	   this	   increase	   in	   CR1	   coverage	   in	   high	  
plaque	  areas	  due	  to	  accumulation	  of	  this	  glial	  cell	  around	  Aβ	  plaques.	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Furthermore	   CR1	   expression	   on	   RBCs	   is	   genetically	   determined	   and	   was	  
demonstrated	  to	  vary	  between	  different	  individuals	  possibly	  contributing	  to	  clearance	  
in	  AD.	  This	  expression	  was	  not	  shown	  to	  inversely	  correlate	  with	  Aβ	  levels	  in	  the	  blood	  
of	   these	   young	   donor	   individuals	   and	   it	   is	   suggested	   that	   the	   experiment	   should	   be	  
carried	  out	  with	  RBCs	  from	  older	  donor	  individuals	  (>60	  yrs).	  
This	   is	  nevertheless	  only	  a	  preliminary	   investigation	   into	  CR1	  expression	   in	   the	  
brain	  and	  confirmation	  of	  the	  cell	  type	  associated	  is	  needed.	  This	  could	  be	  carried	  out	  
by	  the	  use	  of	  laser	  capture	  microdissection	  to	  isolate	  the	  cells,	  and	  mass	  spectrometry	  




























6.	  General	  discussion	  
The	  research	  presented	  in	  this	  thesis	  was	  primarily	  focused	  on	  investigating	  the	  
role	   of	   CR1	   in	   the	   brain;	   the	   ramifications	   of	   how	   CR1	   modulation	   influences	   the	  
microglial	  phenotype	  following	  exposure	  of	  activators	  complicit	  in	  microglial	  responses	  
in	  AD,	   the	  consequences	  of	   these	  responses	  on	  neuronal	  survival	  and	  an	  exploratory	  
investigation	   into	  a	  possible	   correlation	  between	  CR1	  activation	  and	  Aβ	  plaque	   load.	  
The	  data	  presented	  demonstrate	  that	  microglial	  CR1	  has	  a	  proinflammatory	  influence	  
on	   regulating	   neuronal	   survival,	   plays	   a	   role	   in	   Aβ	   triggered	   phagocytosis	   and	  
expression	  may	  coincide	  with	  high	  levels	  of	  Aβ	  plaques	  in	  the	  human	  AD	  brain.	  
Microglia	  are	   the	   immune	  cells	  of	   the	  CNS	  and	  have	  a	   crucial	   role	   in	  detecting	  
and	  removing	  foreign	  particles	  in	  the	  brain.	  They	  function	  to	  protect	  more	  vulnerable	  
cells	   in	   the	   CNS	   such	   as	   neurons,	   from	   damage,	   through	   their	   activation	   to	   a	  more	  
immunocompetent	   phenotype,	   releasing	   cytotoxic	   substances	   and	   mediating	   the	  
phagocytosis	  of	  debris.	  Neuroinflammation,	  a	  hallmark	  of	  which	  is	  chronic	  activation	  of	  
microglia,	   is	  an	   important	  component	  of	  AD	  progression.	   It	   is	   initiated	   in	  response	  to	  
elevated	   Aβ	   levels	   in	   attempt	   to	   slow	   down	   the	   disease,	   however,	   inflammatory	  
mediators	   may	   act	   as	   a	   driving	   force	   for	   AD.	   In	   addition	   to	   Aβ	   plaques	   and	   NFTs,	  
activated	   microglia	   are	   largely	   considered	   important	   hallmarks	   of	   the	   disease	  
(Cameron	   &	   Landreth	   2010).	   The	   complement	   system	   is	   also	   considered	   to	   play	   a	  
central	   role	   in	  AD	  pathogenesis	  with	  Aβ	  plaques	   comprising	  of	   complement	  proteins	  
and	   their	   expression	   coinciding	  with	   dementia	   (Kolev	   et	   al.	   2009).	   Therefore,	   recent	  
GWAS	   linking	  one	  of	   the	  complement	   regulatory	  proteins,	  CR1	   to	  AD	   (Lambert	  et	  al.	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2009;	  Corneveaux	  et	   al.	   2010;	   Zhang	  et	   al.	   2010;	  Carrasquillo	   et	   al.	   2010)	   raised	   the	  
question	  of	  its	  contribution	  to	  AD	  pathogenesis.	  It	  remained	  to	  be	  determined	  whether	  
complement	  activation	  as	  a	  consequence	  of	   the	   inflammatory	   response	   in	  AD,	  had	  a	  
protective	  role	  through	  phagocytosis	  and	  plaque	  clearance	  or	  a	  destructive	  role	  from	  
chronic	  inflammatory	  tissue	  damage	  and	  so	  this	  thesis	  attempted	  to	  explore	  this.	  	  
Although	   complement	   can	   enter	   the	   brain	   through	   a	   compromised	   BBB	  which	  
has	  been	  suggested	  as	  an	  early	  event	  in	  AD	  (Gay	  &	  Esiri	  1991;	  Bowman	  &	  Quinn	  2008),	  
there	   is	   increasing	  evidence	  of	  complement	  mRNA	  in	  the	  AD	  brain	   leaning	  towards	  a	  
possible	  CNS	  origin	  of	  synthesis	  (Shen,	  Li,	  et	  al.	  1997;	  Van	  Beek	  et	  al.	  2000;	  Walker	  et	  
al.	  1995).	  So	  far	  in	  the	  literature,	  there	  have	  been	  a	  number	  of	  reports	  of	  complement	  
protein	   sources	   in	   the	   brain	   including	   neurons,	   astrocytes,	   oligodendrocytes	   and	  
microglia	   (Gasque	  et	  al.	  1993;	  Walker	  et	  al.	  1998;	  Hosokawa	  et	  al.	  2003;	  Rutar	  et	  al.	  
2011).	  However,	  the	  expression	  of	  the	  complement	  regulatory	  protein,	  CR1,	  in	  the	  CNS	  
has	   remained	   controversial	   with	   conflicting	   reports	   of	   its	   expression	   in	   the	   brain	  
(Singhrao	  et	  al.	  1999;	  Singhrao	  et	  al.	  2000;	  van	  Beek	  et	  al.	  2005).	  This	  thesis	  aimed	  to	  
address	   this	   question	   using	   post-­‐mortem	   human	   brain	   tissue	   and	   primary	   rodent	  
microglia.	   Following	   investigation	  with	   a	   range	  of	   highly	   specific	   CR1	   antibodies	   that	  
target	  LHR-­‐A,	  -­‐B,	  -­‐C	  and	  –D,	  CR1	  expression	  was	  present	  in	  human	  control	  and	  AD	  post-­‐
mortem	   brain	   tissue	   in	   the	   four	   regions	   examined.	   It	  may	   be	   possible	   that	   previous	  
work	   trying	   to	   determine	   CR1	   expression	   in	   the	   brain	   did	   not	   have	   highly	   specific	  
antibodies	  as	  these	  available.	  Suggested	  links	  between	  CR1	  pathways	  and	  Aβ	  clearance	  
in	   AD	   have	   made	   microglia	   an	   interesting	   cell	   type	   to	   investigate	   due	   to	   their	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phagocytic	   abilities	   and	   migration	   to	   Aβ	   plaques	   (Fetler	   &	   Amigorena	   2005).	   CR1	  
detected	  at	  160	  kDa	  by	  Western	  blotting	  with	  two	  CR1	  antibodies	  was	  increased	  in	  LPS	  
and	   Aβ1-­‐42	   activated	   microglia	   indicating	   a	   possible	   increase	   in	   neuroinflammation.	  
These	  data	  suggest	  that	  further	  investigation	  into	  a	  possible	  role	  for	  CR1	  on	  microglia	  
could	  yield	  some	  interesting	  and	  potentially	  useful	  results.	  
Phagocytosis,	   a	   microglial	   response	   considered	   important	   in	   regulating	  
homeostasis,	  occasionally	  through	  regulating	  Aβ	  plaque	  burden	  (Bard	  et	  al.	  2000),	  was	  
hypothesized	  to	  be	   impaired	   in	  microglial	  cultures	   following	  reduced	  CR1	  availability.	  
This	  impaired	  response	  is	  thought	  to	  occur	  in	  individuals	  with	  CR1	  mutations,	  resulting	  
in	  a	  disruption	  in	  Aβ	  plaque	  balance.	  Although	  both	  inflammatory	  treatments,	  LPS	  and	  
Aβ1-­‐42,	   significantly	   reduced	   the	   phagocytosis	   of	   dextran	   beads,	   interestingly	   CR1	  
appeared	  in	  this	  case	  to	  play	  less	  of	  a	  phagocytic	  role	  following	  activation	  with	  Aβ1-­‐42.	  
However,	   further	   analysis	   of	   microglial	   phagocytosis	   with	   fluorescently	   tagged	   Aβ	  
curiously	   demonstrated	   a	   different	   response,	   which	   allowed	   us	   to	   suggest	   that	   CR1	  
modulation	   may	   affect	   microglial	   phagocytic	   pathways	   differently.	   Reduced	   iC3b	  
binding	  to	  CR3	  receptor	  on	  microglia,	  as	  a	  result	  of	  lower	  levels	  of	  CR1,	  could	  lead	  to	  a	  
diminished	  stimulation	  of	  phagocytosis.	  
Microglia	  are	  responsible	  for	  protecting	  neurons,	  therefore	  it	  was	  interesting	  to	  
measure	  the	  effect	  of	  CR1	  modulation	  on	  microglial-­‐neuronal	   interactions.	  Modelling	  
microglial	  responses	  within	  CGC	  cultures	  (indirect	  interaction)	  allowed	  the	  creation	  of	  
a	  more	  physiological	  environment.	  Furthermore,	  the	  use	  of	  MGCM	  treatment	  of	  CGC	  
180	  
	  
cultures	  allowed	  us	  to	  identify	  the	  influence	  of	  soluble	  secreted	  factors,	  such	  as	  TNFα,	  
on	   neuronal	   death.	   From	   both	   the	   direct	   and	   indirect	   interactions	   there	   was	   a	  
reduction	   in	   neuronal	   death	   when	   CR1	   was	   blocked,	   however,	   it	   was	   only	   indirect	  
interactions	   that	   demonstrated	   a	   decrease	   in	   neuronal	   death	   following	   blocking	  
microglial	  CR1	  with	  Aβ1-­‐42	  co-­‐treatment,	  suggesting	  that	  soluble	  factors	  released	  from	  
microglia	   following	   CR1	   blockade	   are	   important	   in	   neuronal	   survival	   following	   Aβ	  
stimulation.	   The	   possibility	   of	   reduced	   cell	   number	   accounting	   for	   death	   was	  
eliminated	   in	   the	   live	   cell	   assays	   through	   total	   cell	   number	   counts	   and	   the	   direct	  
treatment	   data	  was	   confirmed	  by	   cleaved	   caspase-­‐3	   ICC.	   The	   complement	   system	   is	  
known	  to	  play	  an	  important	  role	  in	  the	  human	  defence	  system	  and	  its	  activation	  leads	  
to	  the	  formation	  of	  the	  MAC	  complex	  responsible	  for	  the	  lysis	  of	  pathogens	  and	  cells	  
(Shen,	  Halperin,	  et	  al.	  1997;	  Leinhase	  et	  al.	  2006).	   Impairment	  to	  the	  functionality	  of	  
complement	   regulatory	   proteins,	   such	   as	   CR1,	   could	   lead	   to	   increased	   C3b,	   possibly	  
increasing	  MAC	  lysis	  of	  cells.	  The	  decrease	  in	  neuronal	  death	  was	  also	  considered	  to	  be	  
due	   to	   reduction	   in	   the	   release	  of	  microglial	   toxic	  mediators	   therefore	   this	  was	   also	  
investigated.	  
Activated	  microglia	  produce	  neurotoxic	  mediators	   (Cameron	  &	  Landreth	  2010),	  
whereby	   in	   the	  healthy	  brain,	  production	  of	  cytotoxic	   factors	   is	  attenuated	   following	  
neuronal	   rescue	   or	   clearance	   of	   dying	   neurons.	   However	   during	   chronic	  
neuroinflammation	   these	   responses	   are	   not	   regulated	   which	   can	   lead	   to	   neuronal	  
death.	   Cytokine	   production	   is	   a	   microglial	   response	   up-­‐regulated	   during	   persistent	  
activation	  following	  tissue	  injury,	  infection	  or	  inflammation	  (Smith	  et	  al.	  2012).	  TNF-­‐α	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is	   highly	   expressed	   in	   neuroinflammation	   which	   is	   in	   line	   with	   increased	   Aβ	   plaque	  
deposition	   in	   AD	   (Fillit	   et	   al.	   1991;	   Paganelli	   et	   al.	   2002).	   Release	   of	   TNFα	   from	   LPS	  
activated	   microglia	   was	   reduced	   when	   CR1	   was	   blocked	   with	   a	   functional	   blocking	  
antibody.	  This	  was	  considered	  a	  possible	  contribution	  to	  the	  trend	   in	  neuronal	  death	  
observed	  with	  indirect	  LPS	  and	  CR1	  blocking	  treatment	  however	  further	  investigation	  
blocking	   TNFα	   synthesis	   could	   not	   support	   this.	   Aβ1-­‐42	   microglial	   activation	   led	   to	  
increased	   secretion	   of	   IL-­‐1β,	   another	   pro-­‐inflammatory	   cytokine	   associated	  with	   the	  
pathogenesis	  of	  AD	  (Licastro	  et	  al.	  2004;	  Cacabelos	  et	  al.	  1994;	  Cacabelos	  et	  al.	  1991),	  
which	   was	   further	   decreased	   by	   blocking	   CR1.	   This	   correlated	   with	   the	   indirect	  
neuronal	   death	   data	   suggesting	   modulating	   CR1	   can	   protect	   neurons	   from	   death	  
following	   a	   microglial	   neuroinflammatory	   insult.	   This	   however	   would	   need	   to	   be	  
confirmed	  through	  use	  of	  an	  IL-­‐1β	  antagonist	  to	  measure	  any	  influence	  this	  may	  have	  
on	  neuronal	  death	  (Minogue	  et	  al.	  2012).	  Expression	  of	  iNOS,	  as	  measured	  by	  ICC	  was	  
decreased	   in	  microglia	   co-­‐treated	  with	  CR1	  blocking	  antibody	  and	  a	   trend	  showing	  a	  
decrease	  in	  Western	  blotting	  data	  supports	  this,	  however	  this	  data	  was	  not	  significant.	  
Further	   investigation	   inhibiting	   iNOS	  activity	   in	  neuronal	  cultures	  did	  not	  provide	  any	  
subsequent	  findings	  to	  support	  a	  role	  for	  CR1	  in	  iNOS	  activity.	  	  
Interestingly	   blocking	   CR1	   and	   the	  murine	   homolog,	   Crry,	   in	   primary	  microglia	  
and	  BV2	  cultures	  attenuated	  O2
.-­‐	  production.	  Increased	  C3b	  expression,	  which	  could	  be	  
triggered	  by	  the	  accelerated	  activation	  of	  the	  alternative	  pathway	  by	  TNFα,	  IL-­‐1β	  or	  IL-­‐
6	  has	  been	  previously	  demonstrated	  to	  have	  a	  positive	  correlation	  with	  an	  increase	  in	  
respiratory	  burst	   (Hoogerwerf	   et	   al.	   1990).	   Furthermore,	   decreased	  C3b-­‐CR1	  binding	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due	  to	   lack	  of	  CR1	  availability,	  as	  demonstrated	  in	  this	  thesis	   is	  thought	  to	  ultimately	  
lead	  to	  reduced	  generation	  of	  iC3b,	  which	  in	  turn	  reduces	  binding	  to	  CR3,	  resulting	  in	  
impaired	  NADPH	  oxidase	   activity	   shown	   in	   leukocytes	   through	   reduced	   activation	   of	  
RAC2	  (Wymann	  et	  al.	  2000).	   In	  addition,	   the	  data	  presented	  here	  demonstrated	  that	  
CR1	   activation	   induced	   superoxide	   production	   in	   primary	   microglia	   and	   BV2	   cell	  
cultures	   was	   attenuated	   by	   the	   addition	   of	   the	   NADPH	   oxidase	   inhibitor,	   apocynin,	  
thus	  attributing	  NADPH	  oxidase	  involvement	  in	  CR1	  mediated	  O2
.-­‐	  production.	  It	  could	  
be	   suggested	   that	   this	   correlation	   between	   reduced	   in	   O2
.-­‐	   production	   and	   blocking	  
microglial	   CR1	   may	   contribute	   to	   the	   reduced	   neuronal	   death.	   In	   AD,	   microglial	  
activation	  may	  be	  the	  predominant	  source	  of	  oxidative	  stress	  suggesting	  that	  targeting	  
this	  mechanism	  and	  disrupting	  its	  signalling	  cascade	  may	  prove	  a	  useful	  mechanism	  in	  







Figure	  6.1:	  Summary	  of	  results.	  
(a)	  CR1	  contributed	  to	  an	  increase	  in	  a	  number	  of	  toxic	  mediators	  released	  from	  microglia	  
such	  as	  production	  of	  NO,	  SO	  and	  TNFα	  released	  from	  microglia	  following	  activation	  with	  
LPS	  and	  NO,	  SO	  and	  IL-­‐1β	  released	  from	  microglia	  following	  activation	  with	  Aβ1-­‐42.	  CR1	  
may	  also	  contribute	  to	  microglial	  phagocytosis	  of	  Aβ.	  (b)	  Overview	  of	  the	  proposed	  
mechanism	  by	  which	  microglial	  CR1	  contributes	  to	  the	  observed	  neuronal	  toxicity.	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The	   last	   section	   of	   this	   thesis	   investigated	   differences	   in	   CR1	   expression	   in	  
human	  RBCs	  and	  post-­‐mortem	  brain	   tissue.	  As	  previously	  discussed,	   the	  presence	  of	  
CR1	   in	   the	  brain	  has	  not	  been	  definitively	  agreed	  upon,	  and	  so	  with	   that	   there	   is	  no	  
literature	  published	   investigating	   a	  possible	   correlation	  between	  CR1	  expression	  and	  
Aβ	  plaque	  deposition	  in	  the	  AD	  brain.	  This	  thesis	  provides	  a	  preliminary	  investigation	  
into	  this	  due	  to	  the	  small	  size	  of	  the	  study	  but	  nonetheless	  it	  provides	  a	  glimpse	  into	  a	  
possible	   interrelationship.	   Compared	   to	   AMC,	   CR1	   expression	   in	   post-­‐mortem	   brain	  
tissue	  appeared	   lower	   in	  regions	  of	   low	  plaque	  deposition	   in	  the	  AD	  brain.	   In	  the	  AD	  
brain,	  this	  may	  lead	  to	  reduced	  phagocytic	  clearance	  and	  thus	  an	  accumulation	  of	  Aβ	  
plaque.	   Activation	   of	   the	   complement	   system	   by	   Aβ	   (Jiang	   et	   al.	   1994;	   Bradt	   et	   al.	  
1998)	   contributes	   to	   the	   cycle	  of	  events	   leading	   to	  AD	  pathogenesis	  possibly	   though	  
increased	   neuronal	   toxicity.	   However,	   this	   study	   would	   need	   to	   be	   repeated	   to	  
increase	   the	   volume	   of	   brain	   tissue	   investigated	   and	   to	   determine	   the	   cell	   type	  
expressing	  CR1.	  In	  this	  thesis,	  results	  following	  investigation	  of	  CR1	  expression	  on	  RBCs	  
between	  individuals	  supported	  data	  from	  previous	  work	  (Glodek	  et	  al.	  2010),	  however	  
the	   analysis	   determining	   any	   correlation	  with	   Aβ	   levels	   in	   the	   blood,	   would	   require	  







6.1	  Future	  Work	  
The	   observations	   made	   here	   of	   CR1	   mediated	   induction	   of	   an	   activated	  
microglial	   phenotype	   are	   novel,	   however	   further	  work	   could	   be	   done	   to	   investigate	  
this	  is	  greater	  detail.	  Listed	  below	  are	  future	  studies	  that	  would	  improve	  this	  research	  
to	  enable	  a	  greater	  understanding	  of	  the	  role	  of	  CR1	  in	  AD.	  
• Soluble	   Aβ	   oligomers	   and	   protofibrils	   have	   been	   demonstrated	   in	   vitro	   to	   be	  
neurotoxic	   (Walsh	  et	  al.	  1999;	  Walsh	  et	  al.	  2002),	  and	  studies	  have	  shown	  that	  
there	   are	   conformation-­‐dependent	   differences	   contributing	   to	   the	   disease	  
process	  (White	  et	  al.	  2005).	  Therefore,	  it	  would	  be	  interesting	  to	  determine	  what	  
form	  of	  Aβ	  generated	  the	  results	  presented	  in	  this	  thesis.	  Assessing	  the	  structure	  
and	  conformation	  of	  Aβ	  oligomers,	  has	  been	  a	  contentious	  area	  of	  investigation.	  
Recently	   there	   have	   been	   some	   interesting	   results	   following	   characterising	   α-­‐
synuclein	   using	   single-­‐molecule	   fluorescence	   resonance	   energy	   transfer	  
(smFRET)	  (Cremades	  et	  al.	  2012),	  which	  may	  prove	  a	  favourable	  method	  for	  the	  
investigation	   of	   Aβ	   conformation	   present	   in	  microglial	   conditioned	  medium	   at	  
different	   time-­‐points	   following	   activation.	   Also,	   electron	   microcopy	   could	   be	  
used	  to	  examine	  the	  structure	  of	  the	  peptide.	  
• Scavenger	   receptors	  have	  been	   reported	   to	  mediate	  microglial	   phagocytosis	  of	  
fAβ	  (El	  Khoury	  et	  al.	  1996;	  Paresce	  et	  al.	  1996)	  therefore	  the	  phagocytosis	  assays	  
in	   this	   thesis	  could	  control	   for	   this	  with	  pre-­‐incubation	  with	   fucoidan,	  a	  class	  A	  
and	  B	  scavenger	  receptor	  ligand.	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• The	  siRNA	  knockdown	  experiments	  could	  be	  further	  controlled	  by	  carrying	  out	  a	  
rescue	  experiment,	  where	  the	  protein	   is	   re-­‐introduced	  by	  transfection	  with	  the	  
recombinant	  protein.	  
• High	  performance	  liquid	  chromatography	  (HPLC)	  measurement	  could	  be	  carried	  
out	   to	   conclusively	   determine	   whether	   superoxide	   or	   H2O2	   was	   produced	   in	  
chapter	  3.	  
• Measurement	   of	   neurotoxicity	   by	   lactate	   dehydrogenase	   released	   into	   the	  
culture	  medium,	  may	  enhance	  the	  data	  in	  chapter	  4.	  	  
• As	  previously	  mentioned,	  Flow	  cytometry	  analysis	  to	  comparatively	  measure	  CR1	  
and	   Aβ	   levels	   on	   RBCs	   needs	   to	   be	   carried	   out	   with	   fresh	   blood	   from	   donor	  
individuals	  >60yrs.	  	  
• From	  the	  data	  presented	  in	  this	  thesis,	  it	  is	  not	  possible	  to	  state	  which	  cell	  type	  
was	   expressing	   CR1	   in	   the	   human	   AD	   brain	   due	   to	   the	   inability	   to	   carry	   out	  
immunofluorescence	  using	  the	  CR1	  antibodies	  provided.	  However,	  analysis	  using	  
laser	   capture	   microdissection	   to	   isolate	   particular	   cells,	   followed	   by	   mass	  







In	   conclusion,	   the	   data	   presented	   in	   this	   thesis	   provides,	   for	   the	   first	   time	   a	  
possible	   role	   for	   CR1	   in	   the	   brain	   and	   a	   mechanism	   with	   potentially	   important	  
consequences	   in	  AD.	  The	  data	  presented	  here	  using	  two	  phagocytic	  assays	   identified	  
that	   CR1	   modulation	   influenced	   the	   phagocytic	   role	   of	   microglia,	   but	   it	   also	   put	  
forward	   the	   prospect	   of	   CR1	   contributing	   differently	   to	   microglial	   phagocytic	  
pathways.	  Its	  role,	  nonetheless	  contributes	  to	  previous	  suggestions	  of	  participation	  in	  
Aβ	   clearance	   (Rogers	   et	   al.	   2006;	   Lambert	   et	   al.	   2009).	   This	   thesis	   also	   provides	  
evidence	   suggesting	   that	   modulation	   of	   microglial	   CR1	   can	   affect	   neuronal	   survival,	  
which	   is	   possibly	  mediated	   through	   superoxide	   production.	   Production	   of	  which,	   via	  
NADPH	  oxidase	  activity	  has	  been	  previously	  shown	  to	  play	  a	  role	  in	  Alzheimer’s	  disease	  
(Shimohama	  et	  al.	  2000;	  Ansari	  &	  Scheff	  2011).	  Furthermore,	   this	  work	  explored	   the	  
expression	  of	  CR1	  in	  human	  post-­‐mortem	  brain	  tissue,	  and	  was	  able	  to	  provide	  for	  the	  
first	  time	  evidence	  for	  its	  presence	  in	  the	  AD	  brain.	  It	  attempted	  to	  explore	  a	  potential	  
correlation	   between	   the	   expression	   of	   this	   complement	   regulatory	   protein	   and	   Aβ	  
deposition	   in	   the	   AD	   brain	   and	   provided	   preliminary	   results	   featuring	   a	   correlation	  
between	  areas	  of	  high	  plaque	  deposition	  having	  high	  expression	  of	  CR1.	   Finally,	  CR1	  
expression	   on	   RBCs	   was	   shown	   to	   vary	   between	   individuals	   with	   no	   correlation	  
observed	  with	  Aβ	  levels	  in	  control	  blood	  from	  young	  donors.	  It	  is	  understood	  that	  basic	  
neuroscience	  does	  not	  directly	  or	  immediately	  offer	  therapeutic	  benefit	  to	  AD	  suffers,	  
however,	   it	   is	  hoped	   that	   further	  elucidation	  of	   the	  pathways	   involved	  will	   lead	   to	  a	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greater	  understanding	  of	  AD	  pathogenesis	  which	  may	   in	   turn	   lead	   to	  more	  effective	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